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Abstract 
Part 1 
The novel antibacterial DEM30355/A 1 was isolated from the fermentation broth of 
Amycolatopsis DEM30355.  We aimed to synthesise DEM30355/A 1 to determine the absolute 
stereochemistry and access DEM30355/A analogues.  Using a Baylis-Hillman reaction 
between tricarbonyl 2 and ketone 3, we constructed the oxygenated quaternary centre at C4a 
of DEM30355/A 1 in adducts 4 and 5 (Figure 1).  
 
Figure 1: Left – structure of DEM30355/A 1.  Right - Baylis-Hillman reactions to synthesise adducts 4 and 5 
In an alternate route, a Diels-Alder reaction between diene 6 and dienophile 7 was used to 
generate cycloadducts 8 – 11, containing the A, B, C ring core of DEM30355/A 1 (Figure 2). 
 
Figure 2: Synthesis of cycloadducts 8 – 11 via a Diels-Alder reaction from isobenzofuran 6 
Alongside this Diels-Alder route, we aimed to synthesise dienophile 12 from shikimic acid 13, 
to generate DEM30355/A 1 as a single enantiomer (Figure 3).   
 
Figure 3: Planned route to DEM30355/A 1 as a single enantiomer from shikimic acid 13 
Following the synthesis of alkene 14, a key sterically directed dihydroxylation reaction gave 
diol 15, which was oxidised to ketone 16.  Base-catalysed conversion of ketone 16 to 
dienophile 12 was attempted, however the product of this reaction is compound 17 (Figure 4).   
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Figure 4: Two-step synthesis of ketone 16 from alkene 14 and the subsequent reaction with base generating 
aromatic compound 17 
Part 2 
Antibacterial DEM30355/B2 18 was identified in the fermentation broth of A. DEM30355 
(Figure 5). We targeted new drug leads via semi-synthetic modification of DEM30355/B2 18.  
 
Figure 5: Structure of DEM30355/B2 18 
Following isolation of DEM30355/B2 18 via a key acid-base extraction, we successfully 
generated semi-synthetic DEM30355/B2 derivatives 19 and 20 (Figure 6).  These compounds 
are undergoing investigation to assess their inhibition activity against drug-resistant bacterial 
dependent RNA polymerase. 
 
Figure 6: Structures of DEM30355/B2 derivatives 19 and 20 
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Chapter 1. Introduction 
The use of natural products in medicine is recorded as far back as 2600 BC, where clay tablets 
from Mesopotamia reference hundreds of bioactive substances derived from plants.1 These 
medicines were mostly limited to the use of simple plant extracts. Thousands of years later, 
advancements in chemical science allowed small molecule natural products to be manipulated, 
to improve their ability to act as drugs.  For example, in the 19th century, pioneering chemists 
synthesised acetylsalicylic acid (Aspirin) from the plant natural product, salicylic acid.2 Later in 
1928, Alexander Fleming paved the way for drug development from microbial sources, with 
the discovery of penicillin from a Penicillium mould.2,3 There is a constant need to develop new 
therapeutic agents, for example to tackle the emergence of drug-resistant bacteria. Now, 
modern advances in genetics have demonstrated the hidden potential of microorganisms to 
generate new drug leads, with genome sequencing identifying cryptic biosynthetic gene 
clusters (BGCs), as in the genome of Streptomyces coelicolor.  Some BGCs are believed to 
encode novel compounds which, by developing new cultivation methods and utilising 
recombinant DNA technology, may lead to new therapeutic agents in the future.4      
 Natural Products as Drug Sources 
The importance of natural products in the development of new therapeutic agents can be 
deduced by examining the sources of new drugs approved for clinical use (Figure 1).5  
 
Figure 1: Graphical representation of the origins of small molecule drugs introduced for use in the period 1981 - 
20105 
According to a survey of the literature by Newman and Cragg5, the new small molecule drugs 
were defined and categorised as follows: 
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 Synthetic (S) – a totally synthetic drug, not influenced by natural products.  Such drugs 
usually originate from random library screening.  For example the anticancer compound 
sorafenib, was developed using combinatorial chemistry.5 
 Synthetic natural product mimic (S/NM) – a totally synthetic drug that mimics a natural 
product.  An example is the synthetic anticancer drug Gleevec, an inhibitor of BCR-
ABL tyrosine kinase which binds to the adenosine triphosphate binding site.5,6  
 Synthetic* (S*) – a totally synthetic drug, with a pharmacophore from a natural product.  
For example, the antiviral drug famciclovir is a synthetic analogue of the natural 
product, guanosine.7   
 Synthetic* natural product mimic (S*/NM) – a totally synthetic drug with a 
pharmacophore from a natural product.  The drug mimics a natural product.  An 
example is tamibarotene (anticancer), a synthetic retinoid compound that binds to 
retinoic acid receptors.8  
 Natural (N) – an unmodified natural product used as a drug, such as penicillin G. 
 Natural product ‘botanical’ (NB) – natural mixtures of bioactive compounds. For 
example, the anticancer topical treatment Curaderm contains a naturally occurring 
mixture of solasodine glycosides.9  
 Natural derivative (ND) – a drug derived from a natural product, often by semi-synthetic 
means.  An example is roxithromycin, a semi-synthetic derivative of the natural product, 
erythromycin A.10 
In the period 1981 – 2010, 50% of the 1073 new small molecule drugs approved by the  Food 
and Drug Administration (FDA) were S*, S*/NM, N, NB, or ND and thus influenced by natural 
products (Figure 1).5 The ratio of totally synthetic drugs to drugs inspired by natural products 
varies between disease categories.  For example, of the 99 small molecule anticancer drugs 
introduced in 1981-2010, 64% were of natural product origin.  On the other hand, of the 104 
small molecule antibacterial compounds introduced in the same period, an impressive 75% 
were of natural product origin (Figure 2).5   
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Figure 2: Comparison of the origin of anticancer and antibacterial drugs introduced in 1981-20105 
Bioactive small molecules are isolated from a wide range of sources.  These include terrestrial 
and marine animals, plants, fungi and bacteria.  During the years 1970-2006, 24 structurally 
unique natural products from 10 compound classes were discovered, each of which resulted 
in the approval of a new drug entity.11 Of these discovered natural products, 62% were from 
bacterial sources, 21% from plants and 17% from fungi (Figure 3).11  
 
Figure 3: Graphical representation of the source of the new natural products discovered between 1970-2006 that 
led to an approved drug in the period 1981-200611 
From herein we will focus on drugs based on natural products which pertain to the treatment 
of cancer and bacterial infections. 
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 Clinically Used Unmodified Natural Products 
 Natural Products as Anticancer Drugs 
Taxol 1 (paclitaxel) is a diterpene, originally isolated from the bark of Taxus brevifolia (T. 
brevifolia), following a screening programme to identify anticancer compounds (Figure 4).12 It 
was approved for clinical use by the FDA in 1992, for the treatment of ovarian cancer.12,13 In 
cancerous cells, Taxol 1 interferes with microtubule formation, preventing cell mitosis and thus 
cell division.14   
Trabectedin 2 is an alkaloid which was isolated from the sea squirt, Ecteinascidia turbinate 
(Figure 4).15 It was approved for use in 2007 by the European Medicines Agency (EMA) for the 
treatment of soft tissue sarcoma, and in 2009 for the treatment of ovarian cancer.15 In 
cancerous cells, trabectedin 2 binds to the minor groove of DNA, thus interfering with 
transcription and leading to cell death through double strand DNA breaks.16 
 
Figure 4: Structures of Taxol 1 and trabectedin 2 
Both Taxol 1 and trabectedin 2 are examples of unmodified natural products used as drugs, 
although both are now made industrially using chemical synthesis. Due to the problems 
associated with isolating the compound from bark, Taxol 1 is currently obtained through semi-
synthesis of the natural product 10-deacetylbaccatin III 3, by introduction of the ester 
functionality at C13 and the acetoyl group at C10 (Figure 5).12  10-Deacetylbaccatin III 3 is 
isolated from needle extracts of T. baccata. which are more easily harvested and re-grow.17  
Due to the difficulties in farming marine creatures and the limited supply of the natural product 
from this source, trabectedin 2 is also obtained through semi-synthesis.  Optimisation of the 
fermentation of Pseudomonas fluorescens bacteria provided access to kilogram quantities of 
cyanosafracin B 4, a related natural product, which is converted in 21 synthetic steps to 
trabectedin 2 (Figure 5).18  
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Figure 5: Structures of 10-deacetylbaccatin 3 and cyanosafracin B 4 
 Natural Products as Antibacterial Drugs  
Penicillin G 5 is a famous example of an unmodified natural product derived from a fungal 
source, first used clinically in 1941 for the treatment of Gram-positive bacterial infections, like 
Staphylococcus aureus (S. aureus) (Figure 6).19  Penicillin G 5 was originally isolated from the 
mould, Penicillium rubens (P. rubens), after the microbe was observed to have antibiotic 
activity against Staphylococcus bacteria.3,20  Penicillin G 5 is a member of the β-lactam family 
of antibacterial agents, the bactericidal properties of which arise from their ability to inhibit 
penicillin-binding protein, a transpeptidase vital for bacterial cell wall synthesis.21   
 
Figure 6: Structures of penicillin G 5 and daptomycin 6 
The cyclic lipopeptide, daptomycin 6 was isolated from Streptomyces roseosporus, following 
screening of the bacterial fermentation extract for antibiotic activity (Figure 6).22  It was 
introduced for clinical use in 2003, for the treatment of complicated skin infections caused by 
Gram-positive bacteria.23,24 Daptomycin 6 interferes with bacterial cell wall synthesis, by 
inducing oligomerisation within the cytoplasmic membrane, leading to cell death.25  
Chapter 1. Introduction 
 
6 
 
 Clinically Used Modified Natural Products  
As shown in the examples above, the use of unmodified secondary metabolites from a range 
of sources is commonplace in the treatment of cancer and bacterial infection.  However, it is 
often necessary to chemically modify a natural product to improve its pharmacological 
properties, to make it a clinically usable compound.   
 Modified Natural Products as Anticancer Drugs 
In 1966, following screening of plant extracts for biological activity, camptothecin 7 was isolated 
from the tree, Camptotheca acuminate (Figure 7).26,27 Camptothecin 7 showed promising 
anticancer properties, but was too toxic for clinical use.  Topotecan 8 is an analogue of 
camptothecin 7, which contains a solubilising tertiary amine group at C9 (Figure 7).  Topotecan 
8 is made through semi-synthesis of camptothecin 7, through a one-pot, sequential 
hydrogenation then oxidation reaction to generate 9, followed by condensation of compound 
9 with formaldehyde and dimethylamine (Figure 7).28  The hydrochloride salt of topotecan 8 
was approved by the FDA in 1996 for the treatment of ovarian cancer.27  The anticancer 
properties of both topotecan 8 and camptothecin 7 arise from their ability to inhibit 
topoisomerase I, thus disrupting DNA replication, leading to cell death.26   
 
Figure 7: Synthesis of topotecan 8 from camptothecin 7 
 Modified Natural Products as Antibacterial Drugs  
Erythromycin A 10, isolated from Saccharopolyspora erythraea (S. erythraea), was first 
introduced for clinical use in 1952 for the treatment of bacterial infections, such as Legionella 
pneumophil.29,30  It is an orally administered antibiotic, but is degraded in the acidic environment 
of the stomach to inactive compounds 11 and 12 (Figure 8).31  This results in variable 
gastrointestinal absorption that must be compensated for with high drug dosage.10 
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Figure 8: Acid catalysed degradation of erythromycin A 10 to compounds 11 and 12 
To solve this issue, the semi-synthetic drug roxithromycin 13 was developed.  Roxithromycin 
13 is synthesised from erythromycin A 10, by conversion of the ketone at C9 to an oxime 14, 
followed by O-alkylation to give roxithromycin 13 in a 60% overall yield (Figure 9).32  This 
modification prevents acid catalysed degradation of the antibiotic, leading to the introduction 
of roxithromycin 13 for clinical use in 1987.5  Roxithromycin 13 and erythromycin A 10 are 
bacteriostatic drugs that inhibit protein synthesis within bacteria, though disruption of ribosome 
functioning.30  
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Figure 9: Synthesis of roxithromycin 13 from erythromycin A 10 
The precursors to roxithromycin 13 and topotecan 8, erythromycin A 10 and camptothecin 7 
respectively, were made biosynthetically in a living organism and then altered using synthetic 
chemistry to give the target molecules.  This method of biosynthesis followed by chemical 
modification will be herein defined as ‘Bio-Chem’-synthesis.33  
 Increasing Isolated Yield of Natural Products  
 Penicillin G: Darwinian Selective Breeding (‘Bio’-Synthesis) 
For a natural product or natural product derivative to advance to new approved drug status, a 
sustainable, high-yielding source of the natural product must be developed.  In some cases, 
this problem can be overcome by combining the use of an alternative natural source with 
synthetic chemistry, as discussed previously.  However, an alternative approach is to 
selectively breed the natural product producer, to obtain higher isolated yields of the desired 
natural product.  We will define this traditional, biology-only approach as ‘Bio’-synthesis. 
This Darwinian selective breeding method is illustrated with the antibacterial agent, penicillin 
G 5.  Penicillin G 5 was originally isolated from a strain of P. rubens.3,20  The titre of penicillin 
G 5 from this microbe was approximately 1.2 µg mL-1.34  Early screening of other strains 
identified a higher producer, Penicillium chrysogenum (P. chrysogenum), which generated 100 
times more penicillin G 5 than the original.35  This strain was subsequently subjected to cycles 
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of mutation and selection of the highest producing organisms, to give strains of P. 
chrysogenum used industrially today, which produce titres of 42 - 60 mg mL-1.34  
This Darwinian method of applying selection and mutation cycles is very effective in developing 
overproducers and has the advantage that it does not require an in depth understanding of the 
producing organism to affect results.  However the process is very time consuming, with 
industrial strains of P. chrysogenum taking decades to develop, therefore more rapid methods 
are being examined.35  
 Taxol: Plant Cell Cultures (‘Bio’-Synthesis) 
As discussed previously, due to the difficulties in harvesting the natural product directly, Taxol 
1 is produced industrially through chemical modification of the plant natural product, 10-
deacetylbaccatin III 3.12  An alternative method, which avoids the issues associated with 
cultivating and harvesting whole plants, is to produce Taxol 1 using plant cell cultures.17,36,37  
Taxol-producing plant cell cultures are typically established in suspension.  The cultures are 
developed from Taxus calluses, collections of undifferentiated cells growing on a solid medium, 
obtained by harvesting Taxol-producing tissues, such as needle tissue.17,36 A cell suspension 
culture is established by introducing small clusters of these undifferentiated cells into a liquid 
medium.  These suspension cultures can be maintained through regular subculture.  Extensive 
research has been conducted to optimise the yield of Taxol 1 from plant cell cultures.17,36,37 
Like with penicillin-producing microorganisms, the first stage involved screening plant cell 
cultures and selecting the higher producing cells, which were then cloned.  Subsequently, it 
has been found that feeding the cell cultures with precursors like sugars and phenylalanine, 
increased Taxol 1 production compared to the controls.17 The highest yield of Taxol 1 from 
plant cell cultures, 0.5%, was obtained by feeding a culture of  Taxus media with methyl 
jasmonate.17,38  Methyl jasmonate is an elicitor, believed to have a role in the regulation of plant 
defence genes.38 
Following optimisation of the culture conditions to generate higher isolated yields of Taxol 1, 
plant cell culture is likely to develop as a dominant source of the drug in the future. 
 6-Deoxyerythronolide B: Heterologous Host Expression 
In some cases, it is not practical to source a natural product from its native producing organism.  
For example, 99% of bacteria are uncultivatable under laboratory conditions.39  Even if an 
organism can be cultivated, some species like many actinomycete bacteria, grow too slowly 
for economical industrial production.35  An alternative method is to use recombinant DNA 
technology, to enable the production of a desired secondary metabolite in a heterologous 
host.35  
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The use of recombinant DNA technology has been applied to the biosynthesis of the 
erythromycin A 10 precursor, 6-deoxyerythronolide B (6deb) 15, in the common, fast-growing 
heterologous host, Escherichia coli (E. coli) (Figure 10).40 In the native producer of 
erythromycin A 10 (S. erythraea), 6deb 15 is synthesised by deoxyerythronolide B synthase 
(DEBS), an enzyme which consists of 3 modules; DEBS 1, 2 and 3.40 
 
Figure 10: Structure of 6-deoxyerythronolide B 15 
A strain of E. coli was engineered to synthesise 6deb 15, by insertion of the eryAI-III genes 
encoding for DEBS 1 – 3 and insertion of the genes, pccA and pccB, which enable the 
synthesis of the DEBS precursor (2S)-methylmalonyl-coenzyme A, into the genome of E. coli.  
From this mutant E. coli strain, 0.1 mmol of 6deb 15 per gram of cellular protein per day was 
produced.40 Industrial strains of S. erythraea produce 0.2 mmol of erythromycin per gram of 
cellular protein per day, the result of many years of Darwinian selective breeding.40 This 
highlights an advantage of heterologous host expression over selective breeding; it can rapidly 
generate overproducers in a much shorter time period.  
 Discodermolide: Total Synthesis of Natural Products (‘Chem’-Synthesis) 
The success of methods that use living organisms to source a desired natural product is 
evident in the examples discussed, however in some cases this is not possible.  For example, 
the anticancer compound discodermolide 16, was originally isolated from the marine sponge, 
Discodermia dissoluta (D. dissoluta), following screening of marine extracts for biological 
activity (Figure 11).41 In a similar way to Taxol 1, discodermolide 16 stabilises microtubule 
formation, disrupting the replication of cancerous cells.  The isolation of discodermolide 16 
from D. dissoluta, which resides in deep sea waters and gives a 0.002% wet mass yield of 
discodermolide 16, was not feasible to supply sufficient quantities for clinical trials. In addition, 
attempts to identify the biosynthetic gene cluster of discodermolide 16 for use in heterologous 
expression, have so far failed.42 Therefore the only option was to carry out the total synthesis 
of discodermolide 16, a task undertaken by researchers at Novartis.43   
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Figure 11: Structure of discodermolide 16 
In the total synthesis of discodermolide 16, an Evans aldol reaction between aldehyde 17 and 
the enolate of compound 18, was used to generate oxazolidinone 19 (Figure 12). 43 The 
oxazolidinone of 19 was cleaved using hydrogen peroxide and lithium hydroxide.  This yielded 
a carboxylic acid which was coupled with 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) 20 to 
form a triazine ester, followed by reaction with N,O-dimethylhydroxylamine, to give Weinreb 
amide 21.43   
 
Figure 12: Novartis synthesis of discodermolide 16 - generation of Weinreb amide 21 from aldehyde 1743 
From Weinreb amide 21, the intermediate compounds 22, 23, and 24 were synthesised in four, 
seven and five steps respectively (Figure 12).  A Suzuki coupling of intermediates 22 and 23 
was used to give compound 25, which was subsequently converted to α-β-unsaturated 
aldehyde 26 (Figure 13).  A key mismatched aldol reaction was used to synthesise alcohol 27; 
ketone 24 was reacted with (+)-B-chlorodiisopinocampheylborane and triethylamine to 
generate the corresponding boron enolate, which was reacted with α-β-unsaturated aldehyde 
26 to give alcohol 27.  Reduction of the ketone of 27, followed by alcohol deprotection and 
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intramolecular cyclisation gave discodermolide 16, in an overall yield of 0.65% over 39 steps.  
Using this method, 60 g of discodermolide 16 was obtained.43,44 
 
Figure 13: Novartis synthesis of discodermolide 16 from intermediates 22, 23, and 24 
In this case, total synthesis was vital for the progression of discodermolide 16 into clinical trials.  
Although not ideal, with lengthy synthetic sequences and low yields, the total synthesis of 
discodermolide 16 shows that it is possible to source natural products from chemical synthesis.     
 Generation of New Natural Product Inspired Drug Leads 
So far we have focussed on clinically used natural products, which were originally isolated 
following traditional bioassay guided techniques.  In this method, extracts from natural sources 
including plant, microbial and marine isolates, are screened for activity against, for example, 
bacterial or cancerous cells.  This technique remains invaluable in the development of natural 
product inspired drugs.  However, the continual need for new compounds to identify drug leads 
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has encouraged the development of alternative methods, which are not reliant on the discovery 
of novel compounds naturally biosynthesised by an organism.   
 Total Synthesis of Natural Products as a Route to Natural Product Analogues  
Spirotryprostatins A and B were isolated from fermentation of the fungal species, Aspergillus 
fumigatus in 1996.45 They are inhibitors of mammalian tsFT210 cell cycle progression at the 
G2/M phase, with IC50 values of 197 µM for spirotryprostatin A and 14 µM for spirotryprostatin 
B.45 In 1998, Danishefsky and Edmonson published their total synthesis of spirotryprostatin A 
28 (Figure 14).  The synthesis involves a key N-bromosuccinimide (NBS) mediated 
rearrangement of indole 29, believed to proceed via brominated intermediate 30, followed by 
Boc removal to give spirooxindole 31.  Spirooxindole 31 is converted to diketopiperazine 33 
through reaction with acyl chloride 32, followed by Troc removal and subsequent 
intramolecular cyclisation.  Diketopiperazine 33 is then converted to spirotryprostatin A 28 in 3 
steps, in a 10% overall yield.46 
 
Figure 14: Total synthesis of spirotryprostatin A 2846 
Through development of this totally synthetic route to spirotryprostatin A 28, a range of 
analogues 34 - 38 of the natural product was accessed (Figure 15).  The inhibitory activity of 
spirotryprostatin A 28 and analogues 34 – 38 was assessed against two human breast cancer 
cell lines, MCF-7 and MDA-MB-468.  Spirotryprostatin A 28, analogues 34 and 35 showed 
similar activities, with no inhibition of MCF-7 observed (IC50 > 300 µM), but inhibition of MDA-
MB-468 was observed at IC50 concentrations of 85 - 110 µM.  Analogues 36, 37 and 38 showed 
inhibitory activity against both cell lines, with inhibition of MDA-MB-468 observed at IC50 
concentrations of 2.0 x 10-2 – 2.5 x 10-2 µM (Figure 15).47  
Chapter 1. Introduction 
 
14 
 
 
Figure 15: Anticancer activity of spirotryprostatin A 28 and analogues 34 - 38 
Thus, total synthesis is a valuable tool in the generation of bioactive natural product analogues 
as new drug leads, particularly those which cannot be accessed through chemical modification 
of the natural product. 
 Precursor-Directed Biosynthesis of Natural Product Analogues (‘Chem-Bio’-
Synthesis) 
An alternative to totally synthetic methods to generate new drug leads is precursor-directed 
biosynthesis (‘Chem-Bio’-synthesis).  Synthetic precursors are fed to wild-type microorganisms 
and incorporated into a biosynthetic pathway, to generate ‘unnatural’ natural products. 
This method has been applied to synthesise analogues of manumycin 39, a bacterial 
secondary metabolite which shows antineoplastic activity via inhibition of farnesyl protein 
transferase (FTPase) (Figure 16).48  Manumycin 39 consists of a cyclohexenone core with two 
unsaturated side chains, A and B.  The manumycin producer, Streptomyces parvulus (S. 
parvulus) was fed with 36 precursors (both aromatic and non-aromatic) in separate 
fermentations.  The fermentations were harvested, extracted and analysed by TLC.   Feeding 
S. parvulus with 9 of the aromatic precursors led to the isolation of 8 manumycin analogues 
40 - 47, which were categorised into 3 classes: Class 1 analogues contained side chain A 
(analogues 40 - 44), Class 2 analogues contained side chain B (analogues 45 and 46) and the 
Class 3 analogue contained both chains A and B (analogue 47) (Figure 16).49,50   
Chapter 1. Introduction 
 
15 
 
 
Figure 16: Precursor - directed biosynthesis of manumycin analogues 40 – 4749,50 
A disadvantage of feeding wild-type strains to produce analogues is that the synthetic 
precursors are in competition with the natural precursors biosynthesised by the organism.  To 
compensate, high concentrations of synthetic precursors (55 mmol dm-3 in the S. parvulus 
study) must be added to the fermentation.  This is a problem if the synthetic precursors are not 
readily available.  Another disadvantage of using wild-type strains is that the availability of both 
synthetic and natural precursors can lead to the biosynthesis of multiple products, thus 
complicating the purification procedure.44 In the experiment where S. parvulus was fed with   
3-hydroxybenzoic acid, manumycin 39 was isolated in addition to analogue 41 (Figure 16).49 
Precursor-directed biosynthesis (‘Chem-Bio’-synthesis) is a simple method which has allowed 
access to natural product analogues and thus to new drug leads, however the method is limited 
by the natural-product producing organism in both the range and quantity of these compounds 
Chapter 1. Introduction 
 
16 
 
it can produce.  Such issues can be overcome through genetic manipulation of the producing 
organism, or through heterologous host expression. 
 Mutasynthesis (‘Chem-Bio’ Synthesis) 
An alternative method to target new compounds, which avoids the precursor competition 
problem associated with feeding wild-type organisms, is mutasynthesis.  Mutasynthesis is an 
extension of precursor-directed biosynthesis, where genetic modification is used to develop 
mutant organisms that cannot biosynthesise a particular natural product precursor.  Such 
mutant organisms are dependent on precursor feeding to synthesise a particular secondary 
metabolite.44  
Mutasynthesis has been used to generate novel erythromycin analogues.  A mutant strain of 
S. erythraea, unable to biosynthesise erythromycins A 10 and B without supplementation with 
erythronolides A and B, was selected for fermentation.  The fermentation broth of this strain 
was supplemented with (8S)-8-fluoroerythronolide A 48, leading to the isolation of two novel 
erythromycin A analogues, 50 and 51 (Figure 17). Feeding the same strain with (8S)-8-
fluoroerythronolide B 49 also generated two new compounds, 52 and 53.51 
 
Figure 17: Structures of erythromycin analogues 50 - 53 generated through mutasynthesis 
The antibiotic activity of the fluorinated analogues 50 and 52 were comparable to the natural 
erythromycins A and B.  For example, the minimum inhibitory concentration (MIC) values of 
50 and 52 against S. aureus were 0.195 µg mL-1 and 0.097 µg mL-1 respectively, compared to 
0.097 µg mL-1 and 0.195 µg mL-1 for erythromycin A 10 and B respectively.51  
A limitation of both mutasynthesis and also precursor-directed biosynthesis, is the substrate 
specificity of the enzymes involved in the biosynthetic pathway.  For example, in the precursor-
directed synthesis of manumycin analogues 40 - 47 discussed previously, only 9 out of 36 
synthetic precursors tested led to the isolation of a new manumycin analogue.49  In spite of this 
limitation, feeding experiments with both wild-type (precursor-directed biosynthesis) and 
mutant organisms (mutasynthesis), continue to allow access to novel compounds, which would 
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be difficult if not impossible to generate through other means, such as semi-synthetic 
modification of related natural products.33  
 Recombinant DNA Technology  
Recombinant DNA technology, in addition to increasing isolated yields of a natural product, is 
a valuable technique in the generation of novel natural product analogues.  For example, 
manipulation of the eryA genes encoding the polyketide synthase (PKS) that generates 
erythromycin A 10, has given access to novel tylactone derivatives.52   
In wild-type S. erythraea, 6deb 15 is hydroxylated to erythronolide B 54. Following this, 
mycarose is added to the C3 hydroxyl group and desoamine to the C5 hydroxyl group, by the 
mycarosytransferases, EryBV and EryCIII respectively, generating erythromycin A 10 (Figure 
18).   
 
Figure 18: Structures of 6-deoxyerythronolide B 15, erythronolide B 54 and erythromycin A 10 
Leadlay et al. synthesised a hybrid strain of S. erythraea through deletion of eryBV, eryCIII 
and eryA I-III and expression of the mycaminosyltransferase gene, tylm2, from Streptomyces 
fradiae (S. fradiae).52  To test the ability of this new system to synthesise hybrid glycosides, 
the researchers fed tylactone 55 to a fermentation of the novel S. erythraea strain.  The group 
were able to identify two ‘unnatural’ macrolide compounds, 5-o-desosaminyl-tylactone 56 and 
5-o -glucosyl-tylactone 57, from the fermentation broth (Figure 19).52 
 
Figure 19: Structures of tylactone 55, 5-o-desoaminyl-tylactone 56 and 5-o-glucosyl-tylactone 57 
Thus, recombinant DNA technology allows the design and manipulation of biosynthetic 
pathways, to access novel ‘unnatural’ natural products.  Through the continued development 
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of this technology, the potential of such hybrid biosynthetic systems to generate high yields of 
novel compounds as new drug leads, will be realised.33,35,53 
 The Hidden Potential of Wild-Type Microorganisms  
 Genome Mining 
As evidenced by the metabolic engineering of the erythromycin A 10 producer, S. erythraea, 
mutant microbial strains have the potential to uncover new drug leads in the future. Genetic 
sequencing has also revealed the potential of well-studied, wild-type microbes to potentiate 
the generation of novel metabolites.  For example, S. coelicolor contains 16 cryptic biosynthetic 
gene clusters (BGCs), some of which are believed to encode novel compounds.4  It is probable 
that such cryptic BGCs are ‘silent’ under the constraints of laboratory cultivation.  Hence, the 
development of new cultivation techniques may activate cryptic BGCs, leading to the isolation 
of new secondary metabolites.  For example, examination of the genome of Aspergillus 
nidulans (A. nidulans) revealed the presence of multiple copies of genes encoding for 
anthranylate synthases, the function of which was previously unknown within A. nidulans.54  A. 
nidulans was cultured under 40 different conditions and the extracts analysed, which revealed 
the presence of new compounds in the extract where A. nidulans was grown by solid state 
fermentation on rice medium.  A scale-up of this fermentation led to the isolation of 4 novel 
compounds, including alkaloid 58 (Figure 20).54   
Alternatively, ‘silent’ BGCs may be activated through expression in mutant organisms using 
genomics.4  For example, genetic sequencing of Streptomyces avermitilis revealed sav76,  a 
gene encoding a terpene synthase, the function of which was previously unknown.  Cane and 
co-workers developed a synthetic sav76 gene which was incorporated into the heterologous 
host, E. coli, for over-expression of the recombinant SAV_76 protein.  Subsequent incubation 
of the purified SAV_76 protein led to the isolation of a novel compound, avermitilol 59 (Figure 
20).55  
 
Figure 20: Structures of alkaloid 58 and avermitilol 59 
Genome mining has led to the isolation of novel natural products via activation of previously 
silent BGCs, and advancements in recombinant DNA technology and cultivation methods to 
activate silent BGCs are likely to reveal new drug leads in the future.4,56 
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 Extremophiles and “Unculturables” 
To date, it is estimated that less than 1% of bacterial species and 5% of fungal species have 
been discovered.39 The identification of new species, such as microorganisms that grow in 
extreme environments (extremophiles), enables the isolation of new drug leads. For example, 
the novel anticancer compound, berkelic acid 60, was isolated from a fungus obtained from an 
acidic (pH 2.5), metal-contaminated lake (Figure 21).57  Berkelic acid 60 was shown to be 
active against the human ovarian cancer cell line, OVCAR-3, with a GI50 of 91 nM.57  
Berkelic acid 60 was isolated following laboratory cultivation of the natural product producing 
fungus.  However, many microorganisms cannot be grown under laboratory conditions, for 
example it is estimated that 99% of bacteria are uncultivatable, therefore efforts are underway 
to generate new cultivation techniques.  This is exemplified by the development of a method 
by Ling and co-workers, to grow otherwise uncultivatable soil bacteria in their natural habitat, 
in a diffusion chamber device known as the iChip.58 From a new bacterial species, Eleftheria 
terrae, Ling and co-workers isolated teixobactin 61, a novel compound which was active 
against Gram-positive bacteria, with an MIC of 0.25 µg mL-1 against MRSA (Figure 21).58 
 
Figure 21: Structures of berkelic acid 60 and teixobactin 61 
Thus, the discovery of new microbial species in combination with advancements in cultivation 
techniques, will potentially unearth new natural products for use as drugs.   
 Project Focus: Actinomycete Bacteria 
 Project Aims  
This project aims to investigate new antibacterial compounds from a novel actinomycete 
bacterium, Amycolatopsis DEM30355 (A. DEM30355), which was discovered in an extreme 
desert environment.59  We will focus on two secondary metabolites identified from the 
fermentation broth of A. DEM30355 - an ansamycin and a novel polyketide.  We will examine 
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the semi-synthesis of the ansamycin and the total synthesis of the polyketide, to develop new 
antibacterial drug leads. 
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Chapter 2. Isolation and Semi-Synthesis of DEM30355/B2 
 Introduction 
 Global Impact of Tuberculosis 
Tuberculosis (TB) is a global disease, affecting approximately one third of the population.  In 
most cases the infection is latent and asymptomatic, however an estimated 1 in 10 develop 
the active infection.60 In 2014, 9.6 million people were actively infected with TB and there were 
an estimated 500,000 cases of multi-drug resistant TB (MDR-TB).60 1.5 million people died 
from the disease in 2014 alone. 60 Of these deaths, 190,000 were attributed to MDR-TB.60 
 Treatment of Tuberculosis 
The nature of Mycobacterium tuberculosis (M. tuberculosis), the pathogen responsible for most 
human TB infections, makes the disease difficult to treat.61 After the initial infection, the bacteria 
are transported to the pulmonary tissue, where they develop into granuloma. 62   The granuloma 
prevent the bacterial infection from spreading, however they also protect the bacteria, allowing 
them to persist for an extended period of time.62  The ability of M. tuberculosis to enter a 
dormant state and evade antibacterial treatment leads to recurring infection and drug 
resistance.63 
The treatment of TB involves a combination of drugs that target bacteria in differing states of 
metabolic activity, over a period of months.  The standard treatment for non-resistant TB is a 
daily dose of ethambutol 62, pyrazinamide 63, isoniazid 64 and rifampicin 65 for the first two 
months, followed by daily doses of isoniazid 64 and rifampicin 65 alone for a further four 
months (Figure 22). The lengthy treatment regime for TB is often not completed and has 
contributed to the emergence of resistant strains.64 
 
Figure 22: Structures of the anti-TB drugs ethambutol 62, pyrazinamide 63, isoniazid 64 and rifampicin 65 
 Isoniazid 64 and Ethambutol 62 in the Treatment of Tuberculosis  
M. tuberculosis has a complex cell wall, which is highly hydrophobic and thus difficult to 
permeate.65 The two synthetic drugs, isoniazid 64 and ethambutol 62, target cell wall synthesis 
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in active M. tuberculosis bacteria (Figure 22).  Isoniazid 64 was discovered in 1952 and is a 
pro-drug which, upon activation, inhibits the biosynthesis of mycolic acid, a major component 
of the bacterial cell wall, leading to cell death. 64-66 In 42 – 58% of clinically isolated isoniazid-
resistant strains of M. tuberculosis, there is a mutation of the katG gene which encodes primary 
mycobacterial catalyse-peroxidase, the enzyme believed to be responsible for activating 
isoniazid 64 in non-resistant organisms.65  
Ethambutol 62 (Figure 22), introduced for the treatment of TB in 1966, prevents bacterial cell 
replication by interfering with arabinosyl transferases, which are responsible for the 
biosynthesis of arabinogalactan, another major component of the cell wall.66  In 65% of 
clinically isolated ethambutol-resistant bacteria, there is a mutant embB gene which encodes 
arabinosyl transferase.67   
 Pyrazinamide 63 and Rifampicin 65 in the Treatment of Tuberculosis 
The ability of M. tuberculosis to enter a dormant state whereby the bacterium has low metabolic 
activity and does not replicate, contributes to the difficulties encountered in eradicating the 
disease.61 Most antibiotic compounds only target pathways that are active in replicating 
bacteria, such as cell wall synthesis or DNA replication.  Pyrazinamide 63 (Figure 22), first 
reported in clinical use in 1952, is a synthetic pro-drug which specifically targets partially-
dormant bacteria residing within inflamed tissue.68,69 The bactericidal properties of 
pyrazinamide 63 are believed to arise from disruption of the bacterial cell membrane 
potential.69 Pyrazinamide 63 is converted to its active from, pyrazinoic acid, by pyrazinamidase 
within the bacterium and mutation of the pncA gene which encodes pyrazinamidase, gives rise 
to resistant strains.69 
Rifampicin 65 (Figure 22) is a bactericidal drug against active and semi-dormant bacteria and, 
in addition to pyrazinamide 63, significantly reduced the length of TB treatment from 12 -18 
months to 6 - 9 months.64  Rifampicin 65 is a semi-synthetic derivative of the bacterial natural 
product, rifamycin B.  In this project we aim to identify new drug leads to target rifampicin-
resistant (Rifr) strains of bacteria, therefore we will discuss the mode of action of this drug in 
more detail later. 
 Development of Rifampicin 65 
In 1957, Sensi and co-workers isolated rifamycin B 66 from the fermentation broth of Nocardia 
mediterranei, a species later reclassified as Amycolatopsis rifamycinica (Figure 23).70,71  
Rifamycin B 66 itself is not active against bacteria, but in aqueous oxygenated solutions, 
rifamycin B 66 undergoes oxidation to give rifamycin O 67, followed by  hydrolysis to rifamycin 
S 68 (Figure 23).70  Rifamycin S 68 in turn can be reduced to give rifamycin SV 69 (Figure 
23).The rifamycins S 68 and SV 69 were found to be excellent antibiotics, particularly against 
Chapter 2. Isolation and Semi-Synthesis of DEM30355/B2 
 
23 
 
Gram-positive bacteria, as well as M. tuberculosis.70 It is worth noting that, in biological 
systems, rifamycin S 68 and SV 69 are likely to exist in equilibrium with each other. 
 
Figure 23: Conversion of rifamycin B 66 to rifamycin SV 69 via rifamycin O 67 and rifamycin S 68 
The hydrochloride salt of rifamycin SV 69 was introduced for clinical use for the treatment of 
Gram-positive infections, but the drug was not orally active due to poor absorption in the 
gastrointestinal tract, and it was readily excreted from the body following parenteral 
administration.70 To improve the pharmacokinetic properties, an intensive programme of 
screening rifamycin derivatives for antibiotic activity ensued, which identified rifampicin 65 as 
a promising drug lead.   Rifampicin 65, a semi-synthetic analogue of rifamycin B 66, had 
significantly improved pharmacokinetics; it was active by oral administration and was not 
rapidly excreted from the body, leading to the approval of rifampicin 65 for clinical use by the 
FDA in 1971 (Figure 24).70 Rifampicin 65 and related rifamycin drugs, such as rifabutin 70, 
rifapentine 71 and rifalazil 72, are non-competitive inhibitors of bacterial RNA polymerase 
(RNAP), an enzyme responsible for RNA synthesis (Figure 24).72  
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Figure 24: Structures of the rifamycin antibiotics rifampicin 65, rifabutin 70, rifapentine 71 and rifalazil 72 
 Project Background 
 Introduction to DEM30355/B2 
Our group collaborates with Demuris Ltd., a biology-based company which focuses on the 
identification of new antibiotic compounds from bacterial strains.  From the fermentation of a 
novel strain, Amycolatopsis DEM30355 (A. DEM30355), Demuris identified a new antibiotic 
compound, DEM30355/B1, which appeared to react in the presence of oxygen to give the 
related compound, DEM30355/B2.59  DEM30355/B2 was active against a range of Gram-
positive bacteria (Dr B. Kepplinger).   An X-ray crystal structure was obtained which suggested 
DEM30355/B2 was the previously isolated compound, kanglemycin A 73, a structural relative 
of rifampicin 65 (Figure 25).59,73 
 
Figure 25: Structure of DEM30355/B2 73 (kanglemycin A) 
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An in vitro enzyme inhibition assay was carried out (L. Ceccaroni), which compared the activity 
of DEM30355/B2 73 and rifampicin 65 against wild type and mutant rifampicin-resistant (Mut 
Rifr) RNAP derived from E. Coli (Figure 26). 
 
Figure 26: Results of an in vitro enzyme inhibition assay comparing the inhibition activities of DEM30355/B2 73 
and rifampicin 65 against wild type and mutant rifampicin-resistant RNAP, derived from E. coli.  Gel 
electrophoresis was used to monitor the production of RNA and thus the activity of RNAP.  The black bands 
correspond to RNA, indicative of no inhibition of RNAP 
Interestingly, DEM30355/B2 73 showed much better activity against Mut Rifr RNAP (inhibition 
observed at 10 µg/mL) than rifampicin 65 (Figure 26). 
 Mode of Action of Rifampicin 65 
Studies have shown that rifampicin 65 binds to the β-subunit region of RNAP, the core of which 
is highly conserved within bacterial species.74,75  Campbell et al. solved the crystal structure of 
rifampicin 65 bound in Thermus aquaticus RNAP, illustrating the regions of rifampicin 65 
important for binding in the β-subunit (Figure 27).74,76 Structure activity relationship (SAR) 
studies have shown that the hydroxyl groups at C8, C21 and C23 are important for activity.77,78   
 
Figure 27: Left - crystal structure of rifampicin 65 bound to the RNAP β-subunit.76   Right – schematic drawing of 
the interactions of rifampicin 65 with residues in the RNAP β-subunit:  red = hydrogen bonding; blue = van der 
Waals interactions.   RNAP residues are reported as in T. aquaticus RNAP.  The parenthesis report the 
corresponding RNAP residues as in E. coli RNAP.  The most common mutations leading to Rifr M. tuberculosis 
occur in the residues shown in pink76 
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Genetic mutations are more likely to persist if the result of the mutation does not affect the 
normal functioning of the organism.  The β-subunit of bacterial-dependent RNAP is an 
allosteric site, therefore mutations in this region are well tolerated by the bacterium.  
Rifampicin-resistance commonly arises from single-point mutations in the rpoB gene which 
encodes the RNAP β-subunit; 96% of clinically isolated Rifr strains of M. tuberculosis contain 
a mutated rpoB, with the most common mutations (shown in pink Figure 27) being missense 
mutations at serine 531 (43% of cases) and histidine 526 (36% of cases).79 
Assuming that DEM30355/B2 73 also binds to the β-subunit of bacterial-dependent RNAP, we 
must question why DEM30355/B2 73 shows improved activity compared to rifampicin 65 
against Mut Rifr RNAP. 
 Comparison of DEM30355/B2 73 and Rifampicin 65 
If we compare the structures of DEM30355/B2 73 and rifampicin 65 (not including the imine 
group at C3 of rifampicin 65 that is introduced through semi-synthetic modification of rifamycin 
S 68), we can see that the two molecules share the same ansamycin core (Figure 28).  
DEM30355/B2 73 has three additional groups: a deoxy-sugar moiety at C27, an ester group at 
C31 and a methyl group at C31 in place of an O-methoxy group and two protons respectively in 
rifampicin 65.   
 
Figure 28: Comparison of the structure of DEM30355/B2 73 with rifampicin 65 
Consequently, we postulate that the deoxy-sugar and ester group may offer additional binding 
points in the RNAP β-subunit, through H-bonding and/or van der Waals interactions with the 
groups in this region, leading to the observed activity of DEM30355/B2 73 against Rifr RNAP 
derived from E. coli in the in vitro enzyme inhibition assay (Figure 26).  
 Project Aims 
Due to this observed activity of DEM30355/B2 73 against Rifr RNAP and the importance of 
identifying new treatments against Rifr strains of M. tuberculosis, we will target new drug leads 
via semi-synthetic modification of DEM30355/B2 73.  
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In this project we aim to: 
 Confirm the proposed structure of DEM30355/B2 73 though assignment of the NMR 
data.  
 Develop an efficient isolation protocol to access pure DEM30355/B2 73 from the crude 
fermentation isolate of A. DEM30355. 
 Synthesise new analogues of DEM30355/B2 73 for SAR studies and to identity new 
antibacterial drug leads. 
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 Results and Discussion 
 Structural Assignment of DEM30355/B2 73 
A large scale fermentation of A. DEM30355 was carried out at the Centre for Process 
Innovation (CPI).  The fermentation was harvested and subjected to downstream processing 
by Dr B. Kepplinger.  In preliminary work on the isolation of DEM30355/B2 by Dr B. Kepplinger, 
a crystal structure was obtained, which suggested DEM30355/B2 was the previously isolated 
compound, kanglemycin A 73 (Figure 29).73   
 
Figure 29: Crystal structure of DEM30355/B2 73 and R/S assignment of the stereocentres59 
Due to the structural similarities between our proposed structure of DEM30355/B2 73 with the 
rifamycins, it is likely the two share a similar biosynthetic pathway.  It is known that a mixture 
of rifamycins is isolated from fermentation of the producing bacteria, A. rifamycinica, therefore 
we had reason to suspect that isolated DEM30355/B2 may also contain a mixture of related 
compounds.80  We planned to use NMR analysis to determine whether the bulk DEM30355/B2 
sample was consistent with the X-ray-determined structure 73 (Figure 29).   
DEM30355/B2 73 was provided by Dr B. Kepplinger and a 1H NMR spectrum of the sample in 
deuterated DCM was collected (Figure 30). 
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Figure 30: 1H NMR spectrum of DEM30355/B2 73 prior to size-exclusion chromatography 
The 1H NMR spectrum showed the sample was contaminated with a number of molecules.  
Complex peaks were observed at ~3.5 ppm, indicating the presence of other metabolites, such 
as polypeptides (Figure 30). 
To remove these impurities, the sample was subjected to size-exclusion column 
chromatography (LH20 in methanol) and the resultant material analysed by 1H NMR in 
deuterated DCM (Figure 31). 
 
Figure 31: 1H NMR spectrum of pure DEM30355/B2 73 following size-exclusion chromatography 
At this stage, analysis showed the sample was sufficiently pure to collect additional NMR data 
for structure confirmation.  Therefore we conducted further NMR experiments on 
DEM30355/B2 and attempted to map the observed data onto the X-ray-derived structure 73, 
to determine if the two were consistent.  
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 1H and 13C NMR Assignment of DEM30355/B2 73 
Herein we will present the key NMR data of DEM30355/B2 73 which were important for our 
structural assignment.  Upon examination of the 1H NMR spectrum, two distinctive signals 
were apparent at 2.66 ppm (1H, d, J = 16.8 Hz) and 2.54 ppm (1H, d, J = 16.8 Hz), which 
implied a geminally coupled methylene group, assigned as C35H2.  The HMBC spectrum 
showed correlations (shown in red, Figure 32) from the proton signals at 2.66 and 2.54 ppm, 
to two carbonyl carbon signals at 172.0 ppm (C33) and 176.0 ppm (C36), and a geminal dimethyl 
group (C34).  In conjunction with a key HMBC correlation (shown in blue, Figure 32) which was 
observed from a proton signal at 5.07 ppm (1H, app q, J = 6.4 Hz), corresponding to C31H, to 
the carbon signal at 176.0 ppm (C33), we were able to assign the C31 – C36 fragment of 
DEM30355/B2 73 shown below. 
 
Figure 32: 1H and 13C NMR assignment of the C31 – C36 fragment of DEM30355/B2 73.  Selected HMBC and 
COSY interactions are shown 
An important HMBC correlation (shown in blue, Figure 33 (a)) was observed from the proton 
signal at 5.07 ppm (C31H) to a carbon signal at 52.4 ppm (C20).   A COSY interaction (shown 
in blue, Figure 33 (b)) was observed between a proton signal at 2.17 ppm (1H, app t, J = 9.7 
Hz), corresponding to C20H, and a signal at 5.83 ppm (1H, dd, J = 9.7 Hz), corresponding to 
C19H.  Further COSY interactions (shown in green and pink, Figure 33 (b)) enabled us to 
deduce C19H was part of a butadiene moiety.  We observed HMBC correlations (shown in 
green, Figure 33 (a)) between a signal at 5.97 ppm (1H, dd, J = 15.9, 6.2 Hz), corresponding 
to C18H of the butadiene group, and a carbon signal at 171.0 ppm (C15).  Furthermore, a HMBC 
correlation (shown in red, Figure 33 (a)) was observed between the carbonyl signal at 171.0 
ppm (C15) and a broad, singlet proton signal at 8.35 ppm, suggesting an amide group.  Based 
on these data, we assigned the C15 – C20 fragment of DEM30355/B2 73 shown below. 
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Figure 33: 1H and 13C NMR assignment of the C15 – C20 fragment of DEM30355/B2 73.  Key HMBC (a) and 
COSY (b) interactions are shown  
In the HMBC spectrum, there were correlations (shown in red, Figure 34) from the proton signal 
at 8.35 ppm (amide NH) to two carbonyl carbon signals at 184.3 ppm (C1) and 185.3 ppm (C4).  
Further HMBC correlations (shown in blue, Figure 34) were observed from a proton signal at 
7.80 ppm (1H, s) corresponding to aromatic C3H, to the carbon signals at 184.3 ppm (C1) and 
185.3 ppm (C4).  In addition, HMBC correlations (shown in green, Figure 34) were detected 
from a proton signal at 2.34 ppm (3H, s), associated with C14H3, to six carbon signals in the 
aromatic region.  One of these aromatic carbon signals at 131.5 ppm, assigned to the 
quaternary carbon signal at C10, was HMBC correlated (shown in blue, Figure 34) with the 
proton signal at 7.80 ppm (C3H).  This suggested a 1,4-naphthoquinone moiety.  Using the 
observed data, we assigned the C1 – C10 fragment of DEM30355/B2 73 shown below. 
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Figure 34: 1H and 13C NMR assignment of the C1 – C10 fragment of DEM30355/B2 73.  Selected HMBC 
correlations are shown 
If we return to the proton signal at 2.17 ppm (C20H), we observed a COSY interaction (shown 
in orange, Figure 35 (b)) between this signal and a proton signal at 3.70 ppm (1H, d, J = 10.1 
Hz), corresponding to C21H.  We observed HMBC correlations (shown in brown, Figure 35 (a)) 
from the signal at 3.70 ppm (C21H) in the 1H spectrum to signals corresponding to the carbon 
atoms in a branched hydrocarbon chain.  The significant HMBC correlations were as follows; 
- A HMBC correlation (shown in orange, Figure 35 (a)) from a proton signal at 3.86 ppm (1H, 
dd, J = 9.1, 3.0 Hz), corresponding to C27H, to a carbon signal at 96.8 ppm, associated with 
C44.  
- A HMBC correlation (shown in green, Figure 35 (a)) from a proton signal at 4.39 ppm (1H, d, 
J = 9.9 Hz) corresponding to C25H, to a quaternary carbon signal at 173.6 ppm (C41), 
corresponding to the carbonyl carbon atom of an acetoxyl group.    
In addition, the 1H NMR spectrum contained signals at 5.14 ppm (1H, d, J = 12.8 ppm) and 
6.37 ppm (1H, d, J = 12.8 ppm), corresponding to two vicinally coupled alkene protons (C28H 
and C29H).  An important HMBC correlation (shown in blue, Figure 35 (a)) was detected from 
the proton signal 6.37 ppm (C29H) to a carbon signal at 23.1 ppm (C13).  In combination with 
key HMBC correlations (shown in red, Figure 35 (a)) from a proton signal at 1.68 ppm (3H, s), 
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associated with C13H3, to two quaternary carbon signals at 193.5 ppm (C11) and 109.3 ppm 
(C12), we assigned the C11 - C13 and C20 - C29 fragments of DEM30355/B2 73 shown below.    
 
Figure 35: 1H and 13C NMR assignment of the C11 - C13 and C20 - C29 fragments of DEM30355/B2 73. Key HMBC 
(a) and COSY (b) interactions are shown 
In the COSY spectrum of DEM30355/B2 73, starting from a proton signal at 4.66 ppm (C44H), 
we observed COSY interactions (shown in black, Figure 36 (b)) that were characteristic of a 
cyclic structure.  In addition, we observed HMBC correlations (shown in green, Figure 36 (a)) 
from two proton signals at 5.13 ppm (1H, s) and 4.87 ppm (1H, s), corresponding to C47H2, and 
carbon signals at 75.5 ppm (C48) and 74.3 ppm (C46).  Thus we were able to assign the deoxy-
sugar fragment from C44 – C50 of DEM30355/B2 73 shown below. 
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Figure 36: 1H and 13C NMR assignment of the C44 – C50 fragment of DEM30355/B2 73.  Key HMBC (a) and 
COSY (b) interactions are shown 
The NMR analysis of DEM30355/B2 was consistent with our proposed structure as determined 
by X-ray analysis, confirming that the bulk material isolated was kanglemycin A 73 (Figure 37).   
Thus we chose to continue to investigate this system as a starting point for semi-synthesis, to 
develop new anti-tuberculosis compounds for medical application in the future.  To adhere to 
this aim, we needed to isolate more DEM30355/B2 73 from the crude isolate of A. DEM30355.  
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Figure 37: 1H NMR spectrum of DEM30355/B2 73 
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 Isolation of DEM30355/B2 73 from the Crude Isolate of Amycolatopsis DEM30355 
The next step was to develop an efficient isolation protocol to access DEM30355/B2 73 in a 
high purity for use in our semi-synthetic approach to new bioactive variants.  We were supplied 
with crude isolate from the fermentation of A. DEM30355, which had been pre-processed by 
Dr B. Kepplinger following the procedure below, to concentrate the bioactive material in 
preparation for isolation (Figure 38).  
 
Figure 38: Pre-processing procedure carried out by Dr B. Kepplinger on the crude isolate of A. DEM30355 
This crude isolate contained a mixture of DEM30355/A (see Chapter 3) and DEM30355/B2 73 
along with a number of other secondary metabolites.  Several isolation protocols were 
developed in conjunction with Dr B. Kepplinger and Dr J. Cowell, focussing on the purity of the 
isolated DEM30355/B2 73, the isolation of associated natural products and the efficiency of 
the isolation procedure.   During our purifications, a mixture of 1H NMR, TLC, HPLC and 
bioassay were used as appropriate to monitor the presence and purity of the bioactives of 
interest.  Here we will present a representative isolation protocol, focussed on the efficient 
production of DEM30355/B2 73, which was developed independently (for further information 
on isolation protocols see Chapter 5).   
A sample of crude isolate (4.420 g) was subjected to normal phase column chromatography 
(eluent: gradient 100% ethyl acetate to 100% methanol, buffered with 0.1% formic acid), to 
remove lipid residues (Figure 40).  From here, a second normal phase chromatography step 
(eluent: gradient 100% diethyl ether to 100% ethyl acetate then 100% methanol) was used to 
separate the two main bioactive compounds present, DEM30355/A and DEM30355/B2 73.  At 
this point it was necessary to carry out an additional procedure to further purify the sample 
containing DEM30355/B2 73.  We envisaged that the carboxylic acid group at C36 could be 
used to aid the purification procedure, through use of an acid/base extraction (Figure 39).  
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Figure 39: Reversible formation of water-soluble carboxylate anion from organo-soluble carboxylic acid of 
DEM30355/B2 73 
Thus the sample was dissolved in toluene and DEM30355/B2 73 was extracted into aqueous 
5% NaHCO3 solution, with the non -polar impurities remaining in the organic layer.  Following 
acidification of the aqueous layer, DEM30355/B2 73 was recovered through extraction with 
ethyl acetate (Figure 40).  
 
Figure 40: Isolation of pure DEM30355/B2 73 from the crude fermentation isolate of A. DEM30355 
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Following this protocol, DEM30355/B2 73 (0.102 g) was isolated in a 3% overall yield with 
respect to the mass of the crude isolate.  At this stage DEM30355/B2 73 was suitably pure for 
use in our planned semi-synthesis work, however if required, a late stage size exclusion 
column chromatography step could be used to further improve the purity of DEM30355/B2 73 
(Figure 40). 
With a successful large scale isolation protocol developed and a sufficient quantity of purified 
DEM30355/B2 73 in hand (~150 mg), we began the examination of semi-synthetic approaches 
to the modification of DEM30355/B2 73, for the development of a SAR model against Rifr 
RNAP.  We ultimately aimed to synthesise derivatives of DEM30355/B2 73 to identify new drug 
leads for the treatment of Rifr infection, including Rifr M. tuberculosis infection. 
 Structure Activity Relationship Studies of the Rifamycins  
An extensive SAR study of the rifamycins was conducted by Wehrli and Staehelin.77,78  Prior 
to this study, it was found that rifamycin B 66 did not possess antibacterial activity.70  However 
antibacterial activity was observed if the free carboxylic acid of rifamycin B was ‘blocked’, for 
example through conversion to an amide 74 (Figure 41).81  
 
Figure 41: Structures of rifamycin B 66 and antibacterial rifamycin B derivative 74 
Interestingly in Wehrli and Staehelin’s study, it was found that rifamycin B 66 inhibited bacterial 
–dependent RNAP (E. coli) in an in vitro enzyme inhibition assay.77 They suggested that the 
polar carboxylic acid group of rifamycin B 66 prevents permeation of the molecule through 
bacterial membranes, thus preventing the compound from reaching RNAP in vivo.77     
In general, Wehrli and Staehelin found that any modification to the ansamycin chain of the 
rifamycins (reduction and epoxidation of the C=C bonds, acetylation of the hydroxyl groups 
and cleavage of the chain) resulted in reduced inhibition activity against RNAP (E. coli) (Figure 
42).  For example, with rifamycin SV 69 the percentage inhibition activity of RNAP was > 90% 
at 0.6 µg/mL.  This was reduced to 50% at the same concentration, in the rifamycin derivative 
where all three C=C bonds were saturated.  No inhibition activity was observed in the derivative 
whereby the ansamycin chain had been cleaved at C12.77,78 
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In addition, it was found that functionalisation at C3 and substitution of the OH at C4 were well 
tolerated, and led to improved RNAP inhibition (Figure 42).  The exception was that 
introduction of a bulky 3-barbiturate group at C3 caused low RNAP inhibition activity (30% at 
0.6 µg/mL), likely the result of a change in conformation of the ansamycin chain.   Furthermore, 
the study showed that rifamycin S 68 (quinone form) and rifamycin SV 69 (hydroquinone form) 
were equally active, with >90% inhibition of RNAP observed at 0.6 µg/mL.  Wehrli and 
Staehelin also found that the OH groups at C8, C21 and C23 were important for RNAP inhibition, 
as acetylation of these hydroxyl groups led to diminished activity (Figure 42).77,78 
 
Figure 42: SAR study of the rifamycins77 
 Planned Semi-Synthetic Modifications of DEM30355/B2 73 
We were interested in the synthesis of bioactive DEM30355/B2 derivatives therefore, with 
consideration of the results from the SAR study on the rifamycins, we planned to conduct semi-
synthetic modifications of DEM30355/B2 73 which would not alter the ansamycin chain.77,78  
Instead we would focus on modifications which had enhanced the activity of the rifamycins, 
namely functionalisation at C3 and substitution of the oxygen at C4 of DEM30355/B2 73 (Figure 
43). 
As discussed previously (see section 2.2.3), DEM30355/B2 73 contains additional groups in 
comparison to the rifamycins, namely a deoxy-sugar moiety at C27 as well as a methyl and an 
ester group at C31.  We postulated that these additional groups may have been responsible for 
the observed activity of DEM30355/B2 73 against Rifr RNAP.  To test this theory, we planned 
to examine removal of the deoxy-sugar moiety at C27 and the C33-C36 fragment of 
DEM30355/B2 73 via acetal hydrolysis and ester hydrolysis respectively (Figure 43).  
In addition, we would investigate methods to “block” the free carboxylic acid group at C36 of 
DEM30355/B2 73, to examine the effect on RNAP inhibition and in vivo bioassay studies 
against pathogenic bacteria (Figure 43).  We postulated that removal of the free carboxylic 
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acid at C36 may improve the pharmacokinetic properties of the DEM30355/B2 derivatives, for 
the same reasons as described previously (see section 2.3.3) with regards to rifamycin B 66. 
 
Figure 43: Planned semi-synthetic modifications of DEM30355/B2 73 
 Semi-Synthesis of Rifamycin S 68  
Given the limited availability of the starting material, DEM30355/B2 73, we would first test our 
planned semi-synthetic modifications on the structurally related ansamycin, rifamyicin S 68, 
which was readily available through oxidation of commercially available rifamycin SV Na salt 
75. 
 Conversion of Rifamycin SV Na Salt 75 to Rifamycin S 68 
Thus rifamycin SV Na salt 75 was dissolved in water and the solution was acidified with 
hydrochloric acid (2 M).  The resultant red precipitate, rifamycin SV 69, was isolated by 
filtration. In a second step, potassium hexacyanoferrate (III) was used to oxidise rifamycin SV 
69 to rifamycin S 68 (Figure 44).70  
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Figure 44: Conversion of rifamycin SV Na salt 75 to rifamycin SV 69 then rifamycin S 68 
Following solvent extraction, rifamycin S 68 was obtained in a 97% yield over the two steps    
(Note: if desired, rifamycin S 68 can be reduced to rifamycin SV 69 with ascorbic acid).70 
With a sufficient quantity of rifamycin S 68 in hand, we moved on to investigate semi-synthetic 
modification of the compound.  The aim was to optimise the chemistry to aid in the future semi-
synthetic modification of DEM30355/B2 73, of which we had a very limited supply. 
 Functionalisation at C3 of Rifamycin S 68  
The SAR study by Wehrli and Staehelin indicated that functionalisation of position C3 in the 
rifamycins led to improved activity against RNAP derived from E. coli.77,78 Thus 
functionalisation of the analogous position in DEM30355/B2 73 was a key objective in our 
planned semi-synthetic modifications to target bioactive DEM30355/B2 derivatives.  There 
have been many reported procedures for the functionalisation of C3 in rifamycins S 68 and SV 
69, however the experiments were conducted on gram scales.82-84 We needed to optimise the 
chemistry for use on the milligram scale, as suitable for our future reactions with DEM30355/B2 
73.   
A range of reaction conditions was screened in order to examine functionalisation of rifamycin 
S 68 at the C3 position of the naphthoquinone ring.  In each case, TLC was used to monitor 
the reaction, with 1H NMR and/or mass spectrometry used to identify any new products formed 
(Figure 45). 
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Figure 45: Reactions examined to generate rifampicin 65 via semi-synthetic modification of rifamycin S 68 
We also examined halogenation of the C3 position through the reaction of rifamycin S 68 or SV 
69 with iodine in pyridine, tetrabutylammonium bromide and NBS, however only starting 
material 68 or 69 was recovered in each case.85 
 Synthesis of Rifamycin Mannich Bases 76 - 78  
In our reactions we focused on the synthesis of rifampicin 65, as in future we wanted to apply 
the same chemistry to generate the rifampicin analogue of DEM30355/B2 73, for a direct 
comparison of the biological activity. There was literature precedent to suggest that Mannich 
bases 76 – 78 (blue box, Figure 45) could be converted in two steps to rifampicin 65, via 
oxidation to 3-formyl rifamycin 79 (green, Figure 45) then condensation with 1-amino-4-
methylpiperazine 80.83 
To synthesise Mannich bases 76 - 78, rifamycin S 68 (1 eq.) was reacted with formaldehyde 
(3 eq.) and a chosen secondary amine (2 eq.) in THF (blue arrow, Figure 45).82 In each case 
the crude material was purified by column chromatography and analysed by mass 
spectrometry.  The mass spectra showed peaks corresponding to desired products 76 – 78, 
therefore we deduced the reactions were successful. The best yield of the Mannich product 
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was obtained from the reactions using pyrrolidine and diethylamine as the nucleophile (blue 
Table, entries 1 and 2, Figure 45).  The poor yield of morpholino derivative 78 (blue Table, 
entry 3, Figure 45) was the result of the compound’s instability towards silica gel 
chromatography. 
With a successful route to Mannich bases 76 – 78 developed, we moved on to examine 
oxidation reactions to generate 3-formyl rifamycin 79. 
 Synthesis of 3-Formyl Rifamycin SV 79  
To synthesise 3-formyl rifamyicin 79 (green, Figure 45), Mannich bases 76 – 78 (blue, Figure 
45) were screened under a range oxidising conditions using potassium hexacyanoferrate (III), 
manganese dioxide, ceric ammonium nitrate (CAN), n-amyl nitrite and lead(IV) acetate (Figure 
45).83  However in each case the starting material was recovered.  As an alternative method, 
we examined a Vilsmeier acylation of rifamycin SV 69, however no product 79 was formed and 
starting material 69 decomposed (Figure 45).  At this stage we chose to examine a different 
route to the synthesis of rifampicin 65. 
 One-Pot Synthesis of Rifampicin 65 from Rifamycin S 68  
There was literature precedent to suggest that rifampicin 65 could be prepared in a one-pot 
procedure from rifamycin S 68.86 
Rifamycin S 68 (1 eq.) was reacted with tert-butylamine (1.4 eq.) and an excess of 
paraformaldehyde in DMF, in the presence of acetic acid (3.7 eq.) (red arrow, Figure 45).  After 
3 hours at 50 °C, 1-amino-4-methylpiperazine 80 was added, and the reaction continued for a 
further hour at 50 °C. 86 
 The 1H NMR spectrum of the crude material showed disappearance of the signal at 7.58 ppm 
corresponding to C3H in rifamycin S 68, and new signals were apparent at 3.24 - 3.04 ppm 
(4H, m) and 2.57 ppm (4H, m) which suggested four CH2 groups.  Therefore we could deduce 
that desired rifampicin 65 had been generated in the reaction.  This was subsequently isolated 
following column chromatography in a 52% yield (70 µmol scale).  It was found that the isolated 
yield of rifampicin 65 was dependent on the scale of the reaction (red Table, Figure 45). 
After successfully generating Mannich bases 76 – 78 and rifampicin 65 from semi-synthetic 
modification of rifamycin S 68, we moved on to apply the same chemistry to synthesise 
derivatives of DEM30355/B2 73. 
 Semi-Synthetic Investigations of DEM30355/B2 73 
Our aim was to generate semi-synthetic derivatives of DEM30355/B2 73, a structural relative 
of rifamycin S 68, to target new drug leads against rifampicin-resistant (Rifr) strains of bacteria.  
One of our targeted derivatives was the DEM30355/B2 rifampicin analogue, to allow 
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comparison of the antibacterial activity of rifampicin 65 and the DEM30355B2 analogue against 
both rifampicin susceptible and Rifr bacteria.   
 Synthesis of the DEM30355/B2 Rifampicin Analogue 81 
To synthesise rifampicin DEM30355/B2 analogue 81, we planned to use the same synthetic 
procedure we had developed for the small scale synthesis of rifampicin 65 from rifamycin S 68 
(Figure 46).86  
DEM30355/B2 73 was reacted with tert-butylamine and an excess of paraformaldehyde in 
DMF, followed by addition of 1-amino-4-methylpiperazine 80 (Table 1). 
 
Figure 46: Reaction scheme to synthesise DEM30355/B2 rifampicin analogue 81 from DEM30355/B2 73 
Table 1: Reaction conditions examined to synthesise DEM30355/B2 rifampicin analogue 81 from DEM30355/B2 
73 
 
In the first experiment, we employed the same reaction conditions that were previously used 
to synthesise rifampicin 65 from rifamycin S 68.  Analysis of the crude reaction material by 
mass spectrometry showed no peaks corresponding to desired product 81 and DEM30355/B2 
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73 was recovered (Table 1, entry 1).  We hypothesised this may be a concentration issue as 
a result of the small reaction scale, therefore the concentration was increased 2.5 fold 
compared to the initial experiment (Table 1, entry 2).  Once again unreacted starting material 
73 was recovered.  Increasing the reaction time (Table 1, entry 3) and increasing the 
equivalencies of the reactants (including paraformaldehyde) (Table 1, entry 4) also did not 
result in product 81 as shown by mass spectrometry and 1H NMR analysis of the crude 
material. 
There are several explanations as to why DEM30355/B2 rifampicin analogue 81 was not 
isolated in the reactions we tested.  DEM30355/B2 73 is more polar than rifamycin S 68 for 
which this chemistry was optimised, due to the presence of the carboxylic acid.  With access 
to more DEM30355/B2 73, in future we would examine using a more polar aprotic solvent like 
DMSO, which may be required to sufficiently solvate DEM30355/B2 73, to allow the desired 
reaction to occur.  However, given our limited supply of DEM30355/B2 73 and the time 
constraints, optimisation of this route to generate desired analogue 81 was not feasible, 
therefore we decided to investigate alternative semi-synthetic modifications.  
 Synthesis of DEM30355/B2 Rifalazil Analogue 82 
Rifalazil 72 is an alternative semi-synthetic rifamycin antibiotic, which has been shown to be 
up to 64 times more active against TB infections than rifampicin 65 (Figure 22).87  In addition, 
rifalazil 72 is active against certain strains of Rifr M. tuberculosis, although a large proportion 
of Rifr bacterial strains remain resistant to all the rifamycin antibiotics.88  
 
Figure 47: Structure of rifalazil 72 
We aimed to synthesise rifalazil DEM30355/B2 analogue 82, for comparative bioassay studies 
against pathogenic bacteria (Figure 48).  DEM30355/B2 73 was reacted with aminophenols 
83 and 84, followed by an oxidative work-up (Table 2).89  The reactions were monitored by TLC 
and the crude material was analysed using mass spectrometry.  
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Figure 48: Reaction scheme to synthesise DEM30355/B2 rifalazil analogue 82 from DEM30355/B2 73 
Table 2: Reaction conditions examined to synthesise DEM30355/B2 rifalazil analogue 82 from DEM30355/B2 73 
 
In the first reaction we tested using 2-amino rescorcinol hydrochloride 83 (R = OH), no reaction 
was observed by TLC after a lengthy reaction time (Table 2, entry 1).  Increasing the 
equivalencies of 2-amino recorcinol 83 also did not result in an observed reaction by TLC, and 
starting material 73 was recovered (Table 2, entry 2).  There was literature precedent to 
suggest that the presence of two hydroxyl units in the nucleophile 83 may result in a redox 
reaction generating hydroquinone DEM30355/B2.90 Therefore we changed the nucleophile to 
2-amino phenol 84, however once again no product 82 was observed by TLC or through mass 
spectrometry analysis, and starting material 73 was recovered (Table 2, entry 3). 
In future, we would examine alternative nucleophiles to generate rifalazil analogue 82, however 
given the time constraints and limited starting material 73 supply, we decided to investigate 
different modifications.  
 Acidic and Basic Hydrolysis of DEM30355/B2 73  
We hypothesised that the observed inhibitory activity of DEM30355/B2 73 against Rifr RNAP 
(taken from E. coli) may be the result of additional stability induced by H-bonding and/or van 
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der Waals interactions with the deoxy-sugar moiety of DEM30355/B2 73 at C27 (Figure 49).  
To test this theory, we wanted to generate derivatives of DEM30355/B2 73 without the deoxy-
sugar group in place for SAR studies.   
To remove the deoxy-sugar group at C27, we planned to cleave the acetal unit that connected 
the sugar to DEM30355/B2 73.  DEM30355/B2 73 was reacted under acidic and basic 
hydrolysis conditions and the crude material analysed by mass spectrometry for new product 
peaks (Table 3).  We anticipated that hydrolysis may affect other groups of DEM30355/B2 73, 
so we included these masses in our search (Figure 49).  In each case an excess of the acid or 
base was used.  
 
Figure 49: Reaction scheme showing the possible areas of DEM30355/B2 affected by the reaction of 
DEM30355/B2 73 with acid or base 
Table 3: Reaction conditions examined in the hydrolysis of DEM30355/B2 73 
 
The mass spectra of the crude material from the initial reactions using NaOH and pTSA 
showed no peaks corresponding to starting material 73 (Table 3, entries 1 and 2).  Peaks with 
a lower mass than DEM30355/B2 73 were evident, however these did not correspond to our 
targeted product(s).  We repeated the reaction with pTSA using a shorter reaction time (Table 
3, entry 3).  In this case we observed peaks corresponding to starting material 73 and 
hydrolysis product 85, where the sugar group of DEM30355/B2 73 had been cleaved (Figure 
50). 
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Figure 50: Structure of DEM30355/B2 derivative 85 associated with a peak at m/z 862.3 [M+Na]+ in the mass 
spectrum 
In future, with access to more DEM30355/B2 73, we would optimise this reaction and isolate 
derivative 85, to allow further characterisation to be carried out. 
 Synthesis of DEM30355/B2 Derivative 86 via EDCI Coupling     
We aimed to block the free carboxylic acid group of DEM30355/B2 73, to determine the effect 
on the antibacterial activity of the compound.  We anticipated this may be achieved through 
EDCI coupling of DEM30355/B2 73 to generate amide 86 (Figure 51). 
DEM30355/B2 73 (1 eq.) was reacted with EDCI (1.5 eq.) and 4-methoxybenzylamine (1.5 
eq.) in the presence of nucleophilic catalysts (Table 4).   
 
Figure 51: Reaction scheme for the synthesis of amide 86 from an EDCI coupling reaction of DEM30355/B2 73 
with 4-methoxybenzylamine 
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Table 4: Reaction conditions examined in the ECDI coupling reaction of DEM30355/B2 73 with 4-
methoxybenzylamine 
 
The crude reaction material from each experiment was analysed by mass spectrometry.  In 
each case, peaks corresponding to unreacted starting material 73 were observed.  However, 
in one experiment using hydroxybenzotriazole (HOBT), we also observed m/z peaks at 
1101.3* and 1123.4* corresponding to desired product 86 (Table 4, entry 2) (*Note: the masses 
stated have been corrected by -0.7 mass units, using the cluster of ions at [M+H]+, [M+Na]+ 
and [M-H+2Na]+ of DEM30355/B2 73 as a standard). 
With this promising result, we opted to scale up this reaction, to isolate a sufficient quantity of 
amide 86 for further analysis and bioassay, therefore the reaction was repeated using the 
same conditions, on a 5 fold larger scale. 
The 1H NMR spectrum of the crude material appeared to show signals corresponding to 
unreacted starting material 73 and a new product(s) (Figure 52).  
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Figure 52: Expansion of the 1H NMR spectra of DEM30355/B2 73 and the crude material from the EDCI reaction.  
Left – signals corresponding to the methyl groups of the ansa chain.  Right – signals corresponding to the CH2 
group next to the carboxylic acid    
The crude material was subjected to size exclusion chromatography (LH20 in methanol), 
followed by semi-preparative HPLC.  The HPLC spectrum showed a peak at 30 minutes 
corresponding to unreacted DEM30355/B2 73, and three new peaks at 18 minutes, 22 minutes 
and 28 minutes corresponding to unidentified products (Figure 53).   
 
Figure 53: HPLC trace of sample from EDCI reaction of DEM30355/B2 
Unfortunately the negative peak at 22 minutes was not recognised by the automated collection 
system, however the new peaks at 18 minutes and 28 minutes were collected and analysed 
by mass spectrometry (Figure 54).  
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Figure 54: Expansion of the mass spectra of sample-18 min and sample-28 min isolated by semi-preparative 
HPLC of the EDCI reaction material  
 
To our surprise, the mass spectra of both samples did not contain any peaks corresponding to 
desired product 86, only a peak at m/z = 1004.4, corresponding to [M+Na]+ of starting material 
73 (Figure 54).  This suggested that the signals in HPLC spectrum corresponded to 
DEM30355/B2 73 in a different oxidation state to the quinone form which appeared at 30 
minutes (Figure 53). 
This prompted us to consider that the apparently new signals we had observed in the 1H NMR 
spectrum of the crude material (Figure 52) may correspond to the hydroquinone form of 
DEM30355/B2. 
 Reduction of Quinone DEM30355/B2 73 to Hydroquinone DEM30355/B2 87 
To test this theory, DEM30355/B2 73 was reacted with an excess of the reductant, ascorbic 
acid, at room temperature to generate hydroquinone DEM30355/B2 87 (Figure 55).   
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Figure 55: Reduction of quinone DEM30355/B2 73 to hydroquinone DEM30355/B2 87 
After 1 hour, when TLC indicated the reaction was complete, the reaction mixture was 
extracted with ethyl acetate and the crude material analysed by 1H NMR.   
We compared the 1H NMR of the spectrum of DEM30355/B2 73 (quinone form), hydroquinone 
DEM30355/B2 87 and the crude material of the EDCI reaction (Figure 56).  Analysis of the 
spectra indicated the ECDI crude sample contained both hydroquinone DEM30355/B2 87 and 
quinone DEM30355/B2 73, which was consistent with our hypothesis.  However, a doublet 
peak at 0.4 ppm was observed, which did not correspond to either quinone DEM30355/B2 73 
or hydroquinone DEM30355/B2 87, suggesting the presence of a new product arising from the 
EDCI reaction.  
 
Figure 56: Expansion of the 1H NMR spectra of quinone DEM30355/B2 73, the crude material from the EDCI 
reaction and hydroquinone DEM30355/B2 87, in the region showing signals corresponding to the methyl groups 
of the ansa chain 
We postulate that redox chemistry of the naphthalene group of DEM30355/B2 73 may interfere 
with the EDCI reaction.  Therefore in future we would try conducting the reaction both in the 
presence of a reductant and an oxidant to render the naphthalene in one oxidation state, to try 
and push the EDCI reaction to completion.  Following optimisation of the reaction and isolation 
of amide 86, the sample would be subjected to bioassay, to identify any interesting biological 
activity. 
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 Synthesis of DEM30355/B2 Methyl Ester 88 
As an alternative to EDCI coupling to “block” the free carboxylic acid of DEM30355/B2 73, we 
investigated methylation of the carboxylic acid OH to give methyl ester 88 (Figure 57).  We 
reacted DEM30355/B2 73 (1 eq.) with TMS-diazomethane (4 eq.) in methanol.  
 
Figure 57: Methylation of DEM30355/B2 73 to synthesise methyl ester 88 
After a reaction time of 2 days, TLC showed DEM30355/B2 73 remained in the reaction mixture 
therefore a further 4 eq. of TMS-diazomethane were added.  After 4 days, TLC showed loss 
of starting material 73 and the reaction was quenched.  Following purification by column 
chromatography, the sample was analysed by NMR, which indicated a new product had been 
generated.  Through analysis of the HSQC spectrum, we were able to identify signals at 2.65 
ppm and 2.43 ppm corresponding to C35H2 in the new derivative of DEM30355/B2 (Figure 58).  
 
Figure 58: Expansion of the 1H NMR spectra of quinone DEM30355/B2 73, the new product from the methylation 
reaction and hydroquinone DEM30355/B2 87.  The highlighted signals correspond to C35-H, with JH35-H35 reported    
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The geminal coupling constant of the C35 proton at 2.65 ppm in the sample (J = 16.3 Hz) did 
not correspond to the analogous proton at C35 in either quinone DEM30355/B2 73 (J = 16.8 
Hz) or hydroquinone DEM30355/B2 87 (J = 16.6 Hz), suggesting a new DEM30355/B2 
derivative (Figure 58).  
The sample was analysed by High Resolution Mass Spectrometry (HRMS).  We were able to 
observe m/z peaks at 996.4 and 1018.4 corresponding to the [M+H]+ and [M+Na]+ ions 
respectively of singly-methylated product 88 (Figure 59).  
 
Figure 59: Expansion of the mass spectrum of methyl ester 88 showing m/z peaks corresponding to [M+H]+ and 
[M+Na]+ ions 
In future, we hope to scale up this reaction to obtain more methyl ester 88 for further analysis 
using NMR, to confirm our proposed structure. 
With this positive result, we examined other semi-synthetic modifications of DEM30355/B2 73. 
 Synthesis of Pyrrolidino DEM30355/B2 89 
In our preliminary work on the semi-synthesis of rifamycin S 68, we successfully synthesised 
Mannich bases 76 - 78 (see section 2.3.5).  The best reaction generated pyrrolidino rifamyicn 
76, in terms of yield and product stability.  Therefore we applied the same synthetic procedure 
to synthesise the analogous pyrrolidino DEM30355/B2 derivative 89 (Figure 60).82 
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DEM30355/B2 73 (1 eq.) was reacted with pyrrolidine (2 eq.) and formaldehyde (3 eq.) in THF.  
 
Figure 60: Mannich reaction of DEM30355/B2 73 to generate pyrrolidino DEM30355/B2 89  
After 24 hours at room temperature, TLC showed new spots in addition to starting material 73, 
and the reaction was stopped.  The crude material was initially purified by column 
chromatography; unreacted 73 was recovered and a new product was isolated.  Mass 
spectrometry analysis of the purified sample showed ions corresponding to desired product 
89, with a m/z peak at 1065.48 ([M-H]-), in addition to starting material 73.  To separate desired 
product 89 from DEM30355/B2 73, the sample was subjected to size-exclusion 
chromatography (LH20, methanol) and the resultant sample analysed by HPLC.  The HPLC 
spectrum contained three peaks at 24.7 minutes, 26.6 minutes and 27.0 minutes, suggesting 
a mixture of products (Figure 61).  
 
Figure 61: HPLC trace of the sample from the Mannich reaction of DEM30355/B2 following size-exclusion 
chromatography 
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We attempted to separate the mixture using semi-preparative HPLC.  The compound 
corresponding to the well resolved peak at 24.7 minutes was collected in one fraction, however 
the peaks at 26.6 and 27.0 minutes could not be separated and were collected together. 
The two fractions collected, sample-24.7 min and sample-26.6+27.0 min, were analysed by 
HRMS (Figure 62). 
 
Figure 62: Expansion of the mass spectra of sample-24.7 min and sample-26.6+27.0 min isolated following semi-
preparative HPLC 
The mass spectrum of sample-24.7 min showed a peak at 1067.5 m/z, corresponding to 
hydroquinone pyrrolidino product 89 (Figure 60).  The spectrum of sample-26.6+27.0 min, 
showed peaks at 1067.5 and 1065.5, consistent with pyrrolidino product in a mixture of the 
hydroquinone 89 and quinone 90 forms (Figure 63).   
 
Figure 63: Structure of hydroquinone pyrrolidino-DEM30355/B2 90 
Thus we could conclude we had isolated hydroquinone pyrrolidino-DEM30355/B2 89 (2.7 mg, 
2.5 µmol, 17% yield) and a mixed sample of quinone and hydroquinone pyrrolidino-
DEM30355/B2 89 and 90 (2.0 mg).  
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 Conclusions and Future Work 
Through analysis of extensive NMR data in combination with an X-ray structure (Dr B. 
Kepplinger), we have assigned DEM30355/B2 as kanglemycin A 73, which had previously 
been isolated.73 An in vitro enzyme inhibition assay indicated that DEM30355/B2 73 inhibited 
rifampicin-resistant (Rifr) RNAP derived from a mutant E. coli strain (L. Ceccaroni), therefore 
we aimed to generate analogues of this compound through semi-synthesis to identify new 
antibiotic drug leads. We have developed an efficient isolation protocol to access pure 
DEM30355/B2 73 in sufficient quantities (~150 mg) for semi-synthesis, through use of a key 
acid-base extraction 
The most successful procedure we examined to functionalise the C3 position of DEM30355/B2 
73 was a Mannich reaction using formaldehyde and pyrrolidine, to give Mannich bases 89 and 
90 (blue, Figure 64).  In addition, the most successful method to functionalise the free 
carboxylic acid group of DEM30355/B2 73 was to methylate using TMS-diazomethane, 
generating methyl-ester 88 (red, Figure 64). Derivatives 88, 89, and 90 are currently 
undergoing investigation to assess their inhibition activity against Rifr RNAP (H. M. Sejzi). 
 
Figure 64: Structures of DEM30355/B2 73 and the semi-synthetic derivatives methyl ester 88, hydroquinone 
Mannich base 89 and quinone Mannich base 90 
In the future, we would resume our efforts to synthesise rifampicin and rifalazil analogues of 
DEM30355/B2.  We anticipate that our previous attempts to functionalise the C3 position of 
DEM30355/B2 73 to synthesise these derivatives may have been hindered by unwanted side 
reactions involving the carboxylic acid.  Therefore we would protect the carboxylic acid of 
DEM30355/B2 as the methyl ester 88, then repeat the chemistry we have examined before, to 
generate analogues 91 and 92 (Figure 65). 
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Figure 65: Structures of future DEM30355/B2 73 semi-synthetic targets, methyl ester rifampicin analogue 91 and 
methyl ester rifalazil analogue 92 
We also considered that redox reactions of the naphthalene ring of DEM30355/B2 73 may 
have hindered the synthesis of rifampicin and rifalazil analogues 81 and 82 respectively, as 
well as amide 86 from the EDCI reaction (Figure 66).  Therefore in future, to target these 
derivatives, we would examine redox buffered reactions using a mild reductant or oxidant.  If 
this redox buffering approach was successful, we would apply the same method to synthesise 
halogenated derivatives 93, which may be used to generate other compounds through Pd 
cross-coupling.  
 
Figure 66: Structures of future DEM30355/B2 73 semi-synthetic targets, amide 86, rifampicin analogue 81, 
rifalazil analogue 82 and halogenated derivative 93 
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Chapter 3. Total Synthesis of the C and B Rings of DEM30355/A   
 Introduction to Total Synthesis  
Total synthesis (“Chem”-synthesis) is the construction of a natural product using chemical 
reactions, from commercially available starting materials.  In Chapter 1 we discussed the 
importance of total synthesis as a source of the natural product, discodermolide 16, a 
compound which could not be economically obtained through typical “Bio”-synthetic 
approaches, such as cultivating the natural-product producing organism (Figure 67).42,43  We 
also discussed the use of total synthesis to generate new drug leads, using analogues of 
spirotryprostatin A 28 which were made by total synthesis and showed inhibitory activity 
against two human cancer cell lines, as an example (Figure 67).46,47  
 
Figure 67: Structures of discodermolide 16 and spirotryprostatin A 28 
From a non-therapeutic point of view, the total synthesis of complex natural products, which 
often contain multiple stereocentres, is a worthwhile challenge to synthetic chemists.  Through 
the practice of total synthesis, many important synthetic techniques and theories have 
emerged, such as the Barton reaction, developed in the total synthesis of aldosterone, and the 
Woodward-Hoffman rules, sparked by observations in Woodward’s synthesis of vitamin B12.91-
94  In addition, total synthesis is a useful tool to elucidate the absolute stereochemistry of a 
compound.  For example, early total syntheses of both enantiomers of discodermolide 16 
revealed the absolute stereochemistry of the molecule, an important consideration for both 
target investigation and for subsequent manufacture of the compound for use in drug trials.95 
 Project Aims 
In this chapter we will discuss work towards the total synthesis DEM30355/A 94, a novel 
compound isolated from the fermentation broth of Amycolatopsis DEM30355 (Chapter 2) 
(Figure 68).  The relative stereochemistry of DEM30355/A 94 is shown, as determined through 
X-ray crystallography analysis (Dr M. J. Hall) however the absolute stereochemistry has not 
been determined.  
 
Figure 68: Structure of DEM30355/A 94 (relative stereochemistry shown) 
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DEM30355/A 94, which has a highly oxygenated polyketide structure, is active against Gram-
positive bacteria (Dr B. Kepplinger).  By developing a synthetic route to DEM30355/A 94, we 
aim to: 
 Determine the absolute stereochemistry of the natural product   
 Synthesise DEM30355/A analogues for SAR studies and to probe the mode of action 
 Synthesise DEM30355/A analogues to identify new antibiotic drug leads 
DEM30355/A 94 is structurally related to rishirilides A 95 and B 96, isolated from Streptomyces 
rishiriensis in the 1980s (Figure 69). The rishirilides are α2-macroglobulin inhibitors, with IC50 
values of 100 μg/mL and 35 μg/mL for rishirilides A 95 and B 96 respectively.96 α2-
Macroglobulin is a glycoprotein that inhibits fibrinolysis, the breakdown of blood clots. 
Therefore α2-macroglobulin inhibitors are useful in the treatment of thrombosis and related 
conditions.  Furthermore, rishirilide B 96 is an inhibitor of glutathione S- transferase, with an 
IC50 value of 26.9 µM.97 Glutathione S-transferase is an enzyme implicated in promoting 
resistance to particular anticancer agents.  Combining an inhibitor of this enzyme with other 
anticancer therapeutic agents, has the potential to overcome this resistance, improving the 
efficacy of treatment.98 
 
Figure 69: Structures of rishirilide A 95 and rishirilide B 96 
 Total Synthesis of Rishirilide B 96 
 Danishefsy’s Total Synthesis of (-)-Rishirilide B  
The interesting bioactivity of rishirilide B 96 has prompted several research groups to pursue 
the total synthesis of the molecule. Danishefksy et al. devised a convergent synthesis of 
racemic and ent-rishirilide B 97, based upon a key regioselective Diels-Alder (D-A) reaction 
(Figure 70).99  The total synthesis of ent-rishirilide B 97 starts with the synthesis of dienophile 
98 (Figure 70).  Cyclohexenone 99, synthesised from enantiopure (R)-3-methylcyclohexan-1-
one, is subjected to Rubottom oxidation conditions, by first reacting compound 99 with NaH 
and tert-butyl dimethylsilyl trifluoromethanesulfonate (TBSOTf) to generate the silyl enol ether, 
followed by oxidation with dimethyldioxirane (DMDO).  The Me group at C2 sterically directs 
epoxidation to the opposite face, generating product 100 with an anti-arrangement with respect 
to the C3 alcohol, as seen in the natural product.  The allylic position of compound 100 is then 
oxidised in two steps, through a Wohl-Ziegler reaction with azobisisobutyronitrile (AIBN) and 
N-bromosuccinimide (NBS) to generate a brominated intermediate, followed by solvolysis to 
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give diol 101.  The secondary alcohol of diol 101 is subsequently oxidised using Dess-Martin 
periodinane (DMP), to give dienophile 98, corresponding to the A ring of ent-rishirilide B 97.99 
 
Figure 70:  Synthesis of Danishefky's dienophile 98 in the total synthesis of ent-rishirilide B 97 
The next stage was to build the B ring of ent-rishirilide B 97.  Danishefsky uses 
benzocyclobutene 102 to generate a reactive dimethide diene in situ, which undergoes a 
regioselective and exo selective D-A reaction with dienophile 98, to give D-A cycloadduct 103 
(Figure 71).99 
 
Figure 71: Key Diels-Alder reaction to generate adduct 103 in Danishefsky's synthesis of ent-rishirilide B 97 
Following the D-A reaction, two TBS protected alcohol groups are removed from D-A adduct 
103 with camphorsulfonic acid in refluxing methanol (Figure 72).  This is followed by a directed 
Grignard addition of iso-pentylmagnesium bromide to resultant naphthalene 104 to give diol 
105.  The tertiary alcohol of naphthalene 104 directs addition of the isopentyl group to the 
same face, by chelating with the organomagnesium reagent, resulting in an anti-arrangement 
of the adjacent hydroxyl groups at C3 and C4 as seen in ent-rishirilide B 97.  Finally, 
deprotection of diol 105 using tris(dimethylamino)sulfur(trimethylsilyl)difluoride (TASF) gives  
(-)-rishirilide B 97, in an overall yield of 0.4% over 10 steps from (R)-3-methylcyclohexan-1-
one. 99,100 
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Figure 72: Conversion of Diels-Alder cycloadduct 103 to ent-rishirilide B 97 in Danishefksy’s total synthesis 
Through the total synthesis of (-)-rishirilide B 97 and subsequent specific rotation 
measurements, Danishefsky et al. were able to establish the absolute stereochemistry of the 
naturally occurring product as (+)-rishirilide B 96.99  The use of total synthesis to determine the 
absolute stereochemistry of natural products is widespread.  It is one of the options available 
if the absolute stereochemistry of a natural product cannot be determined through other 
methods, such as using X-ray crystallography (often via synthetic modification to include a 
heavy atom), or via comparison of experimental and calculated electronic circular dischroism 
(ECD) and vibrational circular dichroism (VCD) spectra.  
 Pettus’ Total Synthesis of Rishirilide B 96 
The Pettus group were the first to synthesise (+)-rishirilide B 96 as found in nature.100 Following 
the synthesis of protected aromatic diol 106, the total synthesis then proceeds with a 
Mitsunobu reaction with chiral N-alkoxyamide 107, followed by removal of the Boc protecting 
group to give aryl-ether 108 (Figure 73).100  Oxidative dearomatisation by the reaction of aryl-
ether 108 with iodosylbenzene-trimethylsilyl triflate, followed by intramolecular cyclisation is 
used to synthesise lactone 109, corresponding to the A ring of rishirilide B 96.100 
 
Figure 73: Synthesis of Pettus' dienophile 109 via a key oxidative dearomatisation of aryl-ether 108100 
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The enantioselectivity of the cyclisation results from the effect of the chiral auxiliary on the 
transition state which, to minimise the dipole, adopts a boat conformation over a chair 
conformation (Figure 74).  Thus lactone 109 is generated as the major product, which has the 
correct stereochemistry at C4 as seen in (+)-rishirilide B 96.100  
 
Figure 74: Origin of the enantioselectivity in the conversion of aryl-ether 108 to dienophile 109 
Compound 109 is then employed as a dienophile in a regioselective D-A reaction with a 
dimethide diene,  generated in situ by heating sulfone precursor 110 (Figure 75).  At the high 
temperatures used in this reaction, the D-A cycloadduct undergoes spontaneous β-elimination 
of the methoxy group, to generate an intermediate which is subsequently oxidised with DDQ 
to give naphthalene 111.  N-(dimethylaluminium)-N’-N’-dimethylhydrazide is used as a Lewis 
acid to ring open the lactone of 111, followed by the addition of Hünig’s base to form an enolate 
which is trapped with dimethylcarbamyl chloride, to give compound 112.  In a similar way to 
the OH directed addition of iso-pentylmagnesium bromide to diol 105 in Danishefsky’s 
synthesis, the carbonyl of compound 112 undergoes a directed addition with lithiated vinyl 
ether, ultimately setting up the anti arrangement of the adjacent hydroxyl units at C3 and C4 as 
seen in rishirilide B 96, followed by oxidation with DMDO to give triol 113.  Triol 113 undergoes 
four subsequent  steps, leading to the isolation of (+)-rishirilide B 96 in an overall yield of 12.5% 
over 18 steps.100  
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Figure 75: Key Diels-Alder reaction to generate cycloadduct 111 and its subsequent conversion to rishirilide B 96 
in Pettus’ total synthesis100 
Through the total synthesis of (+)-rishirilide B 96, Pettus et al. developed an innovative method 
towards the enantioselective oxidative-dearomatisation of 2-alkyl substituted rescorcinol 108 
to give an oxygenated, cyclic product 109 with a stereogenic centre (Figure 73).100 Such highly 
functionalised compounds have application as precursors to a variety of other natural products, 
such as (+)-bisorbicillinol 114 (Figure 76).101 
 
Figure 76: Structure of (+)-bisorbicillinol 114 
 Comparison of Rishirilide A 95 and DEM30355/A 94 
In spite of the progress made in the synthesis of rishirilide B 96, there have been no published 
total syntheses of rishirilide A 95 (Figure 77).  Presumably, this is due to the difficulty in 
constructing the quaternary centre at C4a, whilst avoiding competing aromatisation of the B 
ring, leading to rishirilide B-like structures.  
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Figure 77: Structure of rishirilide A 95 and rishirilide B 96 
This quaternary centre at C4a is present in our target, DEM30355/A 94, and construction of this 
site will be carefully considered in our planned routes.  By devising a working synthetic route 
to DEM30355/A 94, we could also apply this method to the synthesis of rishirilide A 95. 
Due the acidity of the proton at C2, DEM30355/A 94 exists as an epimeric mixture at this 
position (Figure 78). 
 
Figure 78: DEM30355/A 94 exists as an epimeric mixture due to the acidity of the proton at C2 
Therefore to simplify our synthetic approach, we will target C2 de-methyl DEM30355/A 115 
(DM-DEM30355/A 115) (Figure 79).  DEM30355/A 94 may still be reached, if desired, through 
a late stage methylation.  
 
Figure 79: Structure of C2 de-methyl DEM30355/A 115 
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 Results and Discussion 
We examined a multitude of synthetic routes to C2 de-methyl DEM30355/A 115 (DM-
DEM30355/A 115) (Figure 80).  In Chapter 4, we discuss our work towards the construction of 
the A, B and C ring core framework of DEM30355/A 94 using Diels-Alder (D-A) chemistry.  In 
this chapter, we focus on the construction of the C and B rings of DM-DEM30355/A 115, 
including the synthesis of the key oxygenated centre at C4a. 
 
Figure 80: Structures of DEM30355/A 94 and C2 de-methyl DEM30355/A 115 
 Barbier Coupling Route to DM-DEM30355/A 115 
The first route we will discuss, examines disconnections of bonds C10-C10a and C4a-O of DM-
DEM30355/A 115 (Figure 81). In this route, we planned to use a Barbier coupling reaction 
between 3,6-dimethoxyphthalaldehyde 116 and compound 117, followed by ring closure of the 
resultant adduct 118 to generate the target, DM-DEM30355/A 115.102 
 
Figure 81: Planned synthetic route to DM-DEM30355/A 115 using Barbier coupling chemistry 
 Synthesis of 3-Iodo-6,6-dimethylcyclohex-2-en-1-one 119 
We planned to synthesise 3-iodo-6,6-dimethylcyclohex-2-en-1-one 119 as a test system for 
our proposed route, via a modified Appel reaction (Figure 82).103 4,4-Dimethylcyclohexenone 
120 (1.0 eq.) was added to a stirred suspension of iodine (1.1 eq.), triphenylphosphine (1.1 
eq.) and triethylamine (1.1 eq.) in solvent and heated at reflux (Table 5).  In each case, the 
crude material was analysed by 1H NMR and purified through column chromatography.  
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Figure 82: Synthesis of 3-iodo-6,6-dimethylcyclohex-2-en-1-one 119 
Table 5: Reactions conditions examined in the synthesis of 3-iodo-6,6-dimethylcyclohex-2-en-1-one 119 
 
In our initial reactions which tested the reaction solvents THF, toluene and MeCN, the best 
yield of iodo-compound 119 was obtained from the reaction in MeCN (Table 5, entry 3).103  An 
interesting observation was that in refluxing toluene, a second minor compound was isolated 
alongside expected product 119 (Table 5, entry 2). Based on 1H NMR analysis, we have 
assigned this compound to be isomer 121 (Figure 82).  Presumably this more sterically 
encumbered isomer is generated as a result of the higher reaction temperature in this 
experiment.  Repetition of the modified Appel reaction in MeCN gave variable yields, which 
may be due to the practical difficulties of reacting a relatively volatile starting material, 4,4-
dimethylcyclohexenone 120, at high temperatures for long periods of time. However, with 
careful optimisation of the reaction set up and isolation protocols, 3-iodo-6,6-dimethylcyclohex-
2-en-1-one 119 could be obtained in a yield of 86% (Table 5, entry 6). 
 Barbier Coupling Reactions Using 3-Iodo-6,6-dimethylcyclohex-2-en-1-one 119  
With 3-iodo-6,6-dimethylcyclohexenone 119 in hand, we moved on to test the Barbier coupling 
with indium metal, which was selected as ‘RIn’ type reagents are known to be functional group 
and moisture tolerant.102  The equivalencies of phthaldialdehyde 122 (0.5 mmol, 1 eq.) and the 
reaction concentration (THF, 5 mL) were kept constant throughout all the reactions (Table 6).   
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Table 6: Reaction conditions examined in the attempted synthesis of product 124 via Barbier coupling 
 
 
In the initial reaction (Table 6, entry 1), the 1H NMR spectrum of the crude material after 18 
hours showed that no reaction had occurred as the starting materials, 3-iodo-6,6-
dimethylcyclohexenone 119  and phthaldialdehyde 122 remained unchanged.  We anticipated 
this may be due to the low reactive surface area of indium shot, slowing the formation of desired 
organoindium species 123.  Therefore we increased the equivalencies of indium shot from 1.1 
eq. to 5.0 eq. (Table 6, entry 2) and tried using indium powder (Table 6, entry 3) to increase 
the available surface area, but once again no desired product 124 could be observed using 1H 
NMR analysis.  Due to the low reactivity of indium alone, we investigated additives and indium 
metal activating agents, namely lithium chloride to facilitate the insertion of indium into the C-I 
bond and to generate mixed metal organoindium/ lithium species (Table 6, entries 2 and 4), 
the Lewis acid catalyst indium (III) chloride, to increase the electrophilicity of aldehyde 122 
(Table 6, entry 3) and the entrainment agent, 1,2-dibromoethane (Table 6, entry 3) (Note: In 
our experiments (Table 6, entries 2 – 4), the reaction conditions were altered when no reaction 
was observed by TLC).104 
A new product was observed by TLC using lithium chloride and the higher reaction temperature 
of 40 °C (Table 6, entry 4).  Analysis of the crude material by 1H NMR showed unreacted 
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starting materials 3-iodo-6,6-dimethylcyclohexenone 119 and phthaldialdehyde 122 and a new 
compound, with peaks at δH 6.80 (1H, dt, J = 10.1, 4.0 Hz), 5.84 (1H,  dt, J = 10.1, 2.0 Hz), 
and 2.30 (2H, tdd, J = 6.0, 4.0, 2.0 Hz).  This new compound was, however, shown to be 6,6-
dimethyl-2-cyclohexen-1-one 125, likely resulting from the formation of desired organoindium 
123 followed by protonation rather than reaction with aldehyde 122 (Figure 83).105  
 
Figure 83: Expansion of the 1H NMR spectrum leading to the assignment of 6,6-dimethyl-2-cyclohexen-1-one 125 
This suggested that the desired reaction had not occurred due to the poor reactivity of aldehyde 
122.  Therefore we tested the reactivity of electron rich and electron poor aromatic aldehydes, 
namely benzaldehyde 126 and 4-nitrobenzaldehyde 127 respectively (Table 7). 
Table 7: Reaction conditions examined in the synthesis of product 128 via Barbier Coupling 
 
 
In both cases, unreacted 3-iodo-6,6-dimethylcyclohex-2-en-1-one 119 and the aromatic 
aldehyde were recovered (Table 7).  With failure of the organoindium reactions to generate 
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desired product, we moved on to examine different organometallic reagents, specifically 
organomagnesium and organolithium, which we expected to be more nucleophilic.  
 Examination of Organomagnesium and Organolithium Species Derived from 3-
Iodo-6,6-dimethylcyclohex-2-en-1-one 119 
We decided to investigate an alternative method to convert iodo-compound 119 to the 
corresponding organometallic, namely a halogen-metal exchange reaction with iso-
propylmagnesium chloride or n-butyl lithium, followed by reaction with arylaldehydes (Table 
8).106 
Table 8: Reaction conditions examined in the synthesis of product 128 
 
 
In each reaction, no signals corresponding to desired product 128 could be observed in the 1H 
NMR spectra of the crude material, although 6,6-dimethyl-2-cyclohexen-1-one 125 was 
generated in the reaction with iso-propylmagnesium chloride (Table 8, entry 1). 
As it was apparent from our experiments that coupling aromatic aldehydes 122, 126, 127 and 
129 to 6,6-dimethyl-2-cyclohexen-1-one 119 via a Barbier type reaction looked unfeasible, we 
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moved on to investigate a different synthetic route to DM-DEM30355/A 115 which would rely 
on an alternative disconnection approach. 
 Enolate Coupling Route to DM-DEM30355/A 115  
Next we examined disconnections of bonds C10-C10a and C5-C5a of DM-DEM30355/A 115 
(Figure 84).  Following this retrosynthetic analysis, we envisaged DM-DEM30355/A 115 could 
be synthesised by initially constructing the C3-C4 bond using an enolate reaction between 
alkyne 130 and ester 131.  
 
Figure 84: Planned synthetic route to DM-DEM30355/A 115 using enolate coupling 
Alkyne 130 had already been synthesised within our group (A. Bayazeed), therefore the first 
step was to synthesise ester 131, which we envisaged achieving by first synthesising ethyl 2-
hydroxy-3-(2-methyl-1,3-dioxolan-2-yl)propanoate 132 and subsequently protecting the 
alcohol (Figure 85).  
 
Figure 85: Planned synthesis of ester 131 via radical chemistry to synthesise alcohol 132 followed by OH 
protection 
 Synthesis of Ethyl 2-hydroxy-3-(2-methyl-1,3-dioxolan-2-yl)propanoate 132 
Ishii et al. reported that methyl 2-hydroxy-3-(2-methyl-1,3-dioxolan-2-yl)propanoate 136 could 
be synthesised in a good yield (81%) in the reaction between 2-methyl-1,3-dioxolane 133 and 
methyl acrylate 135 (Figure 86).107 The reaction was conducted under an atmosphere of 
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oxygen, in the presence of catalytic quantities of N-hydroxyphthalimide (NHPI) and cobalt (II) 
acetate. 
 
Figure 86: Ishii’s synthesis of methyl 2-hydroxy-3-(2-methyl-1,3-dioxolan-2-yl)propanoate 136 via the reaction 
between 2-methyl-1,3-dioxolane 133 and methyl acrylate 135107 
We adapted this approach to synthesise ethyl 2-hydroxy-3-(2-methyl-1,3-dioxolan-2-yl) 
propanoate 132.  Ethyl acrylate 134 was added to a stirred solution of 2-methyl-1,3-dioxolane 
133, NHPI, and cobalt (II) acetate tetrahydrate at room temperature (Table 9). 
Table 9: Reaction conditions examined in the synthesis of ethyl 2-hydroxy-3-(2-methyl-1,3-dioxolan-2-yl) 
propanoate 132 from 2-methyl-1,3-dioxolane 133 
 
The reaction was initially carried out at room temperature for 3 hours as described in the 
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literature, albeit in an open system as opposed to an atmosphere of oxygen.107   After this time, 
2-methyl-1,3-dioxolane 133 was removed under reduced pressure and the crude material was 
purified using column chromatography, to give ethyl 2-hydroxy-3-(2-methyl-1,3-dioxolan-2-yl) 
propanoate 132 in a 14% yield (Table 9, entry 1).  Attempts to improve the yield of the reaction 
through increasing the reaction time or employing a more constant reaction temperature (22-
25 °C in an oil bath) and moving to a closed system (to reduce reagent evaporation), proved 
inconclusive (Table 9, entries 2-9).  It was noticable that the reaction yields suffered 
significantly when the equivalencies of reagents used differed to those described in the 
literature (Table 9, entries 4 and 6).107 Oxygen is a key reagent in the reaction, thus we 
postulated that under air, the partial pressure of oxygen in the reaction may be too low and 
that an atmosphere of oxygen may be necessary to increase the reaction yields.   Therefore 
the reaction was repeated under 1 atmosphere of oxygen, using literature equivalencies of 
reagents.107  TLC analysis of the reaction after 2 hours showed that product 132 had been 
formed, however no 132 was isolated, potentially due to its volatility during work up (Table 9, 
entry 9). 
Given the problems associated with using volatile reagents (2-methyl-1,3-dioxolane 133 and 
ethyl acrylate 134) under an atmosphere of oxygen and in isolating a volatile product 132, we 
decided to test the next stage in the synthesis.  Despite the low yields in these reactions, we 
were able to isolate sufficent quantities of product 132 to continue and attempt the OH 
protection.  Should the following planned synthetic route to DM-DEM30355/A 115 prove 
successful, more time would be invested in optimising the synthesis of precursor 132. 
 OH-Protection of Ethyl 2-hydroxy-3-(2-methyl-1,3-dioxolan-2-yl)propanoate 132  
The next step was to protect the hydroxyl group of ethyl 2-hydroxy-3-(2-methyl-1,3-dioxolan-
2-yl)propanoate 132 (Table 10).  Alcohol protection is required at this stage to both allow 
orthogonal deprotection of different hydrdroxyl groups later in the synthesis and to reduce the 
volatility of 132.  A benzyl protecting group was selected as, when necessary, we anticipated 
the group would readily be removed under orthogonal hydrogenation conditions.  
Ethyl 2-hydroxy-3-(2-methyl-1,3-dioxolan-2-yl) propanoate 132 was reacted with benzyl 
bromide in the presence of a suitable base (Table 10).
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Table 10: OH Protection reaction conditions examined in the synthesis of benzyl-protected compound 137 
 
 
In the first attempt at the protection reaction with benzyl bromide, NaH was used as the base. 
After a reaction time of 30 minutes, only starting material 132 was seen in the 1H NMR 
spectrum of the crude reaction mixture (Table 10, entry 1).  Increasing the reaction time and 
temperature led to the isolation of unidentified decomposition products (Table 10, entry 2).  
Reactions employing benzyl bromide and the more organosoluble base, lithium 
diisopropylamide (LDA), also showed no formation of desired product 132 Table 10, entry 3).  
We then examined the replacement of LDA with the sterically bulky base, sodium 
bis(trimethylsilyl)amide (NaHMDS).  After a reaction time of 2 hours, two compounds - a major 
by-product 138 and a minor product - could be isolated by column chromatography, in addition 
to unreacted starting material 132 (Table 10, entry 4). 
1H NMR analysis of the minor product showed two, one proton doublets at 4.49 ppm and 4.30 
ppm, which were coupled to each other with J = 11.3 Hz, characteristic of a benzylic O-CH2 in 
close proximity to a chiral centre.  Therefore based on the 1H NMR data, we have assigned 
the minor compound to be desired product 137 (~5% isolated yield) (Figure 87). 
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Figure 87: Structure of benzyl-protected compound 137, isolated as a minor product in the reaction of alcohol 132 
with benzyl bromide 
With desired product 137 identified, we attempted to improve the yield of 137. The reaction 
time was increased from 2 to 18 hours (Table 10, entry 5), however the yield of 137 remained 
low and the yield of by-product 138 increased. Consequently we decided to investigate the 
structure of by-product 138 to gain a better understanding of the reaction. 
The 1H NMR spectrum of by-product 138 contained two, one proton doublets at 2.95 and 2.84 
ppm, coupled to each other with J = 13.3 Hz, again suggesting a geminally coupled CH2 group.   
HMBC data showed this proton spin system was in close proximity to a quaternary aromatic 
carbon centre at 135.7 ppm, suggesting that these protons were part of a benzylic CH2 group 
attached to carbon, not oxygen as expected. Thus we have determined that compound 138 is 
in fact a structural isomer of 137 (10% isolated yield), the result of deprotonation of the proton 
α to the carbonyl of 132, followed by enolate attack on benzyl bromide (Figure 88).    
 
Figure 88: Structure of compound 138, the major product generated in the reaction of alcohol 132 with benzyl 
bromide.  Key NMR data which aided the structural assignment is shown 
The unexpected product 138 appears to be formed preferentially in this reaction over desired 
benzyl-protected compound 137. This may be due to an intramolecular hydrogen bond helping 
to stabilise the OH group and making the proton - to the carbonyl more acidic, resulting in 
deprotonation and benzylation at the -position (Figure 89). 
 
Figure 89: Intramolecular hydrogen bonding may favour the formation of compound 138 over OH protected 
compound 137 in the reaction of alcohol 132 with benzyl bromide 
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As the major product of the reaction between alcohol 132 and benzyl bromide was undesired 
isomer 138, we believed this method would not be a feasible route to sufficient quantities of 
OH-protected compound 137, required to proceed in our planned synthetic route.  Therefore 
we moved on to examine an alternative synthetic route to OH-protected compound 137. 
 Synthesis of Ethyl 2-hydroxy-4-oxopentanoate 140 via Selective Reduction of 
Ethyl 2-hydroxy-4-oxopentanoate 139  
We envisaged that OH-protected compound 137 may alternatively be synthesised using a 
selective reduction of the -keto ester of ethyl 2,4-dioxopentanoate 139 to generate  ethyl 2-
hydroxy-4-oxopentanoate 140, followed sequentially by OH and ketone protection (Figure 90).    
 
Figure 90: Planned synthesis of OH-protected compound 137 via selective reduction of ethyl 2,4-dioxopentanoate 
139 then alcohol and ketone protection 
The first step was to investigate the reduction of ethyl 2,4-dioxopentanoate 139 with hydride 
reducing agents, namely sodium tetraborohydride and DIBALH (Table 11).  
Table 11: Reaction conditions examined in the synthesis of ethyl 2-hydroxy-4-oxopentanoate 140 
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In the first reaction we tested, we obtained two fractions following column chromatography 
(Table 11, entry 1).  1H NMR analysis of the minor fraction showed that the spectrum contained 
two signals at 2.96 ppm (1H, dd, J = 17.4, 4.1 Hz) and 2.88 ppm (1H, dd, J = 17.4, 6.2 Hz).  
Through coupling constant analysis, we could deduce that these two protons were geminally 
coupled to each other (J = 17.4 Hz).  The two protons at 2.96 and 2.88 ppm were coupled to 
another proton at 4.46 ppm (1H, dd, J = 6.2, 4.1 Hz), which suggested the presence of an ABC 
spin system, corresponding to a CH2CH moiety.  Through interpretation of these data, we have 
assigned this compound as desired alcohol 140 (14% isolated yield) (Figure 91).  
 
Figure 91: Key NMR data in the assignment of ethyl 2-hydroxy-4-oxopentanoate 140 
1H NMR analysis of the major fraction indicated a complex mixture of products.  The spectrum 
contained a doublet Me group signal at 1.39 ppm and a doublet Me group signal at 1.33 ppm, 
which is consistent with each Me group being adjacent to a CH moiety.  Based on these 1H 
NMR data we proposed the major fraction contained the singly and doubly reduced products, 
141 and 142 respectively (Figure 92). 
 
Figure 92: Structure of additional products 141 and 142 generated by reduction of ethyl 2,4-dioxopentanoate 139, 
identified through the appearance of doublet Me signals in the 1H NMR spectrum 
Reducing the equivalents of sodium borohydride (Table 11, entry 2) and the reaction time 
(Table 11, entries 3 and 4) did not result in significant improvements to the isolated yield of 
desired product 140, whilst attempting the reduction at a low temperature in the presence of 
DIBALH resulted in the recovery of starting material 139 only (Table 11, entries 5 and 6).  
Given the difficulties associated with the reduction reactions tested, we decided to examine a 
different route to ethyl 2-hydroxy-4-oxopentanoate 140. 
 Synthesis of Ethyl 2-hydroxy-4-oxopentanoate 140 via Reduction of Ethyl 2,4-
dioxopentanoate 139 then Selective Oxidation  
As an alternative route to ethyl 2-hydroxy-4-oxopentanoate 140, we hypothesised that we 
could reduce both of the ketones of ethyl 2,4-dioxopentanoate 139 to give ethyl 2,4-
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dihydroxypentanoate 142, then selectively oxidise the least hindered alcohol to generate the 
target compound 140 (Figure 93).  
 
Figure 93: Proposed synthesis of ethyl 2-hydroxy-4-oxopentanoate 140 via the reduction of ethyl 2,4-
dioxopentanoate 139 to compound 142 followed by selective oxidation 
Therefore ethyl 2,4-dioxopentanoate 139 was reacted with an excess of sodium borohydride 
at room temperature, followed by purification of the crude reaction material by column 
chromatography (Table 12). 
Table 12: Reaction conditions examined in the reduction of ethyl 2,4-dioxopentanoate 139 
 
 
From the first reaction we tested, a new product 143 was isolated in addition to a mixture of 
unidentified reduction products (Table 12, entry 1).  The 1H NMR spectrum of the new product 
143 contained two overlapping one proton signals at 4.64 – 4.45 ppm.  One of these signals 
could be distinguished at 4.57 ppm (1H, dd, J = 8.3, 11.2 Hz).  The spectrum also contained 
two signals at 2.73 ppm (1H, dd, J = 12.5, 8.3 Hz) and 1.86 ppm (1H, dd, J = 12.5, 11.2 Hz), 
suggestive of a geminally coupled CH2 group (J = 12.5 Hz), adjacent to the CH at 4.57 ppm.  
The chemical shift of this CH group suggested it was in close proximity to an electronegative 
moiety, which considering the starting materials, was likely to be an oxygen atom and/or 
carbonyl group.  In addition, the presence of a signal at 1.47 ppm (3H, d, J = 6.2 Hz) suggested 
a CH3CH moiety.  Therefore, based on these 1H NMR data, we have assigned the new 
compound as hydroxy-lactone 143 (30% isolated yield) (Figure 94).  Lactone 143 likely results 
from the reduction of ethyl 2,4-dioxopentanoate 139 to ethyl 2,4-dihydroxypentanoate 141, 
followed by intramolecular cyclisation (Figure 95).   
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Figure 94: Structure of lactone 143 and the key NMR data which aided in structural assignment 
 
Figure 95: Mechanism showing the formation of lactone 143 from the reduction of 139 to alcohol 141 followed by 
intramolecular cyclisation  
We envisaged OH-protected hydroxy-lactone 143 could be used as an alternative to our initial 
target 140.  Consequently, to increase the yield of compound 143 for subsequent use in OH-
protection reactions, we increased the reaction time from 18 hours to 4 days, which resulted 
in the isolation of hydroxy-lactone 143 as the sole product, in a much improved yield of 58% 
(Table 12, entry 2). 
With a working route to hydroxy-lactone 143 developed, we then examined the OH-protection 
chemistry. 
 Synthesis of 3-(Benzyloxy)dihydrofuran-2(3H)-one 145 
As a test system, we decided to investigate OH-protection of a compound structurally related 
to hydroxyl-lactone 143 synthesised previously, namely α–hydroxy–γ-butyro lactone 144 
(Figure 96).  We planned to react α–hydroxy–γ-butyro lactone 144 with benzyl bromide to 
generate benzyl-protected hydroxy-lactone 145, for use in our proposed enolate coupling 
reactions with alkyne 130 (Figure 96).  
 
Figure 96: Planned synthesis of adduct 146 via an enolate coupling reaction between alkyne 130 and OH- 
protected lactone 145 
α–Hydroxy–γ-butyro lactone 144 was reacted with benzyl bromide and the base, NaHMDS at 
room temperature (Figure 97). 
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Figure 97: OH protection of α–hydroxy–γ-butyro lactone 144 to give benzyl compound 145 
Following purification of the crude material by column chromatography, a new compound was 
isolated.  The 1H NMR spectrum of the product contained two signals at 4.91 ppm (1H, d, J = 
11.8 Hz) and 4.71 ppm (1H, d, J = 11.8 Hz).  These signals are characteristic of a benzylic O-
CH2 in close proximity to a stereogenic centre.  Therefore, based on the 1H NMR data, we 
have assigned the isolated product as desired OH-protected compound 145 (39% yield). 
With a sufficient quantity of OH-protected lactone 145 in hand, we could proceed to the next 
step.  
 Enolate Reaction Between 3-(Benzyloxy)dihydrofuran-2(3H)-one 145 and 1-(2-
Methyl-1,3-dioxolan-4-yl)but-2-yn-1-one 130 
The next stage was to test the enolate reaction between OH-protected lactone 145 and 1-(2-
methyl-1,3-dioxolan-4-yl)but-2-yn-1-one 130, which had previously been synthesised (A. 
Bayazeed), to generate adduct 146.  Alkyne 130 was added to a pre-mixed solution of lactone 
145 and NaHMDS (Figure 98). 
 
Figure 98: Reaction conditions examined in the attempted synthesis of adduct 146 
After a reaction time of 1 hour, analysis of crude reaction material by 1H NMR showed 
unreacted 145, and no peaks corresponding to our desired product 146 could be observed.   
Given the time constraints, we decided at this point to focus on alternative synthetic routes to 
DM-DEM30355/A 115.  In future we would screen different reaction conditions, including the 
use of alternative bases such as NaH or LDA, to encourage the desired enolate reaction 
between 145 and 130 to proceed.   
 Synthesis of DM-DEM30355/A 115 via a Michael Addition/ Enolate Trapping Multi-
Component Reaction  
The third synthetic route to DM-DEM30355/A 115 we will discuss, examines disconnections of 
the C10a - C4a and C5- C5a bonds (Figure 99).  We envisaged using a multi-component reaction, 
consisting of Michael addition to (E)-4-(2,5-dimethoxyphenyl)but-3-en-2-one 147 followed by 
trapping of the resultant enolate with a reactive carbonyl compound, to generate alcohol 148.   
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This would construct the oxygenated quaternary centre at C4a, a key component in the 
synthesis of the target, DM-DEM30355/A 115.  From here, β-elimination of 148 to give 149, 
followed by ring closure would give diol 150, with the B ring of DM-DEM30355/A 115 in place.  
 
Figure 99: Proposed synthetic route to alcohol 150 containing the C and B rings of DM-DEM30355/A 115 via a 
key Michael addition/ enolate trapping multi-component reaction 
The first step was to synthesise the starting material, ketone 147. 
 Synthesis of (E)-4-(2,5-Dimethoxyphenyl)but-3-en-2-one 147  
We anticipated that (E)-4-(2,5-dimethoxyphenyl)but-3-en-2-one 147 could be synthesised 
using a Wittig reaction between 2,5-dimethoxybenzaldehyde 151 and 
(acetylmethylene)triphenylphosphorane 152 (Figure 100).  
 
Figure 100: Wittig synthesis of (E)-4-(2,5-dimethoxyphenyl)but-3-en-2-one 147 
After 60 hours at reflux, (E)-4-(2,5-dimethoxyphenyl)but-3-en-2-one 147 was isolated by 
column chromatography in a 76% yield, which was improved to 82% by increasing the reaction 
time to 96 hours (Figure 100).   
With gram quantities of compound 147 in hand, we proceeded to the following stage in the 
synthetic route. 
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 Investigations into a Michael Addition/ Enolate Trapping Reaction from (E)-4-(2,5-
Dimethoxyphenyl)but-3-en-2-one 147 
The next step in our planned route was to react compound 147 with a nucleophile and trap the 
resultant enolate 154 with a reactive carbonyl species to generate adduct 156, thereby 
constructing the oxygenated quaternary centre at C4a.  We envisaged that small aromatic thiols 
would be suitable soft nucleophiles to undergo Michael addition with compound 147.     
(E)-4-(2,5-Dimethoxyphenyl)but-3-en-2-one 147 (1 eq.) was reacted with sodium 
thiophenolate 153 (1 eq.), followed by the addition of diethyl ketomalonate 155 (1 eq.) as a 
reactive carbonyl species, to trap enolate 154 and generate adduct 156 (Table 13).   
Table 13: Reaction conditions examined in the synthesis of adduct 156 from ketone 147 
 
 
In the reactions tested, a long reaction time (Table 13, entry 1), the addition of a Lewis acid 
catalyst and increasing the reaction temperature (Table 13, entry 2), failed to generate any 
desired adduct 156 as shown by analysis of the 1H NMR spectrum of the crude reaction 
material.  Therefore we moved on to examine the alternative reagent, thiophenol 157, which 
we anticipated would be more reactive.  
Initially (E)-4-(2,5-dimethoxyphenyl)but-3-en-2-one 147  was reacted with thiophenol 157 
under basic conditions, followed by addition of diethyl ketomalonate 155 (Figure 101). 
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Figure 101: Initial reaction tested using thiophenol 157, in the attempted synthesis of adduct 156  
Following column chromatography of the crude material, two new compounds were isolated, 
in addition to unreacted starting material 147.  The 1H NMR spectrum of the less polar product 
contained two signals at 5.11 ppm (1H, t, J = 7.4 Hz) and 3.02 ppm (2H, d, J = 7.4 Hz), 
suggesting an AB2 spin system, which we assigned as a CHCH2 moiety.  The HMBC spectrum 
showed correlations between the signal at 5.11 ppm and signals at 134.7 ppm and 130.4 ppm, 
which correspond to two quaternary aromatic carbon atoms.  This suggested that the CH 
corresponding to the signal at 5.11 ppm, was connected to two different benzene-like ring 
systems.  In addition, the HMBC spectrum showed correlations between the signals at 5.11 
ppm and 3.02 ppm, with a carbon signal at 205.9 ppm.  This suggested the CHCH2 group 
(associated with signals at 5.11 ppm and 3.02 ppm) was connected to a ketone carbonyl group.  
Thus, we have determined that the isolated compound was not desired product 156, rather 
sulfide 158, isolated in a 15% yield, generated by Michael addition of thiophenol 157 to (E)-4-
(2,5-dimethoxyphenyl)but-3-en-2-one 147 (Figure 102) (Note: sulfide 158 was the major 
product as shown by the 1H NMR spectrum of the crude reaction material, however the isolated 
yield of sulfide 158 following column chromatography was low due to the similar Rf values of 
sulfide 158 and starting material 147). 
 
Figure 102: Structure of sulfide 158 and key NMR data which aided in the structural assignment 
The 1H NMR spectrum of the more polar isolated product showed two signals at 7.90 ppm (1H, 
d, J = 16.4 Hz) and 6.73 ppm (1H, d, J = 16.4 Hz), suggesting a HC=CH alkene group with a 
trans arrangement of the protons.  The HMBC spectrum showed correlations between the 
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signals at 7.90 ppm and 6.73 ppm, with carbon signals at 123.6 ppm and 153.2 ppm, 
suggesting the alkene was in close proximity to an aromatic group.  In addition, the alkene CH 
signal at 6.73 ppm was correlated to a carbon signal at 197.0 ppm, suggesting the alkene was 
part of an α-β unsaturated ketone.  In addition, this C=O signal at 197.0 ppm was correlated 
to a signal at 3.55 ppm corresponding to a CH2, suggesting a HC=CH-(C=O)-CH2 unit.  Further 
HMBC correlations were observed between the signals at 3.55 ppm (CH2) and a carbon signal 
77.3 ppm, corresponding to a quaternary carbon bonded to several electron withdrawing 
groups, and a carbonyl carbon at 169.7 ppm, characteristic of an ester carbonyl group.  HMBC 
correlations were also observed between the C=O at 169.7 ppm and a four proton signal at 
4.28 ppm (q, J = 7.1 Hz), suggesting the presence of two equivalent ethyl ester groups.  
Therefore we were able to deduce that this new compound was not desired product 156 but 
alcohol 159, isolated in a 15% yield (Figure 103). 
 
Figure 103: Structure of alcohol 159 with key NMR data important in the structural assignment shown 
Alcohol 159 is likely generated from deprotonation of the alkyl proton α to the α-β unsaturated 
ketone 147, followed by attack of the resultant enolate 160 on diethyl ketomalonate 155 (Figure 
104). 
 
Figure 104: Mechanism of the formation of alcohol 159 from ketone 147 
Crystals of sulfide 158 and alcohol 159 were grown by slow evaporation from DCM and X-ray 
crystal structures were obtained, which support our proposed assignments (Figure 105). 
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Figure 105: X-ray crystal structures of sulfide 158 (left) and alcohol 159 (right) 
Sulfide 158 and alcohol 159 crystallise in the monoclinic space groups, P21/c and C2/c 
respectively. 
After determining that both isolated products, sulfide 158 and alcohol 159, from our initial 
reaction did not correspond to the targeted adduct 156 (Table 14, entry 1), we moved on to 
examine alternative reaction conditions (Table 14, entries 2 – 5) such as using a Lewis acid to 
activate both the α-β unsaturated ketone towards Michael addition, and diethyl ketomalonate 
155 towards condensation with the resultant enolate 154. 
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Table 14: Reaction conditions examined in the attempted synthesis of adducts 156 and 162 
 
 
In the subsequent Michael addition/ enolate trapping reactions of compound 147, the addition 
of diethyl ketomalonate 155 earlier in the reaction and reducing the equivalencies of both 
diethyl ketomalonate 155 and triethylamine (Table 14, entry 2), as well as addition of the Lewis 
acid catalyst, dimethylaluminium chloride (DMAC) (Table 14, entry 3), did not result in the 
formation of desired adduct 156 according to the 1H NMR spectrum of the crude material, only 
sulfide 158.  The use of the more electrophillic carbonyl compound, pentafluorobenzaldehyde 
161, as the enolate trapping agent, also failed to generate desired adduct 162 (Table 14, 
entries 4 and 5).  
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Thiophenol 157 is a very powerful nucleophile, therefore it was surprising that a significant 
quantity of (E)-4-(2,5-dimethoxyphenyl)but-3-en-2-one 147 remained unreacted in the 
reactions.  The observation suggested that the α-β unsaturated system of (E)-4-(2,5-
dimethoxyphenyl)but-3-en-2-one 147 was a poor Michael acceptor, which may be explained 
by ‘push-pull’ stabilisation from the conjugated electron rich aromatic ring. If we consider (E)-
4-(2,5-dimethoxyphenyl)but-3-en-2-one 147 as a model for the α-β-unsaturated system in the 
DEM30355/A 94, our results suggest that the observed antibacterial activity of this compound 
against Gram-positive bacteria (Dr B. Kepplinger) is unlikely to arise from Michael addition, for 
example of cysteine residues, to the α-β-unsaturated system.  
As the reaction conditions tested did not generate desired Michael addition/ enolate trapping 
adducts 156 and 162, we moved on to examine alternative synthetic routes to DM-
DEM30355/A 115. 
 Baylis-Hillman Synthesis of DM-DEM30355/A 115 
As an alternative synthetic route to DM-DEM30355/A 115, we envisaged using a key Baylis-
Hillman reaction between tricarbonyl 163 and methyl vinyl ketone 164 to synthesise alcohol 
165, with construction of the oxygenated quaternary centre at C4a (Figure 106).  Following the 
synthesis of alcohol 165, we imagined using two synthetic strategies to generate DM-
DEM30355/A 115 and saturated analogues of DEM30355/A 166.  
 
Figure 106: Proposed Baylis-Hillman route to DM-DEM30355/A 115 and DEM30355/A saturated analogues 166 
To begin with, we planned to synthesise ethyl 3-(2,5-dimethoxyphenyl)-2,3-dioxopropanoate 
167 as a test system to examine our proposed Baylis-Hillman route (Figure 107). We 
anticipated that the central carbonyl group of compound 167 would be the most reactive 
towards nucleophilic attack, as it is activated by two electron withdrawing C=O groups.  In 
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addition, we expected both the benzylic carbonyl and ester carbonyl groups to be less 
electrophilic and therefore less reactive, due to resonance stabilisation from the aromatic group 
and OEt group respectively. 
 
Figure 107: Planned synthesis of Baylis-Hillman product 168 from tricarbonyl 167 
The first step was to synthesise ethyl 3-(2,5-dimethoxyphenyl)-2,3-dioxopropanoate 167. 
 Friedel-Crafts Synthesis of Ethyl 3-(2,5-Dimethoxyphenyl)-3-oxopropanoate 171 
We anticipated ethyl 3-(2,5-dimethoxyphenyl)-2,3-dioxopropanoate 167 could be synthesised 
via a Friedel-Crafts reaction between 1,-4-dimethoxybenzene 169 and ethyl 3-chloro-3-
oxopropionate 170 to give ethyl 3-(2,5-dimethoxyphenyl)-3-oxopropanoate 171, followed by 
oxidation (Figure 108).  
 
Figure 108: Planned synthesis of tricarbonyl 167 
The first step was to synthesise ethyl 3-(2,5-dimethoxyphenyl)-3-oxopropanoate 171.  1,4-
Dimethoxybenzene 169 and ethyl 3-chloro-3-oxopropionate 170 were reacted in DCM in the 
presence of a Lewis acid (Table 15). 
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Table 15: Reaction conditions examined in the Friedel-Crafts synthesis of ethyl 3-(2,5-dimethoxyphenyl)-3-
oxopropanoate 171 
 
In the first Friedel-Crafts reactions we tested, no product 171 was observed in the 1H NMR 
spectra of the crude material (Table 15, entries 1 and 2).  We postulated that in our reactions, 
aluminium coordinated to the two carbonyl oxygens of ethyl 3-chloro-3-oxopropionate 170, 
preventing the formation of the reactive acylium ion species and, as a result, the formation of 
desired product 171.   To overcome this problem, we increased the equivalencies of AlCl3, 
which resulted in the isolation of our targeted dicarbonyl product 171, although in a poor yield 
of 19%, with starting material 169 recovered (Table 15, entry 3).  Increasing the reaction 
temperature did not improve the isolated yield of product 171, possibly due to the volatility of 
ethyl 3-chloro-3-oxopropionate 170.  We contemplated that the yield of product 171 from the 
Friedel-Crafts reaction may be improved by increasing the equivalencies of AlCl3 and through 
syringe-pump mediated addition of acyl chloride 170. 
However, given the time constraints, we decided to examine a different synthetic route to ethyl 
3-(2,5-dimethoxyphenyl)-3-oxopropanoate 171. 
 Synthesis of Ethyl 3-(2,5-dimethoxyphenyl)-3-oxopropanoate 171 Using Enolate 
Chemistry 
As an alternative route to synthesise ethyl 3-(2,5-dimethoxyphenyl)-3-oxopropanoate 171, we 
examined enolate chemistry between 2,5-dimethoxyacetophenone 172 and diethyl carbonate 
173, under basic conditions (Table 16).108    
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Table 16: Reaction conditions examined in the enolate synthesis of ethyl 3-(2,5-dimethoxyphenyl)-3-
oxopropanoate 171 
 
 
In the first reaction using NaH, two new compounds were isolated following purification of the 
crude material by column chromatography (Table 16, entry 1).108 By comparison of the 1H NMR 
data with those of ethyl 3-(2,5-dimethoxyphenyl)-3-oxopropanoate 171 previously synthesised, 
we could conclude one of the compounds was indeed desired product 171, isolated in a 16% 
yield.   
The 1H NMR spectrum of the second isolated compound showed two signals at 5.08 ppm (1H, 
q, J = 6.5 Hz) and 1.50 ppm (3H, d, J = 6.5 Hz), suggesting an AB3 spin system, corresponding 
to a CHCH3 moiety.  The chemical shift of the signal at 5.08 ppm, corresponding to the CH 
group, suggested that the CH was bonded to an electron withdrawing group.  In addition, the 
1H NMR spectrum showed three signals at 6.97 ppm (1H, d, J = 2.9 Hz), 6.81 ppm (1H, d, J = 
8.8 Hz) and 6.76 ppm (1H, dd, J = 8.8, 2.9 Hz) corresponding to a 1,2,4-trisubstituted aromatic 
system and two, three proton singlets at 3.82 and 3.78 ppm, corresponding to two methoxy 
groups.  Thus, based on the 1H NMR data, we were able to deduce that the compound was 
alcohol 174 (~3% isolated yield) (Figure 109). 
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Figure 109: Structure of alcohol 174 and the key NMR data which aided structural assignment 
Unusually, this alcohol 174 appeared to be the product of the keto-reduction of 2,5-
dimethoxyacetophenone 172, possibly from the NaH at high temperatures.  Using a lower 
reaction temperature did not result in a reaction (Table 16, entry 2), therefore we examined an 
alternative base, NaHMDS (Table 16, entries 3 – 5).   These reactions successfully generated 
desired product 171, however reduction product 174 was still observed in the 1H NMR spectra 
of the crude reaction material, albeit in a much lower concentration than observed in the 
reaction with NaH (Table 16, entry 1).  Purification of the crude material by column 
chromatography led to the isolation of desired product 171, as well as a new compound 175.   
The 1H NMR spectrum of new compound 175 contained two signals at 1.00 ppm (3H, d, J = 
6.6 Hz) and 2.65 ppm (1H, app dt, J = 13.4, 6.6 Hz), indicating a CH3 group adjacent to a CH 
unit, coupled to each other with J = 6.6 Hz.  The COSY NMR spectrum showed coupling 
between this CH signal at 2.65 ppm and signals at 3.06 ppm (2H, dd, J = 16.1, 6.0 Hz) and 
2.89 ppm (2H, dd, J = 16.1, 7.5 Hz), consistent with two equivalent sets of geminally coupled 
(J = 16.1 Hz) CH2 groups, thus we could deduce the molecule was symmetrical about the 
carbon of the CH group.  In addition, the HMBC spectrum showed a correlation between the 
signals at 3.06 ppm and 2.89 ppm, corresponding to the geminally coupled CH2, with a signal 
at 201.9 ppm, consistent with a ketone carbon atom.  The HMBC spectrum also showed a 
correlation between this signal at 201.9 ppm and two signals at 7.19 ppm (2H, d, J = 3.2 Hz) 
and 6.87 ppm (d, J = 9.0 Hz), corresponding to two equivalent aromatic rings. Based on this 
data, we proposed the new product was diketone 175 (2% isolated yield) (Figure 110). 
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Figure 110: Structure of diketone 175 with the key NMR data for structural assignment shown 
In the previous reaction between 2,5-dimethoxyacetophenone 172 and diethyl carbonate 173 
where NaH had been used as the base (Table 16, entry 1) we had postulated that the 
generation of  alcohol 174 may be the result of an unusual hydride addition to 2,5-
dimethoxyacetophenone 172.  However, alcohol 174 was also generated in our reactions using 
NaHMDS and since this reagent does not contain hydride, we were prompted to consider an 
alternative explanation.  We propose that under our reaction conditions, a Meerwein Ponddorf 
Verley reaction occurs between 2,5-dimethoxyacetophenone 172 and ethoxide 176, generated 
from the decomposition of diethyl carbonate 173, to give alcohol 174 and ethanol (Figure 111).   
 
Figure 111: Proposed mechanism of the formation of alcohol 174 via a Meerwein Ponddorf Verley reaction 
This mechanism also can be used to explain the generation of diketone 175.  Initially an aldol 
reaction between the enolate of 2,5-dimethoxyacetophenone 177 and ethanal occurs, followed 
by an E1cB reaction to give α-β-unsaturated ketone 178 (Figure 112).   This compound 178 
then undergoes a Michael addition reaction with the enolate 177 of a second molecule of 2,5-
dimethoxyacetophenone, followed by tautomerisation to give diketone 175.    
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Figure 112: Proposed mechanism for the formation of diketone 175 
Despite the formation of unwanted side products 174 and 175, we were able to obtain sufficient 
quantities of the target product from the enolate reactions, ethyl 3-(2,5-dimethoxyphenyl)-3-
oxopropanoate 171, to proceed to the next step. 
 Synthesis of Ethyl 3-(2,5-dimethoxyphenyl)-2,3-dioxopropanoate 167  
We then moved on to examine oxidation of ethyl 3-(2,5-dimethoxyphenyl)-3-oxopropanoate 
171 to generate the tricarbonyl compound, ethyl 3-(2,5-dimethoxyphenyl)-2,3-
dioxopropanoate 167, which would act as a key intermediate in the synthesis of DM-
DEM30355/A 115 and saturated analogues of DEM30355/A (Table 17). 
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Table 17: Reaction conditions examined in the oxidation of compound 171 to tricarbonyl 167 
 
 
In the initial reactions using ceric ammonium nitrate (CAN) (Table 17, entries 1 – 4), the 
reactions were very slow, with new product 167 only observed after 7 days (Table 17, entry 4).  
Following purification of the crude material by column chromatography, product 167 was 
isolated and analysed.  The 13C NMR spectrum showed a new carbonyl carbon signal at 192.7 
ppm and the two proton singlet at 3.94 ppm in the 1H NMR spectrum of starting material 171, 
had disappeared. Thus, in combination with HRMS data, we concluded that the new compound 
was desired tricarbonyl 167, isolated in a 29% yield.  As oxidation of compound 171 using CAN 
was very slow, we decided to examine alternative oxidising conditions. 
We anticipated that the hypervalent iodine compound, Dess-Martin periodinane (DMP) would 
be more reactive than CAN towards the oxidation of ethyl 3-(2,5-dimethoxyphenyl)-3-
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oxopropanoate 171.  This proved to be the case, as after 18 hours at room temperature, the 
1H NMR spectrum of the crude reaction material indicated product 167 had been generated. 
The formation of hydrates 179 of the product 167 made purification by column chromatography 
difficult (Figure 113), resulting in the isolation of desired compound 167 in poor yields of 32 
and 40% (Table 17, entries 5 and 6), although these were much improved when compared to 
the oxidations using CAN.  
 
Figure 113: Formation of hydrate 179 
Next we examined radical oxidation of ethyl 3-(2,5-dimethoxyphenyl)-3-oxopropanoate 171, 
mediated by N-bromosuccinimide in DMSO (Table 17, entries 7 – 9).109  Although the yields of 
product 167 generated from these reactions were variable, the proportion of product hydrates 
179 generated was much lower than in the DMP reactions and, following optimisation of the 
column chromatography conditions, desired 3-(2,5-dimethoxyphenyl)-2,3-dioxopropanoate 
167 could be isolated in yields as high as 74% (Table 17, entry 9). 
With a working synthetic route to tricarbonyl 167 developed, we could then move on to examine 
Baylis-Hillman reactions. 
 Baylis-Hillman Reaction Between Ethyl 3-(2,5-dimethoxyphenyl)-2,3-
dioxopropanoate 167 and Methyl Vinyl Ketone 164 
The next stage in the synthesis was to use Baylis-Hillman chemistry between 3-(2,5-
dimethoxyphenyl)-2,3-dioxopropanoate 167 and methyl vinyl ketone 164, to synthesise 
compound 168 (Figure 114).  The reaction would allow construction of the quaternary 
oxygenated centre at C4a, a key site in our planned route to DM-DEM30355/A 115.110   
3-(2,5-Dimethoxyphenyl)-2,3-dioxopropanoate 167 was reacted with methyl vinyl ketone 164 
in the presence of a nucleophilic catalyst (Table 18, entries 1-4). 
 
Figure 114: Planned Baylis-Hillman reaction between tricarbonyl 167 and methyl vinyl ketone 164 to generate 
adduct 168 
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Table 18: Baylis-Hillman reaction conditions examined to synthesise adduct 168 
 
In the first reactions using DABCO, the 1H NMR spectrum of the crude material showed 
unreacted starting material 167 in addition to a new product, with signals at 6.28 ppm and 6.02 
ppm,   however we found that the new compound degraded under column chromatography 
conditions (Table 18, entries 1 and 2).  Increasing the equivalencies of DABCO 10 fold (Table 
18, entry 3) and changing the nucleophilic catalyst to DMAP (Table 18, entry 4), improved the 
ratio of new product to starting material 167 as shown by analysis of the 1H NMR spectrum of 
the crude material.  After purification of the crude material by column chromatography, we were 
able to isolate the new compound.  Following analysis of the 1H NMR spectrum of this new 
product, which contained a signal at 4.35 ppm (2H, app qd, J = 7.1, 2.4 Hz) characteristic of a 
diastereotopic CH2 group and two, one proton doublets at 6.28 ppm and 6.02 ppm, 
characteristic of geminally coupled (J = 1.3 Hz) alkene protons, we could deduce that the 
product was target alcohol 168 (30% and 17% isolated yield, following reaction with DABCO 
and DMAP respectively) (Figure 115).   
 
Figure 115: Structure of Baylis-Hillman adduct 168 with the NMR data key for structure elucidation shown 
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Given the poor yields and long reaction times of the reactions tested, we then examined the 
use of a Lewis acid, titanium tetrachloride, in our Baylis-Hillman reactions to generate alcohol 
168 (Figure 116). 
 
Figure 116: Baylis-Hillman reaction examined using titanium chloride 
A new compound was isolated following purification of the crude material by column 
chromatography, however analysis of the 1H NMR spectrum showed that it was not Baylis-
Hillman product 168. 
The 1H NMR spectrum of the new product 180 showed a signal at 4.00 ppm (1H, dd, J = 9.0, 
4.4 Hz), and two signals at 3.88 ppm (1H, dd, J = 11.6, 4.4 Hz) and 3.77 ppm (1H, dd, J = 11.6, 
9.0 Hz), characteristic of an ABC spin system, which corresponded to a CH group bonded to 
a CH2 group.  The chemical shift associated with the carbon atom of this CH2 group was 40.9 
ppm, suggesting a CH2-X group.  In addition, the HMBC spectrum showed correlations 
between the CH2 proton signals and a peak at 209.7 ppm, characteristic of a ketone carbon 
atom.  Furthermore, a broad, one proton singlet at 4.71 ppm showed HMBC correlations to a 
carbon signal at 168.3 ppm, suggesting an OH group in close proximity to an ester carbonyl 
carbon atom.  From these data, in combination with the mass spectrum which showed an 
isotopic pattern characteristic of one chlorine atom, we deduced that the new compound was 
chlorinated Baylis-Hillman adduct 180 (31% yield) (Figure 117).111   
 
Figure 117: Structure of chlorinated Baylis-Hillman product 180, with the NMR data important for structure 
elucidation shown 
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Even though chlorinated compound 180 was not the intended target, we anticipated the 
chlorine atom would be an advantage in later stages of the synthesis, as it would allow ring 
closure using Friedel-Crafts alkylation. 
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 Conclusions and Future Work 
In this project we aimed to develop a synthetic route to DEM30355/A 94, a novel polyketide 
isolated from fermentation of A. DEM30355, which was shown to be active against Gram-
positive bacteria (Dr. B. Kepplinger) (Figure 118).  In this chapter we focused on the 
construction of the C and B rings of DM-DEM30355/A 115, as well as the quaternary 
oxygenated centre at C4a (Figure 118).  
 
Figure 118: Structures of DEM30355/A 94 and DM-DEM30355/A 115 
The most successful method we examined to synthesise the left hand portion of DM-
DEM30355/A 115 including C4a was a Baylis-Hillman reaction between methyl vinyl ketone 
164 and 3-(2,5-dimethoxyphenyl)-2,3-dioxopropanoate 167.  In the presence of the 
nucleophilic catalysts, DABCO and DMAP, the product of this reaction is alkene Baylis-Hillman 
adduct 168, however in the presence of titanium tetrachloride, the product is chlorinated 
compound 180 (Figure 119). 
 
Figure 119: Synthesis of Baylis-Hillman adducts 168 and 180 and proposed route to close the B ring of both 
compounds 
To continue this route, the next step would be to carry out ring closure and generate the B ring 
of DM-DEM30355/A 115.  An advantage of continuing the synthesis from chlorinated adduct 
180 is that we could use Friedel-Crafts alkylation to carry out ring closure, allowing access to 
a new class of saturated DEM30355/A analogues 181 (Figure 119).  On the other hand, 
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continuing from alkene Baylis-Hillman product 168 would allow us to construct the α-β 
unsaturated system as found in the natural product, via epoxidation of alkene 168 followed by 
ring closure and elimination to give 182 (Figure 119). 
Following ring closure to generate the B ring, OH-directed reduction of the C5 ketone of 
naphthalene 182 would generate diol 183, with an anti- arrangement of the two OH groups at 
C4a and C5 as seen in DM-DEM30355/A 115 (Figure 120).112 After the synthesis of ester 185 
via nucleophilic attack of C4a – OH of compound 183 on acyl chloride 184, an intramolecular 
aldol reaction may be used to generate lactone 186.  Subsequently, a key pinacol coupling 
reaction would simultaneously close the A and D rings of DM-DEM30355/A 115 (Figure 120) 
(Note: protection and deprotection steps are omitted from our discussion of our planned future 
work for clarity).113  
 
Figure 120: Proposed synthetic route to form the A and D rings of DM-DEM30355/A 115 via a key pinacol 
reaction 
When R is a propyne group, a final stage Lindlar reduction may be used to give DM-
DEM30355/A 115. The highly oxygenated small molecules synthesised in each step would be 
subjected to bioassay, to identify any interesting biological activity. 
We will now discuss an alternative synthesis of DEM30355/A 94, which examines the synthesis 
of the A, B, C ring core structure, using Diels-Alder chemistry.   
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Chapter 4. Diels-Alder Synthesis of DEM30355/A 
 Introduction  
In this chapter we continue our investigations towards the total synthesis of DEM30355/A 94 
and analogues to develop new bioactive drug leads, for SAR studies and to determine the 
absolute stereochemistry of the natural product.  Previously we focused on the synthesis of 
the C and B rings of DEM30355/A 94 (Chapter 3).  In this chapter, we discuss our work towards 
the synthesis of the A, B and C rings of DEM30355/A 94 through Diels-Alder chemistry (Figure 
121). 
 
Figure 121: Structure of DEM30355/A 94 
 Mechanism of the Diels-Alder Reaction 
One of the most important developments in the total synthesis of natural products came in 
1928, when Otto Diels and Kurt Alder published their findings on the [4+2] cycloaddition 
reaction that bears their names.114  The Diels-Alder (D-A) reaction is a pericyclic reaction 
between a diene 187 and a molecule possessing a multiple bond 188 (the dienophile), allowing 
the formation of two new C-C bonds and new stereocentres in a simultaneous, 100% atom 
efficient reaction (Figure 122). 
 
Figure 122: Reaction mechanism of the Diels-Alder reaction, with the construction of 4 new stereocentres 
In general, the D-A reaction is stereoselective in favour of the endo product, due to stabilising 
secondary orbital interactions between the HOMO and LUMO of the reactants (Figure 123).115 
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Figure 123: Origin of endo selectivity in the Diels-Alder reaction between cyclopentadiene and cis-crotononitrile at   
25 °C115 
The ability of the D-A reaction to construct 6-membered rings and new stereocentres, has been 
exploited in the total synthesis of many natural products.114 
 The Diels-Alder Reaction in Total Synthesis  
 The Total Synthesis of Reserpine 189 
Reserpine 189 was isolated from the plant, Rauwolfia Serpentina, in 1952 by Schlittler et al., 
and possesses antihypertensive and antipsychotic properties (Figure 124).116,117  Woodward 
et al. reported their total synthesis of reserpine 189 in 1956.118  The first step in Woodward’s 
synthesis is an endo D-A reaction between vinylacrylic acid 190 and quinone 191, giving 
cycloadduct 192 (Figure 124).116,118   
 
Figure 124: Right - structure of reserpine 189. Left - key Diels-Alder synthesis of the E ring of reserpine 189 
This initial D-A step successfully constructed the 6-membered E ring of reserpine 189 and 
introduced three contiguous stereogenic centres at C15, C16 and C20 as seen in the natural 
product (Figure 124). 116,117   
 The Total Synthesis of Halenaquinone 193 
Another example of the D-A reaction in total synthesis is described in Rodrigo and co-workers’ 
synthesis of the antibiotic, halenaquinone 193, which was isolated from the marine sponge, 
Xestospongia exigua, in 1983 (Figure 125).119,120 The synthesis of (±)-halenaquinone 193 
involves an oxidative ketalisation reaction between 2-methoxy-4-methylphenol 194 and dienol 
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195 in the presence of (bis(trifluoroacetoxy)iodo)benzene (BTIB), succeeded by an 
intramolecular D-A reaction of the resultant ketone 196 to generate compound 197.  
Compound 197 then undergoes a Cope rearrangement to generate tricyclic ketone 198, which 
is subsequently employed as a dienophile in another key D-A reaction with isobenzofuran 199 
as the diene, to give D-A adduct 200.120 
 
Figure 125: Rodrigo's total synthesis of halenaquinone 193120 
Using this method, Rodrigo et al. were able to synthesise racemic halenaquinone 193 in a 4% 
yield over 8 steps (Figure 125).120 
 The Partial Synthesis of Dynemicin A 202 
Magnus et al. also describe the use of this isobenzofuran diene 199 in their synthesis of the 
anthraquinone moiety 201 of dynemicin A 202 (Figure 126).  Dynemycin A 202, an antitumour 
compound, was isolated from the soil bacterium, Micromonospora chersina in 1989.121   The 
synthetic procedure involves a D-A reaction between isobenzofuran 199 and alkyne 203 as 
the dienophile, to generate D-A cycloadduct 204.122 
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Figure 126: Structure of dynemicin A 202 and the key Diels-Alder reaction in the synthesis of the anthraquinone 
moiety 201 
The starting material, diene 199, was itself synthesised via a cascade series of pericyclic 
reactions from 5,8-dimethoxy-1,4-dihydro-1,4-epoxynaphthalene 205 (Figure 127).  
Epoxynaphthalene 205 was subjected to an inverse electron demand D-A reaction with 3,6-di-
2-pyridyl-1,2,4,5-tetrazine 206 to give D-A cycloadduct 207, which rapidly undergoes a retro 
D-A reaction to give tricyclic compound 208, with the concurrent release of N2.  Compound 
208 then undergoes a second retro D-A reaction to generate the desired isobenzofuran 199 
and pyridazine 209.122 
 
Figure 127: Reaction mechanism to synthesise isobenzofuran diene 199 
Despite the apparent instability of isobenzofuran 199, Magnus et al. were able to isolate the 
compound through column chromatography for use in their D-A reactions.122 
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 Project Aims 
In this chapter we aim to synthesise the three ring carbon skeleton of DEM30355/A 94, via a 
key D-A step.  Through disconnections of bonds C10-C10a and C4a-C5, we plan to construct the 
A, B, C ring core structure of DEM30355/A 94, using a D-A reaction between isobenzofuran 
diene 199 and a cyclic dienophile 210, to generate D-A adducts 211 (Figure 128).  This 
approach will allow construction of the key quaternary centre at C4a.  Following the synthesis 
of D-A adducts 211, we aim to introduce the benzylic alcohol and α-β-unsaturated ketone as 
in DEM30355/A 94 via base catalysed ring opening to generate compound 212 (Figure 128).    
 
Figure 128: Planned synthetic route to DEM30355/A analogues 212 
In concurrence with our D-A investigations, we aim to synthesise DEM30355/A 94 as a single 
enantiomer.  We will target the enantiomer of DEM30355/A 94 which is analogous to the 
proposed absolute configuration of rishirilide A 95 (Figure 129).99 
 
Figure 129: Proposed absolute stereochemistry of rishirilide A 95 
Starting from shikimic acid 213, we will examine the diastereoselective synthesis of dienophile 
214, with the aim of constructing the chiral centre at C3 (Figure 130).  Following the synthesis 
of dienophile 214, we will investigate a D-A reaction to give D-A cycloadduct 215, which may 
be subsequently converted to DEM30355/A 94.  With consideration of the Danishefsky and 
Pettus syntheses of rishirilide B 96 (Chapter 3), we predict such a bulky dienophile will undergo 
an exo selective D-A reaction.99,100      
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Figure 130: Planned synthetic route to DEM30355/A 94 as a single enantiomer 
Following the synthesis of DEM30355/A 94, we aim to determine the absolute stereochemistry 
of the molecule through optical rotation measurements.  As in Chapter 3, through our 
investigations we aim to synthesise a range of DEM30355/A analogues for SAR studies and 
target elucidation, as well as to identify new antibacterial drug leads. 
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 Results and Discussion 
We planned to synthesise analogues of DEM30355/A 94 via a D-A reaction between 
isobenzofuran 199 and cyclic dienophiles 210, followed by base catalysed ring opening to give 
compounds 212 (Figure 131).  This would act as a test system for subsequent investigations 
into the D-A synthesis of DEM30355/A 94 as a single enantiomer, as well as provide a range 
of analogues 212 for bioassay and SAR studies.  Such compounds would contain much of the 
functionality as in DEM30355/A 94, including the A, B, C ring framework, a benzylic alcohol 
and an α-β unsaturated ketone.  In addition, the D-A reaction would allow introduction of the 
quaternary centre at C4a.  
 
Figure 131: Planned Diels-Alder synthesis of DEM30355/A analogues 212 
The first step was to synthesise diene 199.  We planned to synthesise 4,7-
dimethoxyisobenzofuran 199 following the method described by Magnus et al. in their partial 
synthesis of dynemycin A 202, from the reaction between 5,8-dimethoxy-1,4-dihydro-1,4-
epoxynaphthalene 205 and 3,6-di-2-pyridyl-1,2,4,5-tetrazine 206 (Figure 132).122  
 
Figure 132: Planned synthesis of diene 199 from epoxynaphthalene 205 
Tetrazine 206 was commercially available and so the first step was to synthesise 
epoxynaphthalene 205. 
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 Synthesis of 5,8-Dimethoxy-1,4-dihydro-1,4-epoxynaphthalene 205 
5,8-Dimethoxy-1,4-dihydro-1,4-epoxynaphthalene 205 was synthesised via a D-A reaction 
between furan and benzyne 217, generated in situ from the reaction between LDA and 2-
bromo-1,4-dimethoxybenzene 216 (Figure 133).123 
In each reaction, LDA (1.1 eq.) was reacted with 2-bromo-1,4-dimethoxybenzene 216 (1.0 eq.) 
in THF at -78 °C, followed by the immediate addition of furan (20 eq.).  
 
Figure 133: Synthesis of 5,8-dimethoxy-1,4-dihydro-1,4-epoxynaphthalene 205 
Following purification of the crude material by column chromatography, desired 
epoxynaphthalene 205 was isolated in an excellent yield (87%).   
With sufficient quantities of epoxynaphthalene 205 in hand, we moved on to the next step.  
 Synthesis of 4,7-Dimethoxyisobenzofuran 199 
The next step was to synthesise 4,7-dimethoxyisobenzofuran 199, using the cascade reaction 
between 5,8-dimethoxy-1,4-dihydro-1,4-epoxynaphthalene 205 and 3,6-di-2-pyridyl-1,2,4,5-
tetrazine 206 (Figure 132).  In their partial synthesis of dynemycin A 202, Magnus et al. 
reported that 4,7-dimethoxyisobenzofuran 199 was isolated following column chromatography 
as a moderately stable solid and an X-ray structure of the compound 199 was published, 
however no isolation procedures have been reported.122,124 
Following the method reported by Magnus et al. for the synthesis of isobenzofuran 199, 
epoxynaphthalene 205 and tetrazine 206 were reacted together under ambient conditions, with 
the reactions monitored by TLC for the loss of starting material 205 (Table 19).122 
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Table 19: Reaction conditions and isolation procedures examined to generate diene 199 
 
 
In the first reaction we examined, the 1H NMR spectrum of the reaction mixture after 1 hour 
showed signals at 7.90 ppm (1H, s), 5.85 ppm (1H, s) and 3.77 ppm (3H, s) corresponding to 
desired 4,7-dimethoxyisobenzofuran 199, however the compound decomposed following 
column chromatography (Table 19, entry 1).  We repeated the reaction with the inclusion of an 
acid wash step to remove pyridazine 209, however once again decomposition of 4,7-
dimethoxyisobenzofuran 199 was observed (Table 19, entry 2).   
Given the difficulties associated with isolating isobenzofuran 199, we considered generating 
the compound in situ in our D-A reactions. 
 Diels-Alder Reactions with in situ Generation of 4,7-Dimethoxyisobenzofuran 199  
As a modification to our original planned D-A reactions, we envisaged a one-pot reaction 
between epoxynaphthalene 205 and tetrazine 206 to generate 4,7-dimethoxyisobenzofuran 
199, followed by addition of dienophile 210 to synthesise desired D-A cycloadduct 211 (Figure 
134).  We anticipated that product 211 would result from an endo selective D-A reaction.     
 
Figure 134: Planned one-pot synthesis of Diels-Alder cycloadduct 211 
We then tested the D-A reactions between 4,7-dimethoxyisobenzofuran 199 and a range of 
dienophiles 210. 
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 Diels-Alder Reaction with 3-Ethoxycyclohex-2-en-1-one 218 as the Dienophile 
Initially we chose to examine 3-ethoxycyclohex-2-en-1-one 218 as the dienophile, to allow 
construction of the quaternary oxygenated centre at C4a, which is present in DEM30355/A 94 
(Figure 135).  
 
Figure 135: Propsed synthesis of cycloadduct 219 via a Diels-Alder reaction between diene 199 and 3-
ethoxycyclohex-2-en-1-one 218 
5,8-Dimethoxy-1,4-dihydro-1,4-epoxynaphthalene 205 was reacted with 3,6-di-2-pyridyl-
1,2,4,5-tetrazine 206, with the reactions monitored by TLC for the loss of epoxynaphthalene 
205.  At this point, 3-ethoxycyclohex-2-en-1-one 218 was added to the reaction mixture (Table 
20). 
Table 20: Diels-Alder reaction conditions examined using 3-ethoxycyclohex-2-en-1-one 218 as the dienophile 
 
In our reactions using ethoxycyclohex-2-en-1-one 218 as the dienophile, no product 219 
signals were observed in the 1H NMR spectrum of the crude reaction material, despite varying 
the solvent, increasing the reaction temperature and time, and increasing the equivalencies of 
dienophile 218 (Table 20, entries 1-3).  We postulated that dienophile 218, which contains an 
electron donating OEt group, was too electron rich to undergo a normal electron demand D-A 
reaction with diene 199, therefore we decided to examine organo-catalysed D-A reactions 
using Schreiner’s bisthiourea catalyst 220 and proline 221 (Figure 136).125,126  We postulated 
that bisthiourea catalyst 220 and proline 221 would lower the LUMO of ethoxycyclohex-2-en-
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1-one 218 via the formation of a hydrogen bonded adduct and enamine 222 respectively, thus 
decreasing the Ea for the D-A reaction. 
 
Figure 136: Structure of Schreiner’s bisthiourea catalyst 220 and proline 221 
5,8-Dimethoxy-1,4-dihydro-1,4-epoxynaphthalene 205 was reacted with 3,6-di-2-pyridyl-
1,2,4,5-tetrazine 206 to generate 4,7-dimethoxyisobenzofuran 199.  When TLC indicated loss 
of starting material 205, 3-ethoxycyclohex-2-en-1-one 218 and a chosen catalyst were added 
to the reaction mixture (Table 21). 
Table 21: Diels-Alder reaction conditions examined using dienophile 218 in the presence of organocatalysts 220 
or 221  
 
 
In both of the reactions we tested using organo-catalysts 220 and 221, the 1H NMR spectrum 
of the crude reaction material showed no signals corresponding to desired D-A cycloadduct 
219, and that diene 199 had decomposed.  Consequently, we chose to examine an alternative 
dienophile in our D-A reactions. 
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 Diels-Alder Reaction with 3-Methylcyclohex-2-en-1-one 223 as the Dienophile 
We postulated that the OEt group of 3-ethoxycyclohex-2-en-1-one 218 may have deactivated 
the alkene towards reaction with 4,7-dimethoxyisobenzofuran 199.  Therefore we decided to 
investigate an alternative dienophile, 3-methylcyclohexen-2-en-1-one 223, which is substituted 
with a less electron donating group.  
4,7-Dimethoxyisobenzofuran 199 was synthesised as before from the reaction between 5,8-
dimethoxy-1,4-dihydro-1,4-epoxynaphthalene 205 and 3,6-di-2-pyridyl-1,2,4,5-tetrazine 206, 
with the reactions monitored by TLC for loss of epoxynaphthalene 205.  At this point, 3-
methylcyclohex-2-en-1-one 223 was added to the reaction mixture (Table 22). 
Table 22: Diels-Alder reaction conditions examined using 3-methylcyclohexen-2-en-1-one 223 
 
 
Once again, no D-A product 224 was observed through analysis of the 1H NMR spectra of the 
crude material (Table 22, entries 1 – 4), even after a long reaction time at a high temperature 
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(Table 22, entry 4), or using a large excess of dienophile 223 (Table 22, entry 3).  The addition 
of catalysts to increase the reactivity of dienophile 223, namely a Lewis acid catalyst (Table 
22, entry 5), H-bonding catalyst 220 (Table 22, entry 6), and proline 221 (Table 22, entry 7), 
also did not result in the formation of desired D-A cycloadduct 224. 
These observations prompted us to consider that 3-substituted cyclohexenones may be too 
sterically hindered to undergo the desired D-A reactions with diene 199, and we proceeded to 
investigate alternative reagents.  
 Diels-Alder Reaction with Cyclohexenone 225 as the Dienophile 
We anticipated that cyclohexenone 225 would be more reactive, both sterically and 
electronically, towards the D-A reaction with 4,7-dimethoxyisobenzofuran 199 than the 3-
substituted cyclohexenones, 218 and 223 we had previously tested. 
Epoxynaphthalene 205 and tetrazine 206 were reacted together to generate diene 199.   
Cyclohexenone 225 was added to the reaction mixture following disappearance of 
epoxynaphthalene 205 by TLC (Table 23).   
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Table 23: Diels-Alder reaction conditions examined to synthesise cycloadduct 226 
 
  
In the D-A reactions we tested, no product 226 was observed in the reactions carried out at 
room temperature – 40 °C (Table 23, entries 1-3) and the use of Lewis acid and H-bonding 
catalyst 220 appeared to accelerate the degradation of diene 199 (Table 23, entries 6-8).  
However, signals corresponding to desired D-A cycloadduct 226 were observed in the 1H NMR 
spectra of the crude material from the reactions conducted in refluxing toluene (Table 23, 
entries 4 and 5) and, following purification of the crude material by column chromatography, 
cycloadduct 226 was isolated in a modest yield of 40% (Table 23, entry 5).  
With this positive result, we decided to examine alternative, more reactive dienophiles in our 
D-A reaction with 4,7-dimethoxyisobenzofuran 199. 
 Diels-Alder Reaction with Benzoquinone 191 as the Dienophile 
Next we investigated benzoquinone 191 as the dienophile.  We expected the Ea barrier for 
these D-A reactions to be small, due to the additional electron withdrawing carbonyl group of 
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benzoquinone 191, resulting in the compound having a much lower LUMO compared to 
cyclohexenone 225. 
Epoxynapthalene 205 (1 eq.) and tetrazine 206 (1.1 eq.) were reacted in DCM for 1 hour to 
generate diene 199, at which point the reaction mixture was cooled to 0 °C and benzoquinone 
191 (1.1 eq.) was added (Table 24). 
Table 24: Diels-Alder reaction conditions examined in the synthesis of cycloadduct 227 
 
 
The 1H NMR spectrum of the reaction mixture after 5 minutes showed no peaks at 7.90 ppm 
(1H, s), 5.85  ppm (1H, s) and 3.77 ppm (3H, s) corresponding to diene 199, suggesting the 
reaction had proceeded in 100% conversion.  The 1H NMR spectrum indicated a mixture of 
products, however following purification by column chromatography, only desired D-A adduct 
227 was isolated in a 56% yield (Table 24, entry 1).    
Increasing the temperature to room temperature (Table 24, entry 2) and increasing both the 
temperature and reaction time (Table 24, entry 3) did not result in a significant change in the 
product distribution, as shown by analysis of the 1H NMR spectrum of the crude material.   In 
the latter reaction, purification of the crude material by column chromatography yielded D-A 
adduct 227 in addition to a minor product 228 (Table 24, entry 3).  The 1H NMR spectrum of 
minor compound 228 was consistent with a diastereomer of major product 227 (Note: the lower 
isolated yields of product 227 (Table 24, entries 1 and 2) could be attributed to the small scale 
the reactions were conducted on). 
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Crystals of major product 227 were obtained through slow evaporation from chloroform and 
analysed by X-ray crystallography. 
 
Figure 137: X-Ray crystal structure of Diels-Alder cycloadduct 227 from two different angles 
Crystals of D-A cycloadduct 227 grow in the monoclinic space group, P21/c, with one molecule 
in the asymmetric unit (Figure 137).  The X-ray crystal structure showed product 227 resulted 
from an endo D-A reaction, therefore we anticipated that the minor product was exo D-A 
cycloadduct 228. 
 
The success of the D-A reaction using benzoquinone 191 prompted us to examine alternative 
diketone dienophiles, to synthesise more varied D-A cycloadducts. 
 Diels-Alder Reaction with 2,6-Dimethylcyclohexa-2,5-diene-1,4-dione 231 as the 
Dienophile 
We anticipated that substituted benzoquinones 229 may be sufficiently reactive to generate D-
A cycloadduct 230, which would contain a quaternary centre at C4a as in DEM30355/A 94 
(Figure 138).   
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Figure 138: Planned synthesis of cycloadduct 230 with the oxygenated centre at C4a in place 
To test this theory, we examined 2,6-dimethylcyclohexa-2,5-diene-1,4-dione 231  as the 
dienophile (Figure 139).  Diene 199 was generated following the reaction between 
epoxynaphthalene 205 (1 eq.) and tetrazine 206 (1.1 eq.).  After a reaction time of 1 hour, the 
reaction mixture was cooled to 0 °C and 2,6-dimethylcyclohexa-2,5-diene-1,4-dione 231 was 
added (Table 25, entry 1).  
 
Figure 139: Synthesis of exo adduct 233-a and endo adduct 233-b from the Diels-Alder reaction between diene 
199 and dienophile 231 
Table 25: Diels-Alder reaction conditions examined using 2,6-dimethylcyclohexa-2,5-diene-1,4-dione 231 as the 
dienophile   
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The 1H NMR spectrum of the reaction mixture indicated 100% conversion of diene 199 to D-A 
cycloadduct as a mixture of diastereomers (1.0: 0.9), after a reaction time of 15 minutes (Table 
25, entry 1).  We repeated the reaction at room temperature (Table 25, entry 2), using a longer 
reaction time (Table 25, entry 3) and using a H-bonding catalyst 220 (Table 25, entry 4).  In 
each case, the 1H NMR spectrum of the crude product showed 100% conversion of diene 199 
to the same (1.0:0.9) diastereomeric ratio of products and, following purification of the crude 
material by column chromatography, D-A cycloadducts 233-a and 233-b were isolated in yields 
of 31-49% and 19-27% respectively. 
A crystal structure of minor product 233-b was obtained, which showed the compound resulted 
from an endo D-A reaction (). We anticipated that major product 233 arose from an exo D-A 
reaction, however we were unable to grow crystals of compound 233 to prove this.   
 
Figure 140: Figure 140: X-Ray crystal structure of Diels-Alder cycloadduct 233-b from two different angles 
Crystals of endo cycloadduct 233-b crystallise in the orthorhombic space group, Fdd2, with 
one molecule in the asymmetric unit. 
With a working method to access D-A cycloadducts 233-a and 233-b developed, we then 
examined other dienophiles. 
 Diels-Alder Reactions with 5- Membered Ring Dienophiles  
We applied our one-pot diene generation/ D-A reaction sequence to other, well studied, 5-
membered ring dienophiles (Table 26). 
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Table 26: Reaction conditions examined in the synthesis of cycloadducts 234 – 236 
 
 
In each case, the D-A reaction proceeded with 100% conversion of the diene to the desired D-
A cycloadduct as shown by TLC (Table 26, entries 3, 5 and 6) or by the 1H NMR spectrum of 
the reaction mixture (Table 26, entries 1, 2 and 4).  A reaction was also conducted in 
deuterated DCM, using 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD) (1 eq.) as the dienophile.  
The 1H NMR spectrum of the reaction mixture after 15 minutes at 0 °C indicated the desired 
D-A cycloadduct had been generated, in addition to compounds related to the degradation of 
diene 199, therefore we did not pursue investigations into this dienophile further. 
D-A cycloadducts 235 and 236 were isolated following an acid wash (to remove pyridazine by-
product 209) and solvent extraction of the reaction mixture, in good yields (Note: no isolated 
yields are reported for Table 26, entries 1, 2 and 4 as these were test scale reactions). 
Once we had examined a range of diketone compounds in our D-A reactions with 
isobenzofuran 199, we decided to investigate more functionalised dienophiles. 
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 Diels-Alder Reaction with 4-Hydroxy-4-methylcyclohexa-2,5-dien-1-one 237 as 
the Dienophile 
We had established that the D-A reactions proceeded well at 0 °C – room temperature using 
1,4-diketone compounds as dienophiles, and the D-A reaction between isobenzofuran 199 and 
cyclohexanone 225 did proceed at high temperatures.  Next we examined 4-hydroxy-4-
methylcyclohexa-2,5-dien-1-one 237 as the dienophile, which we anticipated would be 
intermediate in reactivity in comparison to the 1,4-diketone compounds and cyclohexenone 
225 previously tested (Figure 141).  The resultant D-A cycloadduct 238 would be functionalised 
at the C4 position as in DEM30355/A 94.  
 
Figure 141: Synthesis of cycloadduct 238 via a D-A reaction between  diene 199 and 4-hydroxy-4-
methylcyclohexa-2,5-dien-1-one 237 
 Synthesis of 4-Hydroxy-4-methylcyclohexa-2,5-dien-1-one 237 
The first step was to synthesise dienophile 237.  Benzoquinone 191 was reacted with methyl 
lithium to generate 4-hydroxy-4-methylcyclohexa-2,5-dien-1-one 237 (Figure 142).127   
 
Figure 142: Synthesis of 4-hydroxy-4-methylcyclohexa-2,5-dien-1-one 237 
It is believed the reaction proceeds via a single electron transfer mechanism, with 
benzoquinone 191 as the electron acceptor (Figure 143).127 The quantity of reduction product 
239 compared to addition product 237 is dependent on the steric properties of the alkyl group 
of the organometallic.127 
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Figure 143: Proposed reaction mechanism to synthesise 4-hydroxy-4-methylcyclohexa-2,5-dien-1-one 237 and 
hydroquinone 239127 
Following purification of the crude material by column chromatography, compound 237 was 
isolated in a 28% yield (Note: the 1H NMR spectrum of the isolated product contained a small 
peak corresponding to by-product 239). 
Despite the low yield, a sufficient quantity of compound 237 was obtained to proceed to the 
next step. 
 Diels-Alder Reaction Between Isobenzofuran 199 and 4-Hydroxy-4-
methylcyclohexa-2,5-dien-1-one 237 
Diene 199 was synthesised in situ from epoxynaphthalene 205 (1 eq.) and tetrazine (1 eq.).  
When TLC indicated starting material 205 had disappeared, 4-hydroxy-4-methylcyclohexa-2,5-
dien-1-one 237 was added to the reaction mixture (Figure 144).  
 
Figure 144: Diels-Alder synthesis of cycloadduct 238 
After a reaction time of 2 days, desired D-A cycloadduct 238 was isolated from the reaction 
mixture following an acid wash (to remove pyridazine by-product 209) and solvent extraction, 
in an excellent yield of 92%, as a single diastereomer.  The coupling constants JH4a-H5 = 4.7 Hz 
and JH10a-H9 = 5.7 Hz were comparable to the analogous coupling constant JH10a-H9 = 5.4 Hz in 
endo cycloadduct 233-b previously synthesised, therefore we could deduce compound 238 
also resulted from an endo D-A reaction. 
After investigating a range of dienophiles to synthesise D-A cycloadducts, we could then 
proceed to the next stage in the synthetic procedure.  
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 Examination of the Reaction of Diels-Alder Cycloadduct 233-b with Base 
The next step was to examine the base catalysed ring opening reactions of the D-A 
cycloadducts 211 synthesised.128  We envisaged that deprotonation at C10a would lead to 
enolate 240, followed by an E1cB reaction to generate compound 212, with a benzylic alcohol 
at C5 and an α-β unsaturated system as seen in DEM30355/A 94.  
 
Figure 145: Planned synthesis of alcohol 212 via an E1cB reaction of Diels-Alder adduct 211 
We decided to first look at the base catalysed ring opening reaction using endo D-A 
cycloadduct 233-b, which contained only one acidic proton at C10a.  D-A cycloadduct 233-b 
was reacted with base and the reaction progress was monitored by TLC (Table 27). 
Table 27: Basic reaction conditions examined to generate alcohol 241 from Diels-Alder adduct 233-b 
 
Our preliminary investigations have shown that NaH did not result in the desired E1cB reaction, 
possibly as a result of the poor organo-solubility of NaH, and starting material 233-b was 
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recovered (Table 27, entries 1 and 2).  Unreacted starting material 233-b was also recovered 
from the reaction using NaOMe, which was likely due to the poor solubility of compound 233-
b in the reaction solvent (methanol) (Table 27, entry 3).  In contrast, in the first reaction we 
have examined using LDA, TLC analysis showed disappearance of starting material 233-b 
after 165 minutes at room temperature (Table 27, entry 4).  The 1H NMR spectrum of the 
sample following column chromatography showed signals which did not correspond to starting 
material 233-b, including signals in the 6.79 - 6.56 region which suggested an AB spin system 
corresponding to a new product (Figure 146). 
 
Figure 146: Expansion of the 6.8 - 5.6 ppm region of the 1H NMR spectra of starting material 233-b (bottom) and 
the new unidentified product from the reaction of 233-b with LDA (top) 
However, this reaction was carried out on a test scale and more investigation is required to 
determine whether the new product(s) correspond to desired alcohol 241. 
To coincide with our investigations into the D-A synthesis of analogues of DEM30355/A 94, 
we have examined the synthesis of the A ring of DEM30355/A 94 as a dienophile, with the 
ultimate aim of generating DEM30355/A 94 as single enantiomer.  Herein we will discuss our 
work towards this target. 
  
new unidentified product 
starting material 233-b 
Chapter 4. Diels-Alder Synthesis of DEM30355/A 
 
124 
 
 Single Enantiomer Synthesis of DEM30355/A 94 
We imagined that DEM30355/A 94 could be synthesised as a single enantiomer following a D-
A reaction from the enantiopure dienophile 214 (Figure 147). Through comparison of the 
specific rotation measurements of naturally occurring DEM30355/A 94 and synthesised 
DEM30355/A, the absolute stereochemistry of the molecule could be elucidated.   
 
Figure 147: Proposed Diels-Alder synthesis of DEM30355/A 94 as a single enantiomer 
The initial task was to synthesise dienophile 214.  We envisaged that dienophile 214 could be 
synthesised as a single enantiomer from commercially available shikimic acid 213 (Figure 
148).  We planned to protect the acid OH of shikimic acid 213 as the methyl ester 242, followed 
by acetal protection of the trans vicinal diol, to generate acetal methyl shikimate 243.129  The 
construction of the stereogenic centre at C3 was fundamental to our synthetic plan. We would 
use the hydroxyl group at C4a of acetal methyl shikimate 243 to hydrogen bond direct an 
epoxidation to the top face of the alkene, ultimately setting up the desired stereochemistry at 
the C3 position in product 244.  
 
Figure 148: Proposed diastereoselective synthesis of dienophile 214 
The first stage was to develop a working synthetic method to gram quantities of acetal methyl 
shikimate 243, via methyl shikimate 242. 
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 Synthesis of Methyl Shikimate 242 
Brønsted acid catalysed esterification of shikimic acid 213 was carried out in refluxing 
methanol.  
 
Figure 149: Synthesis of methyl shikimate 242 from shikimic acid 213 
After 48 hours, methyl shikimate 242 was isolated in a 60% yield, which could be improved to 
72% by increasing the reaction time to 70 hours (Figure 149).  We employed a recrystallisation 
as an efficient isolation approach to multi-gram quantities of methyl shikimate 242, facilitating 
the examination of subsequent steps. 
 Synthesis of Acetal Methyl Shikimate 243 
The next stage was to selectively protect the trans vicinal diol of methyl shikimate 242 as the 
acetal.129 
Methyl shikimate 242, trimethyl orthoformate and 2,3-butanedione were reacted together in 
refluxing methanol in the presence of a Brønsted acid catalyst (Figure 150).   
 
Figure 150: Synthesis of acetal methyl shikimate 243 
After 48 hours, two isomers were isolated in 73% and ~22% yields after column 
chromatography.  The 1H and 13C NMR data of the isomers were compared to literature values 
to determine the structures.129 The major isomer 243 was shown to be the desired structure, 
with the minor isomer 245 arising from acetal protection of the cis vicinal diol.  
With multi-gram quantities of acetal methyl shikimate 243 in hand, we then moved on to 
examine the epoxidation chemistry. 
 Investigations into the Epoxidation of Acetal Methyl Shikimate 243 
The next step was to examine the epoxidation of the alkene of acetal methyl shikimate 243.  
We postulated that the allylic alcohol of compound 243 would direct epoxidation, via hydrogen 
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bonding, to the top face of the alkene to give epoxide 244 (Figure 151).130   This would give the 
desired stereochemistry at C3.  From here, an SN2 reaction could be used to ring open the 
epoxide to give alcohol 246.  
 
Figure 151: Proposed synthesis of alcohol 246 via hydrogen bond directed epoxidation of alkene 243 followed by 
nucleophilic ring opening 
We screened acetal methyl shikimate 243 under a range of epoxidation conditions, using 
mCPBA and V(acac)3)/ BuOOH as oxidants (Table 28) 
Table 28: Oxidation reaction conditions examined in the synthesis of epoxide 244 
 
  
In the first reaction we tested using mCPBA as the oxidant, we could not observe any signals 
corresponding to epoxide product 244 in the 1H NMR spectrum of the crude material, only 
unreacted acetal 243 (Table 28, entry 1).  Increasing the reaction temperature (Table 28, 
entries 2- 4) and increasing the equivalencies of a mCPBA (Table 28, entry 4) did not generate 
epoxide 244, however signals corresponding to a new by-product 247 were observed in the 
1H NMR spectrum of the crude material.  We postulated that by-product 247 may be the result 
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of an acid catalysed side reaction from the decomposition of mCPBA to meta-chlorobenzoic 
acid.  Therefore a reaction using NaHCO3 as a buffer was conducted and we also tested the 
alternative oxidant V(acac)3/ 
tBuOOH.   However, in both cases by-product 247 was still 
generated (Table 28, entries 5 and 6). We therefore decided to isolate by-product 247 and 
investigate its structure, to gain a better understanding of the reaction. 
Following purification of the combined crude material from the mCPBA reactions (Table 28, 
entries 3 and 4), by-product 247 was isolated and investigated using NMR.  Compared to the 
spectrum of starting material 243, the 13C spectrum of by-product 247 contained an additional 
carbon signal at 194.5 ppm, characteristic of a ketone carbon atom.  In addition, the 1H NMR 
spectrum contained a signal at 6.80 ppm (1H, d, J = 3.1 Hz), characteristic of an alkene CH.   
Therefore we could deduce that the by-product was ketone 247, the result of oxidation of the 
allylic alcohol in compound 243 (Figure 152). 
 
Figure 152: Structure of ketone 247 
As it was apparent from our experiments that the epoxidation of alkene 243 to epoxide 244 
was not likely to be successful, we moved on to investigate an alternative synthetic method. 
 Dihydroxylation of Acetal Methyl Shikimate 243 
As an alternative method, we decided to examine the dihydroxylation of acetal methyl 
shikimate 243 to generate triol 248 (Figure 153).  In an analogous way to the epoxide reactions, 
we anticipated that the alcohol group at C4a of 243 would direct dihydroxylation to the top face 
of the alkene through hydrogen bonding, using OsO4 in the presence of TMEDA.131 This would 
set up the desired stereochemistry at C3 as in our targeted enantiomer of DEM30355/A 94.  
 
Figure 153: Planned synthesis of triol 248 
Firstly, as a test system, we reacted acetal methyl shikimate 243 with osmium tetroxide (5 
mol%) and N-methylmorpholine N-oxide (NMO) (3 eq.) with the reaction progress monitored 
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by TLC (in the absence of TMEDA, we expected the dihydroxylation to occur on the opposite 
face to the allylic hydroxyl group of starting material 243) (Figure 154).132 
 
Figure 154: Dihydroxylation of alkene 243 
After 28 hours, TLC showed no starting material 243 remained in the reaction mixture and a 
new spot with a lower Rf value than 243 was apparent.  We think it is likely that desired triol 
249 was generated in the reaction, but could not be recovered following aqueous work-up, 
presumably as a result of its high water solubility. To circumvent this issue, we imagined 
protecting the OH of acetal methyl shikimate 243 with a hydrophobic group prior to the reaction 
with osmium tetroxide, so that the dihydroxylation product would be more organosoluble 
compared to our previous target 249.  
 OH Protection of Acetal Methyl Shikimate 243 
We decided to protect the OH of acetal methyl shikimate 243 with TBDMS, to generate OH-
protected compound 250.  TBDMS protected compound 250 would be used as a test system 
in the subsequent dihydroxylation step, as we anticipated the hydrophobic group would enable 
the recovery of dihydroxylation product 251 following an aqueous work-up (Figure 155).   
 
Figure 155: Planned synthesis of organo-soluble diol 251 
Consequently, acetal methyl shikimate 243 (1 eq.) was reacted TBDMSCl (1.6 eq) and 
imidazole (1.6 eq.) in DCM.  
 
Figure 156: OH protection of alkene 243 
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After a reaction time of 4 days, OH-protected alcohol 250 was isolated in an 88% yield after 
purification by column chromatography. 
With product 250 in hand, we could then examine the dihydroxylation reaction. 
 Dihydroxylation of TBDMS Alkene 250 
Using the same reaction conditions as before, TBDMS-compound 250 was reacted with 
osmium tetroxide at room temperature, in a sterically directed reaction (Figure 157).  The 
reaction progress was monitored by TLC. 
 
Figure 157: Dihydroxylation of TBDMS compound 250 
Following a reaction time of 18 hours, TLC showed no remaining starting material 243 and a 
new spot with a lower Rf was apparent.  Following an aqueous work up, the 1H NMR spectrum 
of the crude material showed the desired diol 251 had been generated, in 100% conversion of 
starting material 250.   
We expected that diol 251 would have the opposite stereochemistry at C3 to our targeted 
enantiomer of DEM30355/A 94, as a result of the bulky TBDMS group of starting material 250 
sterically directing the reaction to the back face.  To direct dihydroxylation to the top face of 
the molecule and hence construct the desired chiral centre at C3, we needed to invert the 
stereochemistry of the protected allylic alcohol at C4a, so that the back face would be sterically 
blocked.    
 Mitsunobu Reactions of Acetal Methyl Shikimate 243 
We planned to use Mitsunobu chemistry to both invert the stereochemistry at C4a of acetal 
methyl shikimate 243 and introduce an OH-protecting group, to give compound 252 (Figure 
158).  OH-Protected compound 252 would then be subjected to dihydroxylation conditions, 
whereby the protecting would sterically direct the formation of diol product 253, with the desired 
stereochemistry at C3 (Figure 158).   
 
Figure 158: Planned synthesis of diol 253 with the correct stereochemistry at C3 
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In all of our Mitsunobu experiments, acetal methyl shikimate 243 (1 eq.) was reacted with 
triphenylphosphine (1.5 eq.), a chosen aromatic carboxylic acid (1.5 eq) and diethyl 
azodicarboxylate (DEAD) (1.5 eq.) at room temperature, using THF as the solvent (Table 29). 
We required X-ray crystallography data of Mitsunobu product 252 to monitor the 
stereochemistry at C4a, therefore in the Mitsunobu reactions we used para-nitro benzoic acid, 
to encourage crystallisation of the product (Table 29, entry 5).  We also examined the use of 
halogenated benzoic acids, as the presence of a heavy atom in the product would aid in the 
determination of the absolute stereochemistry of the molecule through X-ray analysis (Table 
29, entries 2 - 4).   
Table 29: Synthesis of Mitsunobu products 254 – 258 from acetal methyl shikimate 243 
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In each experiment, analyisis of the 1H NMR spectrum of the crude material indicated the 
reactions proceeded with 100% conversion of starting material 243 to the desired product and, 
following purification by column chromatography, Mitsunobu products 254 - 258 were isolated 
in yields ranging from 58 – 85%.  The low yield of product 256 was the result of poor separation 
obtained between the carboxylic acid starting material and product 256 (Table 29, entry 3) 
(Note: washing the solvated crude product with sodium bicarbonate aq. solution, failed to 
remove the excess aromatic acid).   
To determine whether the Mitsunobu chemistry had successfully inverted the stereochemistry 
at C4a, crystals of nitro Mitsunobu product 258 (Table 29, entry 5) were grown by slow 
evaporation from DCM/ toluene and analysed by X-ray crystallography.  
 
Figure 159: X-Ray crystal structure of Mitsunobu product 258 
Nitro compound 258 crystallises in the monoclinic space group P21, with two molecules in the 
asymmetric unit.  The crystal structure of nitro product 258 showed the compound had the 
desired stereochemistry at position C4a, with the nitrobenzoyl moiety syn to the proton at C10a 
(Figure 159). 
With the stereochemistry of Mitsunobu product 258 ascertained, we could then examine the 
dihydroxylation chemistry. 
 Dihydroxylation Reaction of Benzoyl Mitsunobu Product 258 
The next step was to investigate the dihydroxylation chemistry of benzoyl compound 254.  Out 
of the Mitsunobu products 254 - 258 synthesised, benzoyl compound 254 was the most 
suitable in terms of electronic and steric properties for our planned exo, normal electron 
demand D-A reaction later in the synthetic route (Figure 160).  
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Figure 160: Planned synthesis of DEM30355/A 94 as a single enantiomer via an exo Diels-Alder reaction 
Therefore benzoyl compound 254 was reacted with osmium tetroxide (5 mol%) and NMO (3 
eq.), with the reaction progress monitored by TLC (Figure 161).   We expected the benzoyl 
group to sterically direct the dihydroxylation reaction to the top face of the molecule, generating 
diol 259, with the correct stereochemistry at C3. 
 
Figure 161: Synthesis of diol 259 via the sterically directed dihydroxylation of alkene 254 
After a reaction time of 5 days, the crude reaction material was purified by column 
chromatography and a new product was isolated.  The 1H NMR spectrum of the new product 
showed no signals corresponding to an alkene CH, and the IR spectrum showed peaks at 
3468 and 3430 νmax cm-1 which were characteristic of OH groups.  In combination with mass 
spectrometry data, we could deduce the new product was desired diol 259, isolated in a good 
yield of 75%. 
At this stage it was imperative to determine if the stereochemistry at C3 of diol 259 was the 
same as in our targeted enantiomer of DEM30355/A 94, therefore crystals of diol 259 were 
grown by slow evaporation from diethyl ether/DCM/ toluene and analysed by X-ray 
crystallography (Figure 162). 
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Figure 162: X-Ray crystal structure of diol 259 
Diol 259 crystallises in the orthorhombic space group P212121.  The asymmetric unit contains 
one molecule of 259 with a partial occupancy of water.  The crystal structure showed the 
hydroxyl groups were positioned on the opposite face to the benzoyl moiety, with the desired 
stereochemistry at C3 (Figure 162).   
With a working synthetic route to diol 259 developed, we could progress to the next stage in 
the synthesis. 
 Synthesis of Ketone 262 
The next step was to oxidise the secondary alcohol of diol 259 to generate ketone 262, followed 
sequentially by an E1cB reaction and selective OH protection to give dienophile 260 (Figure 
163). 
 
Figure 163: Planned synthesis of dienophile 260 from diol 259 
We investigated several oxidising conditions to oxidise the secondary alcohol of diol 259, with 
the reaction progress monitored by TLC (Table 30).  
Chapter 4. Diels-Alder Synthesis of DEM30355/A 
 
134 
 
Table 30: Reaction conditions examined to generate ketone 262 
 
TLC analysis of the reaction using DMP showed unreacted starting material 259 after a lengthy 
reaction time.  We postulated that the insolubility of DMP in DCM may hinder the reaction, 
therefore DCM was replaced with DMSO.  The 1H NMR spectrum of the crude material showed 
lots of unreacted diol 259, however signals corresponding to our desired ketone 262 were 
observed, with a starting material 259 to ketone product 262 ratio of 1.0: 0.2 (Table 30, entry 
1).  As the reaction with DMP was very slow, we decided to examine the alternative oxidant, 
pyridinium chlorochromate (PCC), however after a reaction time of 5 days, only unreacted diol 
259 was recovered (Table 30, entry 2).  We postulated that DMP and PCC were too bulky to 
efficiently oxidise the sterically hindered secondary alcohol of starting material 259, therefore 
we decided to examine an alternative, less bulky oxidant. 
 Swern Oxidation of Diol 259 
Next we investigated the oxidation of diol 259 under Swern conditions.  Diol 259 was reacted 
with oxalyl chloride and DMSO, with the reaction progress monitored by TLC (Figure 164). 
 
Figure 164: Swern oxidation of alcohol 259 to ketone 262 
Following a reaction time of 35 minutes at room temperature, the crude material was purified 
by column chromatography which resulted in the isolation of two new compounds. The 13C 
NMR spectrum of the more polar compound showed a new signal at 196.7 ppm, characteristic 
of a ketone carbon atom therefore, in addition to mass spectrometry data, we were able to 
conclude this compound was the target ketone 262, isolated in a 25% yield. 
The 1H NMR spectrum of the less polar isolated compound 263 contained signals at  4.93 ppm 
(1H, d, J = 10.6 Hz) and 4.67 ppm (1H, d, J = 10.6 Hz), corresponding to two geminally coupled 
protons, in addition to a signal at 2.27 ppm (3H, s) suggesting a Me group.  HMBC data showed 
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a correlation between the signal at 2.27 ppm, corresponding to the Me group, and a signal at 
71.9 ppm, which corresponded to the carbon atom of the CH2 group.  Therefore we could 
deduce the CH2 and Me groups were in close bonding proximity to one another.  In addition, 
the 13C NMR spectrum showed a new carbonyl signal at 196.2 ppm, consistent with oxidation 
of the secondary alcohol in diol 259 to a ketone.  Through analysis of the NMR spectra and in 
combination with HRMS data, we deduced this compound was thioacetal 263, isolated in a 
12% yield (Figure 165).   
 
Figure 165: Structure of thioacetal 263 
The formation of thioacetal 263 can be explained by the reaction of the tertiary alcohol of 
ketone 262 with the sulfur ylide generated during the Swern reaction (Figure 166). 
 
Figure 166: Mechanism of formation of thioacetal 263 
Although we anticipated that the thioacetal of compound 263 could readily be removed 
following hydrolysis, we decided to optimise the Swern reaction so that ketone 262 was the 
sole product, to simplify the purification step.   
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We hypothesised that the formation of thioacetal 263 may result from a large excess of base 
as used in the initial reaction (Table 31, entry 1), therefore we screened reaction conditions 
using fewer equivalencies of triethylamine (Table 31, entries 2-4).  
Table 31: Swern reaction conditions examined to synthesise ketone 262 
 
 
We found that the oxidation of diol 259 to ketone 262 did not go to completion when the 
equivalencies of base were reduced to 1.5 – 2.0, however no undesired thioacetal 263 was 
generated in the reactions (Table 31, entries 2 and 3).  We anticipated that the equivalencies 
of base were too low, leading to only partial conversion of starting material 259 to ketone 262.   
Hence the equivalencies of triethylamine were increased (5 eq.) which resulted in 100% 
conversion to desired ketone 262 as shown by the 1H NMR spectrum of the crude material 
(Table 31, entry 4).  Ketone 262 was subsequently isolated in an excellent yield of 85% 
following column chromatography  
We were able to obtain a crystal structure of ketone 262, following crystal growth using slow 
evaporation from petroleum ether/ diethyl ether (Figure 167). 
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Figure 167: X-Ray crystal structure of ketone 262 
Ketone 262 crystallises in the monoclinic space group P21, with one molecule in the 
asymmetric unit (Figure 167).  The crystal structure confirmed the stereochemistry of molecule 
262 was consistent with our predictions. 
Once we had developed a viable synthetic method to sufficient quantities of ketone 262, we 
could procced to the next step in the synthesis. 
  Reaction of Ketone 262 with Base  
The next stage in our planned synthetic route to DEM30355/A 94 was to use an E1CB reaction 
to synthesise diol 264 (Figure 168).  Following OH protection, we would then use a D-A 
reaction with isobenzofuran 199 to generate adduct 261, with the A, B, C ring core of 
DEM30355/A 94 in place. 
 
Figure 168: Planned synthesis of Diels-Alder adduct 261 from ketone 262 
We anticipated that, apart from the hydroxyl proton, the proton α to the ketone would be the 
most acidic in compound 262.  We envisaged that the reaction of ketone 262 with base would 
lead to the formation of enolate 265, followed by ring opening of the acetal group via an E1cB 
mechanism, leading to alkene 264 (Figure 169). 
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Figure 169: Proposed synthesis of alkene 264 
We screened a range of basic reaction conditions to generate alkene 264 from ketone 262 
(Table 32). 
Table 32: Reaction of ketone 262 under a range of basic reaction condtions 
 
In the first reaction we examined using pyridine as the base, only starting material 262 was 
recovered (Table 32, entry 1), therefore we opted to use a stronger base, namely NaH.  Despite 
a long reaction time, the 1H NMR spectrum of the crude material showed lots of unreacted 
ketone 262 remained, although new signals were observed.  The spectrum contained a one 
proton doublet at 5.64 ppm (J = 1.4 Hz), suggesting a CH group bonded to an electron 
withdrawing moiety, vicinally coupled to a CH group.  We believe this signal at 5.64 ppm 
corresponded to the C4a proton of compound 266, a diastereomer of starting material 262, 
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which arises from the formation of enolate 265 followed by protonation from back face (Table 
32, entry 2). 
 
With this promising result we decided to examine the alternative, more organo-soluble bases, 
NaHMDS (Table 32, entry 3) and LDA (Table 32, entry 4), to try and generate desired alkene 
product 264.  In both cases, the 1H NMR spectrum of the crude material showed signals 
corresponding to a new, aromatic by-product 267, but no signals characteristic of desired 
alkene 264 were observed   We anticipated that the formation of this undesired by-product 267 
may be avoided by using a less reactive base, therefore the reaction was repeated using 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), but once again by-product 267 was the sole product 
from the reaction (Table 32, entry 5). We therefore decided to isolate by-product 267 and 
investigate its structure, to gain a better understanding of the reaction.  
The crude material from the reaction between ketone 262 and NaHMDS (Table 32, entry 3) 
was purified by column chromatography, which led to the isolation of by-product 267 as a 2: 1 
mixture of diastereomers as shown by the 1H NMR spectrum (Figure 170).  The NMR data 
discussed from herein refers to the major diastereomer of by-product 267.  The 1H NMR 
spectrum showed signals at 7.34 ppm (1H, d, J = 8.9 Hz) and 6.42 ppm (1H, d, J = 8.9 Hz), 
characteristic of an AB spin system, corresponding to two adjacent aromatic CH groups.  In 
addition, a signal at 3.84 ppm (3H, s), which showed a HMBC correlation to a carbon signal at 
170.6 ppm, suggested a CO2Me group.  The proton signals at 3.22 pm (3H, s), 1.67 ppm (3H, 
s) and 1.59 ppm (3H, s) belonged to the same spin system, which we deduced had originated 
from the acetal unit of ketone 262.  Furthermore, a peak at 10.99 ppm (1H, s) suggested the 
by-product 267 contained a hydrogen bonded hydroxyl group.   
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Figure 170: 1H NMR spectrum of by-product 267 
Mass spectrometry analysis of the diastereomeric mixture of by-product 267 showed an m/z 
signal at 285.0970.  Based on this NMR and HRMS data, we propose the structure of the by-
product is aromatic compound 267 (Figure 171).  
 
Figure 171: Proposed structure of by-product 267 
The formation of aromatic compound 267 suggested that the benzoyl OH protecting group at 
C4a of the starting material, ketone 262, was too unstable to the basic conditions tested, 
resulting in the removal of the benzoyl group followed by OH elimination at this position.     
To determine whether it was possible to observe the formation of desired alkene 264 in our 
reactions between ketone 262 and base, we carried out a series of experiments in deuterated 
solvents using DBU as the base, with the reaction progress monitored by 1H NMR (Table 33). 
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Table 33: NMR experiments using DBU as the base 
 
 
In all of the solvents we tested, the 1H NMR spectra showed that the reactions proceeded with 
the formation of the same intermediates, with only slight variations in the time scale.  Here we 
will discuss the 1H NMR data for the reaction conducted in deuterated DCM (Figure 172). 
 
Figure 172: Expansion of the 1H NMR spectra of the reaction of ketone 262 with DBU in DCM-d2 at various time 
intervals 
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After a reaction time of 40 minutes, the spectrum showed loss of the peak at 5.88 ppm (1H, d, 
J = 11.5 Hz) corresponding to the C4a proton of starting material 262, which suggested the 
formation of enolate 265 (Figure 172).  After 18 hours, the spectrum showed the emergence 
of a signal at 6.36 (1H, d, J = 8.9 Hz), corresponding to an aromatic proton of undesired by-
product 267.  No signals corresponding to desired alkene 264 were observed throughout the 
reaction, suggesting the degradation of enolate 265 to aromatic compound 267 is a rapid 
process. 
As the reaction between ketone 262 and DBU did not generate alkene 264 via an E1cB 
reaction mechanism, we decided to examine an alternative method. 
 Acetal Deprotection of Ketone 262 
We anticipated that removal of the acetal protecting group from ketone 262, may make the 
hydroxyl group at C10a of product 268 a better leaving group and hence encourage the desired 
E1cB reaction to occur (Figure 173).   
 
Figure 173: Proposed synthesis of alkene 264 via an E1cB reaction of triol 268 
Ketone 262 was reacted under standard acetal removal conditions, using trifluoroacetic acid 
(TFA): water (10:1 v/v) (Table 34).  
Table 34: Diol deprotection reaction conditions examined 
 
In the first OH-deprotection reaction we examined, TLC showed loss of starting material 262 
and a new spot with a lower Rf value was generated, however following aqueous work up, we 
were unable to recover any desired triol 268 from the aqueous extract, presumably due to the 
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high water solubility of product 268 (Table 34, entry 1).  We repeated the reaction in deuterated 
methanol to allow the reaction progress to be monitored by 1H NMR, however no reaction was 
observed and starting material 262 was recovered (Table 34, entry 2).  We then repeated our 
original deprotection reaction in DCM and deuterated DCM, but omitted the aqueous work up 
step to avoid the loss of product 268.  In both cases, the 1H NMR spectrum of the crude material 
showed no peaks corresponding to the acetal group, therefore we could deduce diol 268 had 
been generated (Table 34, entries 3 and 4).  The crude triol 268 was used without purification 
in the subsequent synthetic step.  
With triol 268 in hand, we moved on to examine the E1CB reaction to generate alkene 264.  
 Reaction of Triol 268 with Base  
Crude triol 268 from the deprotection reaction (1 eq.) was reacted with DBU (2 eq.) in 
deuterated methanol, with the reaction progress monitored by 1H NMR (Figure 174).   
 
Figure 174: Propsed synthesis of alkene 264 
After a reaction time of 5 minutes, we observed the disappearance of the signal at 5.81 ppm 
(1H, d, J = 10.3 Hz), corresponding to the proton at C4a.  However, this was in concurrence 
with the appearance of new signals in the aromatic region at 7.88 – 7.80 (m) and 7.32 – 7.19 
(m), suggesting that a similar aromatisation process had occurred as in the reaction of ketone 
262 with DBU. 
We believe that the aromatisation of OH-protected compound 262 and triol 268 occurs 
following base catalysed removal of the benzoyl group at C4a, allowing elimination of the 
resultant deprotected alcohol group at this position.  Therefore, in future we plan to replace the 
benzoyl group with a base stable protecting group, such as a benzyl, before continuing in our 
planned synthetic procedure. 
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 Conclusions and Future Work 
In this chapter we aimed to develop a synthetic route to DEM30355/A analogues 212, in a two-
step procedure consisting of a D-A reaction from isobenzofuran 199, followed by base 
catalysed ring opening of the resultant D-A cycloadducts 211 (Figure 175).  By developing this 
synthetic route we aimed to build the A, B, C ring core structure of DEM30355/A 94, including 
the quaternary centre at C4a and the benzylic alcohol and unsaturated bond in the central B 
ring. 
 
Figure 175: Planned synthetic route to DEM30355/A analogues 212 
The most successful D-A reaction to build the anthracene core and introduce the quaternary 
centre at C4a used 2,6-dimethylcyclohexa-2,5-diene-1,4-dione 231 as the dienophile, which 
generated exo and endo cycloadducts 233-a and 233-b respectively (Figure 176).   
 
Figure 176: Diels-Alder synthesis of exo adduct 233-a and endo adduct 233-b and the proposed synthesis of 
alcohol 241 
We have learned that endo D-A cycloadduct 233-b undergoes a reaction with LDA to generate 
a new product, however more investigation is required to determine whether the new product 
is alcohol 241 (Figure 176).  To continue this route, we would scale up this reaction to aid in 
the isolation and structure elucidation of this new product, to determine if the E1cB reaction is 
successful. 
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The above investigations were prerequisite to our planned single enantiomer synthesis of 
DEM30355/A 94 using D-A chemistry, to ultimately determine the absolute stereochemistry of 
the molecule.  We aimed to generate dienophile 260 as a single enantiomer from shikimic acid 
213, using diastereoselective synthesis to construct the stereocentre at C3.  
The most successful synthetic route to build the stereogenic centre at C3 used a sterically 
directed dihydroxylation reaction of alkene 254 to give diol 259 (Figure 177).  We learned the 
best method to oxidise diol 259 to ketone 262 used Swern conditions.  We attempted to 
generate dienophile 260 via an E1cB reaction from ketone 262, however the product of this 
reaction is not alkene 260, rather aromatic compound 267 (Figure 177).  We anticipate the 
formation of compound 267 may be avoided by replacement of the benzoyl protecting group 
with a base stable protecting group. 
 
Figure 177: Reactions examined in the diastereoselective synthesis of ketone 262 and the subsequent base-
catalysed formation of aromatic compound 267 
Therefore to continue this route to DEM30355/A 94, we would investigate substitution of the 
benzoyl protecting group of ketone 262 with benzyl, followed by an E1cB reaction to generate 
alkene 270 (Figure 178).  Subsequently, alkene 270 would be employed as a dienophile in an 
exo D-A reaction to generate cycloadduct 271, with the quaternary oxygenated centre at C4a 
of DEM30355/A 94 in place.  
 
Figure 178: Proposed synthesis of dienophile 270 
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As an alternative method, we would use a modified Danishefsky route to synthesise compound 
272, which would then be employed as a dienophile in a D-A reaction with isobenzofuran 199 
(Figure 179).99  Following the conversion of the resultant cycloadduct 273 to β-dicarbonyl 274, 
we would use the reaction conditions developed by Miao and Sun to oxidise C4a to generate 
the key oxygenated quaternary centre centre of DEM30355/A 94 (Figure 179).133 
 
Figure 179: Proposed alternative synthetic route to construct the C4a centre of DEM30355/A 94 through oxidation 
of β-dicarbonyl 274 
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Chapter 5. Experimental  
 General Experimental Information  
 Analysis 
Melting points were obtained using Stuart SMP3 melting point apparatus.  Thin-layer 
chromatography (TLC) was conducted on silica gel 60 F254 plates and visualised using 
ultraviolet light unless otherwise stated.  1H and 13C{1H} NMR spectra were recorded on a 
Bruker Avance III 300 MHz, JEOL ECS-400 MHz, Bruker Avance III HD 500 MHz or a Bruker 
Avance III HD 700 MHz spectrometer.   Infrared (IR) spectra were recorded on a Varian 800 
FTIR Scimitar Series spectrometer.  High resolution mass spectra (HRMS) were obtained from 
the National Mass Spectrometry Facility (Swansea University).  X-Ray diffraction data were 
obtained using an Oxford Diffraction Gemini Atlas instrument. 
 Procedures 
Standard Schlenk techniques were used for all manipulations involving air-sensitive reagents, 
under an atmosphere of nitrogen.  Solvents were distilled under an atmosphere of nitrogen 
and used directly; THF was distilled from sodium/benzophenone, toluene was distilled from 
sodium and DCM was distilled from calcium hydride.  Manual flash column chromatography 
was conducted using Geduran silicagel 60 (40 – 63 µm).  Automated flash column 
chromatography was performed using a Biotage Isolera One or a Biotage Isolera LS instrument 
using KP-Sil SNAP cartridges.  Semi-preparative High Performance Liquid Chromatography 
(HPLC) was performed on an Agilent 1100 Series instrument using a 4.6 x 150 mm C18 (2.5 
µm) column (gradient 100% water to 100% acetonitrile, buffered to 0.1% by v/v formic acid).  
Size exclusion chromatography was performed using Sephadex LH-20. 
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 Isolation of DEM30355/B2 73 
The crude isolate of a large scale fermentation of Amycolatopsis DEM30355 was supplied by 
Dr B. Kepplinger.  All solvents used in the silica gel chromatography steps were buffered with 
0.1% (v/v) formic acid.  
 Protocol 1 (Full isolation) 
The crude isolate of A. DEM30355 (4.420 g) was dry loaded onto silica gel and subjected to 
normal phase flash column chromatography (Biotage Isolera One, SNAP 100 g cartridge, 
eluent = gradient 100% ethyl acetate to 100% MeOH).  The active fractions were identified 
using TLC, combined and the solvent removed under reduced pressure, to afford 2.280 g of 
material.  This was subsequently dry loaded onto silica gel and subjected to normal phase 
flash column chromatography (Biotage Isolera One, SNAP 100 g cartridge, eluent = gradient 
100% diethyl ether to 100% ethyl acetate to 100% MeOH).  The active fractions were combined 
based on TLC analysis into Fraction 1 and Fraction 2 and the solvent from each fraction was 
removed under reduced pressure.  The 1H NMR spectrum of Fraction 1 (0.563 g) indicated it 
contained DEM30355/A 94 and the fraction was stored under a nitrogen atmosphere in the 
freezer (- 20 °C).  The 1H NMR spectrum of Fraction 2 (0.558 g) showed it contained 
DEM30355/B2 73.  Fraction 2 was dissolved in toluene (30 mL) and washed with acidic water 
(20 mL, acidified to pH 2 with 2 M HCl aq. solution).  The organic extract was extracted with 
NaHCO3 solution (3 x 30 mL, 5% w/v aqueous solution) and the aqueous extract was acidified 
to pH 2 with 2 M HCl aq. solution.  The acidified aqueous extract was extracted with ethyl 
acetate (3 x 50 mL) and the organic extracts were combined, dried with sodium sulfate, filtered 
and the solvent removed under reduced pressure to afford DEM30355/B2 73 (0.102 g, 2.3% 
yield based on the mass of the crude isolate) as a red/orange solid. 
 Protocol 2 (Partial Isolation) 
Prior to the purification procedures described below, the crude isolate of A. DEM30355 was 
subjected to normal phase column chromatography to isolate DEM30355/A 94 (Dr J. Cowell).  
The remaining fractions, which did not contain DEM30355/A 94 as shown by TLC, were 
combined and the solvent removed under reduced pressure (Dr J. Cowell) to afford the crude 
material (3.780 g). 
The crude material (3.780 g) was dissolved in toluene (200 mL) and extracted with NaHCO3 
solution (3 x 150 mL, 7% w/v aqueous solution). The combined aqueous extracts were washed 
with toluene (3 x 300 mL) then acidified to pH 2 with 2 M HCl aq. solution.  The acidified 
aqueous extract was extracted with ethyl acetate (3 x 300 mL) and the organic extracts were 
combined, washed with brine, dried with sodium sulfate, filtered and the solvent removed under 
reduced pressure to give 1.370 g of material.  This was subsequently dry loaded onto silica 
gel and subjected to normal phase flash column chromatography (Biotage Isolera One, SNAP 
100 g cartridge, eluent = gradient 100% ethyl acetate to 100% MeOH).  The active fractions 
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were identified using TLC, combined and the solvent removed under reduced pressure, to 
afford 1.164 g of material.  This was dry loaded onto silica gel and subjected to normal phase 
flash column chromatography (Biotage Isolera One, SNAP 100 g cartridge, eluent = gradient 
100% ethyl acetate to 100% MeOH).  The active fractions were identified using TLC, combined 
and the solvent removed under reduced pressure, to afford 0.383 g of material.  This was 
subsequently dissolved in toluene (100 mL) and extracted with NaHCO3 solution (3 x 100 mL, 
7% w/v aqueous solution).  The combined aqueous extracts were washed sequentially with 
toluene (2 x 100 mL) and hexane (100 mL), then acidified to pH 2 with 2 M HCl aq. solution.  
The acidified aqueous extract was extracted with ethyl acetate (3 x 100 mL), washed with 
brine, dried with sodium sulfate, filtered and the solvent removed under reduced pressure to 
give 0.133 g of material.  This was dissolved in MeOH (8 mL) and subjected to size exclusion 
column chromatography (LH-20, eluent = MeOH).  The active fractions were identified using 
TLC, combined and the solvent removed under reduced pressure to give DEM30355/B2 73 
(0.043 g, 1.4% yield based on the mass of the crude material) as a red/orange solid. 
Rf  = 0.35 (100% ethyl acetate) 
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 NMR Assignment of DEM30355/B2 73 
All NMR data was collected on a sample of DEM30355/B2 73 in methylene chloride-d2, on a 
Bruker Avance III HD 700 MHz spectrometer.  1H NMR data were collected at 700 MHz.  13C 
{1H} NMR data were collected at 176 MHz.  
Table 35: Assignment of the 1H and 13C NMR data of DEM30355/B2 73 
 
Atom 
no. 
δC  
1H  
δH  
Number of 
protons 
Multiplicity J (Hz) 
1H-1H 
(COSY)  
13C-1H (HMBC) 
35 43.1 
2.54 1 d 16.8 2.66 (35) 1.18 (37), 1.23 
(38) 2.66 1 d 16.8 2.54 (35) 
36 172.0 - - - - - 
2.54 (35), 2.66 
(35) 
34 40.4 - - - - - 
2.54 (35), 2.66 
(35), 1.18 (37), 
1.23 (38) 
38 24.6 1.23 3  s - - 
2.54 (35), 2.66 
(35) 
37 25.7 1.18 3 s - - 
2.54 (35), 2.66 
(35) 
33 176.0 - - - - - 
2.54 (35), 2.66 
(35), 1.18 (37), 
1.23 (38), 5.07 
(31) 
31 67.7 5.07 1 “q” 6.4 1.09 (32) 
3.70 (21), 1.09 
(32), 5.83 (19) 
32 19.3 1.09 3 d 6.4 5.07 (31) 
5.07 (31), 2.17 
(20) 
20 52.4 2.17 1 “t” 9.7 
5.83 (19), 
3.70 (21) 
5.97 (18), 5.83 
(19), 5.07 (31), 
3.70 (21), 3.52 
(OH), 1.87 – 
1.81 (22) 
19 133.6 5.83 1 dd 
15.6, 
9.7 
5.97 (18), 
2.17 (20) 
6.17 (17), 5.97 
(18), 5.07 (31), 
3.70 (21), 2.17 
(20), 2.06 (30) 
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18 127.9 5.97 1 dd 
15.9, 
6.2 
6.17 (17), 
5.83 (19) 
5.83 (19), 2.17 
(20), 2.06 (30) 
17 129.6 6.17 1 “dt” 
6.2, 
1.3 
5.97 (18), 
2.06 (30) 
5.97 (18), 5.83 
(19), 2.06 (30) 
16 132.5 - - - - - 
5.97 (18), 5.83 
(19), 2.06 (30) 
30 20.5 2.06 3 s - 6.17 (17) 6.17 (17) 
15 171.0 - - - - - 
8.35 (NH), 6.17 
(17), 2.06 (30) 
21 68.5 3.70 1 d 10.1 2.17 (20) 
5.83 (19), 5.07 
(31), 3.52 (OH), 
2.86 (23), 2.17 
(20), 1.87 – 
1.81 (22), 0.95 
(39) 
22 33.5 
1.87 – 1.81 
(overlaps 
with 45) 
2[a] m  - 0.95 (39) 
2.86 (23), 2.17 
(20), 0.95 (39) 
39 12.4 0.95 3 d 7.0 
1.87 – 1.81  
(22) 
3.70 (21), 2.86 
(23), 1.87 – 
1.81 (22) 
23 78.5 2.86 1 d 10.3 1.60 (24) 
4.39 (25), 3.70 
(21), 1.87 – 
1.81 (22), 1.60 
(24), 0.95 (39), 
0.70 (40) 
24 36.6 1.60 1 m - 
2.86 (23), 
0.70 (40), 
4.39 (25) 
2.86 (23), 0.70 
(40), 1.87 – 
1.81 (22) 
40 8.9 0.70 3 d 6.7 1.60 (24) 
4.39 (25), 2.86 
(23), 1.60 (24) 
25 73.7 4.39 1 d 9.9 
2.13-2.08 
(26), 1.60 
(24) 
3.86 (27), 2.86 
(23), 2.06 (30), 
0.70 (40), 0.39 
(43) 
 
41 173.6 - - - - - 
4.39 (25), 2.03 
(42) 
42 21.3 2.03 3 s - - - 
26 36.7 2.13-2.08 1 m - 
0.39 (43), 
4.39 (25), 
3.86 (27) 
5.14 (28), 4.39 
(25), 3.86 (27), 
0.39 (43) 
43 12.9 0.39 3 d 7.2 
2.13-2.08 
(26) 
4.39 (25), 3.86 
(27), 2.13-2.08 
(26) 
27 80.9 3.86 1 dd 
9.1, 
3.0 
5.14 (28), 
2.13-2.08 
(26) 
6.37 (29), 4. 66 
(44), 4.39 (25), 
2.13-2.08 (26), 
0.39 (43) 
28 112.8 
5.14 
(overlaps 
with 47) 
2 dd  
12.8, 
9.1 
3.86 (27), 
6.37 (29) 
6.37 (29), 3.86 
(27), ), 2.13-
2.08 (26) 
29 145.8 6.37 1 d 12.8 5.14 (28) 
5.14 (28), 3.86 
(27), 1.68 (13), 
0.39 (43) 
44 96.8 4.66 1 dd 
8.9, 
3.3 
1.87 – 1.81 
(45), 2.22 
(45) 
4.11 (46), 3.86 
(27), 3.37 (49), 
2.22 (45), 1.87 
– 1.81 (45) 
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49 70.0 3.37 1 “dq” 
9.0, 
6.2 
1.28 (50), 
3.63 (48) 
4.87 (47), 4.66 
(44), 4.11 (46), 
1.28 (50) 
48 75.5 3.63 1 dd 
9.0, 
5.2 
3.37 (49), 
4.11 (46) 
5.13 (47), 4.87 
(47), 3.37 (49), 
2.22 (45), 1.28 
(50) 
47 94.9 
5.13 
(overlaps 
with 28) 
2 “s” - - 
3.63 (48) 
4.87 1 “s” - - 
46 74.3 4.11 1 “td” 
4.8, 
2.8 
1.87 – 1.81 
(45), 2.22 
(45), 3.63 
(48) 
5.13 (47), 4.87 
(47), 4.66 (44), 
3.63 (48), 2.22 
(45) 
45 
 
33.0 
 
2.22 1 “dt” 
14.5, 
2.4 
1.87 – 1.81 
(45), 4.11 
(46), 4.66 
(44) 4.66 (44) 
1.87 – 1.81 
(overlaps 
with 22) 
2[a] m  - 
2.22 (45), 
4.11 (46), 
4.66 (44)  
50 18.3 1.28 3 d 6.2 3.37 (49) 
3.63 (48), 3.37 
(49)    
13 23.1 1.68 3 s - - - 
12 109.3 - - - - - 
6.37 (29), 1.68 
(13) 
11 193.5 - - - - - 1.68 (13) 
6[b] 171.4 - - - - - 2.34 (14) 
14 7.3 2.34 3 s - - - 
7[b] 116.4 - - - - - 2.34 (14) 
5[b] 111.3 - - - - - 2.34 (14) 
8[b] 166.9 - - - - - 2.34 (14) 
9[b] 110.9 - - - - - 2.34 (14) 
10[b] 131.5 - - - - - 
7.80 (3), 2.34 
(14) 
1/4 185.3 - - - - - 
8.35 (NH), 7.80 
(3) 
1/4 184.3 - - - - - 8.34 (NH) 
2[b] 140.4 - - - - - 7.80 (3) 
3 116.7 7.80 1 s - - 8.35 (NH) 
NH - 8.35 1 - - - - 
Ar-OH - 12.60 1 - - - - 
OH (21) - 3.52 1 - - - - 
 
[a]The integration of the signals in the 1.87 – 1.81 ppm region corresponded to 3 protons.  2 of 
these protons are assigned as C45-H and C22-H.  It is possible that the remaining signal 
corresponds to an OH. 
[b]Assignments based on ‘best fit’ with ChemDraw model. 
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 Synthesis of DEM30355/B2 Methyl Ester 88 
 
To a stirred solution of DEM30355/B2 73 (2 mg, 2 µmol) in MeOH (500 µL) in a Schlenk flask 
under an atmosphere of nitrogen, was added trimethylsilyldiazomethane (4 µL, 8 µmol, 2 M 
solution in hexanes).  The reaction mixture was stirred at rt for 48 h then 
trimethylsilyldiazomethane (4 µL, 0.008 mmol, 2 M solution in hexanes) was added and stirring 
was continued at rt for 4 d.  The reaction mixture was quenched with 1: 1 MeOH: glacial acetic 
acid (v/v, 0.8 mL), stirred for 10 min and the solvent was removed with a stream of nitrogen.  
The residue was dissolved in DCM (15 mL), washed with saturated aq. NaHCO3 solution (15 
mL), dried with Na2SO4, filtered and the solvent removed under reduced pressure.  The crude 
material was purified by column chromatography (100% Et2O to 100% ethyl acetate, then 
DCM: MeOH 9:1, column diameter = 0.5 cm, silica = 5.5 cm).  An analytical HPLC run (100% 
water 5 min, gradient 100% water to 100% MeCN over 30 min, 100% MeCN 5 min, C18, 
column diameter = 4.6 mm, column length = 150 mm) of the sample showed a peak at 27.21 
min (large), 27.41 min (small) and 28.00 min (medium).  Mass spectrometric analysis of the 
same sample was consistent with methyl ester DEM30355/B2 88 (0.9 mg, 0.9 µmol, 45%), 
isolated as a brown solid. 
Rf = 0.9 (100% ethyl acetate); HRMS (pNSI) calcd for C51H65NO19H [M+H]+:996.4224; 
observed: 996.4228; calcd for C51H65NO19Na [M+Na]+:1018.4043; observed: 1018.4042;  
1H NMR Data of methyl-ester DEM30355/B2 88 in methylene chloride-d2, were collected at 
700 MHz data on a Bruker Avance III HD 700 MHz spectrometer.  The 1H NMR spectrum 
showed the sample contained a mixture of two derivatives in approximately a 1.0: 1.2 ratio 
(Figure 180). 
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Figure 180: Comparison of the 1H NMR spectra of DEM30355/B2 73 (top) and methyl ester 88 (bottom) in the 
8.60 - 5.60 ppm region 
The 1H NMR spectrum of methyl-ester DEM30355/B2 88 showed new sharp singlet peaks in 
the 3.65 – 3.50 ppm region, consistent with ester O-CH3 groups of major and minor products, 
further supporting our assignment (Figure 181). 
 
Figure 181: Comparison of the 1H NMR spectra of DEM30355/B2 73 (top) and methyl ester 88 (bottom) in the 
4.70 - 2.40 ppm region.  Signals corresponding to O-CH3 groups of two methyl ester DEM30355/B2 derivatives 
are highlighted 
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 Synthesis of Pyrrolidino DEM30355/B2 89 and 90 
 
To a stirred solution of DEM30355/B2 73 (15 mg, 15 µmol) in THF (1 mL) was added pyrrolidine 
(3 µL, 30 µmol) and formaldehyde (3 µL, 45 µmol, 37% w/v aq. solution).   The solution was 
stirred at rt for 24 h then ascorbic acid aq. solution (1 mL, 10% w/v) was added and the 
temperature was maintained at 5 – 10 °C.  After stirring for 15 min, the reaction mixture was 
diluted with water (5 mL), extracted with ethyl acetate (3 x 20 mL), dried with sodium sulfate, 
filtered and the solvent removed under reduced pressure.  The crude material was subjected 
to normal phase column chromatography (DCM: MeOH 9:1, column diameter = 2 cm, silica = 
17 cm).  Mass spectrometry analysis of the sample at this point indicated the sample was a 
mixture of hydroquinone pyrrolidino DEM30355/B2 89 and unreacted DEM30355/B2 73, 
therefore the material was purified by size exclusion chromatography (MeOH, LH-20).  An 
analytical HPLC run (100% water 5 min, gradient 100% water to 100% MeCN over 30 min, 
100% MeCN 5 min, C18, column diameter = 4.6 mm, column length = 150 mm) of the resultant 
sample showed 3 peaks at 24.71 min (large), 26.64 min (small) and 27.00 min (medium).  The 
sample was purified using semi-preparative HPLC (100% water 5 min, gradient 100% water 
to 100% MeCN over 30 min, 100% MeCN 5 min, C18, column diameter = 4.6 mm, column 
length = 150 mm).  The compound corresponding to the peak at 24.71 min was collected in 
one fraction.  The compound(s) corresponding to the peaks at 26.64 min and 27.00 min were 
collected as a mixed fraction.  Mass spectroscopy analysis of the 24.71 min sample 
corresponded to hydroquinone pyrrolidino-DEM30355/B2 89 (2.7 mg, 2.5 µmol, 17%), isolated 
as a yellow solid.  Mass spectroscopy analysis of the mixed 26.64/ 27.00 min fraction 
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corresponded to a mixture of quinone pyrrolidino DEM30355/B2 90 and hydroquinone 
pyrrolidino DEM30355/B2 89 (2.0 mg).82 
Data for hydroquinone pyrrolidino DEM30355/B2 89 
Rf = 0.57 (100% ethyl acetate); HRMS (pNSI) calcd C55H75N2O19 [M+H]+: 1067.4964; observed: 
1067.4965.   
Data for hydroquinone pyrrolidino DEM30355/B2 89 and quinone pyrrolidino 
DEM30355/B2 90 mixture 
HRMS (pNSI) calcd C55H73N2O19 [M+H]+ (quinone pyrrolidino DEM30355/B2 90): 1065.4808; 
observed: 1065.4800; calcd C55H75N2O19 [M+H]+ (hydroquinone pyrrolidino-DEM30355/B2 
89): 1067.4964; observed:1067.4914. 
1H NMR data of hydroquinone pyrrolidino DEM30355/B2 89 in methylene chloride-d2, were 
collected at 700 MHz data on a Bruker Avance III HD 700 MHz spectrometer.  The 1H NMR 
spectrum of hydroquinone pyrrolidino-DEM30355/B2 89 was compared with DEM30355/B2 
73.  The absence of an aromatic signal at 7.80 ppm corresponding to C3-H in DEM30355/B2 
73 suggests C3-H substitution, consistent with our assignment of hydroquinone pyrrolidino-
DEM30355/B2 89 (Figure 182). 
 
Figure 182: Comparison of the 1H NMR spectra of DEM30355/B2 73 (top) and hydroquinone pyrrolidino 
DEM30355/B2 89 (bottom) in the 8.50 - 5.70 ppm region.  The signal corresponding to aromatic C3-H in 
DEM30355/B2 73 is highlighted 
 
The appearance of new signals at ~3.08 ppm and ~2.20 ppm in the spectrum of hydroquinone 
pyrrolidino-DEM30355/B2 89 are consistent with pyrrolidine CH2 groups, further supporting our 
assignment (Figure 183). 
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Figure 183: Comparison of the 1H NMR spectra of DEM30355/B2 73 (top) and hydroquinone pyrrolidino 
DEM30355/B2 89 (bottom) in the 4.40 – 2.00 ppm region.  Signals characteristic of pyrrolidino CH2 groups are 
highlighted  
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 Exemplar Procedures in the Semi-Synthesis of DEM30355/B2 73 
 EDCI Coupling Reaction of DEM30355/B2 73 with 4-Methylbenzylamine  
To a stirred solution of DEM30355/B2 73 (10.0 mg, 10 µmol) in DCM (1 mL) was added 1-
hydroxybenzotrazole (0.1 mg, 1 µmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (2.3 mg, 12 µmol) and 4-methylbenzylamine (30 µL of a 0.5 M solution in DCM, 
15 µmol) at rt.  The solution was stirred for 25 h at room temperature, 4-methylbenzylamine 
(30 µL of a 0.5 M solution in DCM, 15 µmol) was added and stirring continued at rt for 22 h.  
The reaction mixture was poured into water (2 mL), the solution acidified with HCl aq. solution 
(1 mL, 1 M) and extracted with DCM (3 x 5 mL).  The combined organic extracts were washed 
with brine (20 mL) and the solvent was removed under reduced pressure. 
 Attempted Synthesis of Rifalazil DEM30355/B2 Analogue 82 
To a stirred solution of DEM30355/B2 73 (2 mg, 2 µmol) in THF 50%: toluene 50% (400 µL) 
was added 2-aminorescorcinol (0.3 mg, 2 µmol) at rt. The reaction mixture was stirred at rt for 
12 d, the solvent was removed under reduced pressure and the residue was dissolved in ethyl 
acetate (5 mL).  To the stirred solution was added potassium hexacyanoferrate (III) (1 mg, 3 
µmol) and stirring was continued at rt for 18 h.  The reaction mixture was washed with PBS 
buffer (2 x 5 mL) then brine (5 mL) and the organic solvent was removed under reduced 
pressure.89,90 
 Attempted Synthesis of Rifampicin DEM30355/B2 Analogue 81 
To a stirred solution of DEM30355/B2 73 (2 mg, 2 µmol) in DMF (400 µL) was added tert-
butylamine (1 µL, 5 µmol), paraformaldehyde (~ 1 mg) and acetic acid (1 µL, 17 µmol).  The 
solution was stirred at 50 °C for 3 h, 1-amino-4-methylpiperazine (1 µL, 9 µmol) was added 
and the solution was stirred at 50 °C for 1 h.  The reaction mixture was cooled to rt and 2% 
acetic acid aq. solution (4 mL) was added.  The reaction mixture was extracted with DCM (3 x 
10 mL), washed with water (20 mL) then brine (2 x 20 mL) and the organic solvent was 
removed under reduced pressure.86  
 Reduction of Quinone DEM30355/B2 73 to hydroquinone DEM30355/B2 87  
To a stirring solution of DEM30355/B2 73 (2 mg, 2 µmol) in THF (200 µL) was added 10% 
ascorbic acid aq. solution (1 mL) and the reaction mixture was stirred vigorously at rt for 1.5 h.  
The reaction mixture was extracted with ethyl acetate (2 x 5 mL), washed with brine (10 mL) 
and the organic solvent was removed under reduced pressure. 
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 3-Iodo-6,6-dimethylcyclohex-2-en-1-one 119 
 
To a round bottomed flask was added iodine (1.198 g, 4.72 mmol) and MeCN (30 mL).  To the 
resulting stirred suspension was added triphenylphosphine (1.238 g, 4.72 mmol), triethylamine 
(0.65 mL, 4.72 mmol) and 4,4-dimethylcyclohexane-1,3-dione (0.601 g, 4.29 mmol).  The 
reaction mixture was heated at reflux for 72 h, concentrated in vacuo, and the crude product 
purified by column chromatography (petroleum ether: diethyl ether, 95: 5, column diameter = 
3.5 cm, silica = 20 cm) to give 3-iodo-6,6-dimethylcyclohex-2-en-1-one 119 (0.925 g, 3.70 
mmol, 86%) as a colourless oil.103 
Rf = 0.33 (petroleum ether: diethyl ether, 95:5); 1H NMR (300 MHz, CDCl3) δH 6.62 (1H, t, J = 
1.7 Hz, H4), 2.87 (2H, td, J = 6.1, 1.7 Hz, H2), 1.77 (2H, t, J = 6.1 Hz, H1), 1.05 (6H, s, H7); 13C 
NMR (101 MHz, CDCl3) δC 200.4 (C5), 139.1 (C4), 124.8 (C3), 40.8 (C6), 38.6 (C1/2), 37.9 (C1/2), 
23.96 (C7); IR (neat): νmax cm-1 2965 – 2870 (CH), 1699 (C=O); HRMS (pAPCI): calcd for 
C8H12IO [M+H]+: 250.9927; observed: 250.9930. 
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 Ethyl 2-hydroxy-3-(2-methyl-1,3-dioxolan-2-yl)propanoate 132 
 
To a round bottomed flask was added 2-methyl-1,3-dioxolane (2.70 mL, 30.0 mmol), N-
hydroxyphthalimide (49 mg, 0.3 mmol) and cobalt acetate tetrahydrate (0.7 mg, 3.0 x10-3 
mmol).  To this was added ethyl acrylate (0.65 mL, 6.0 mmol), and the resulting solution was 
stirred at rt for 18 h.  Excess 2-methyl-1,3-dioxolane was removed under reduced pressure 
and the crude product was purified through column chromatography (petroleum ether: ethyl 
acetate, 2:1, column diameter = 2 cm, silica = 20 cm) to give ethyl 2-hydroxy-3-(2-methyl-1,3-
dioxolan-2-yl)propanoate 132 (157 mg, 0.8 mmol, 13%) as a colourless oil.107 
Rf = 0.25 (petroleum ether: ethyl acetate, 2:1, visualised with KMnO4 aq. solution); 1H NMR 
(300 MHz, CDCl3) δH 4.38 – 4.30 (1H, m, H4), 4.18 (2H, qd, J = 7.1, 2.0 Hz, H6), 4.01 – 3.90 
(4H, m, H8+9), 3.66 (1H, d, J = 5.2 Hz, OH), 2.22 (1H, dd, J = 14.8, 3.3 Hz, H3), 2.09 (1H, dd, J 
= 14.8, 7.7 Hz, H3), 1.35 (3H, s, H1), 1.26 (3H, t, J = 7.2 Hz, H7); 13C NMR (101 MHz, CDCl3) 
δC 173.9 (C5), 109.7 (C2), 68.2 (C4), 64.6 (C8/9), 64.4 (C8/9), 61.3 (C6), 41.7 (C3), 24.4 (C1), 14.2 
(C7); ); IR (neat): νmax cm-1  3470 (OH), 2984 – 2896 (CH), 1731 (C=O); HRMS (ASAP): calcd 
C9H17O5 [M+H]+: 205.1071; observed: 205.1069. 
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 Ethyl 2-benzyl-2-hydroxy-3-(2-methyl-1,3-dioxolan-2-yl)propanoate 138 
 
To a Schlenk flask was added ethyl 2-hydroxy-3-(2-methyl-1,3-dioxolan-2-yl)propanoate 132 
(157 mg, 0.77 mmol) and THF (8 mL) under a nitrogen atmosphere.  The solution was cooled 
to 0 °C, sodium bis(trimethylsilyl)amide (1.54 mL, 1.54 mmol, 1 M solution in THF) was added 
and the solution stirred for 30 min at 0 °C.  Benzyl bromide (0.18 mL, 1.64 mmol) was added 
and the reaction mixture stirred at rt for 2 h then quenched with water (5 mL).  The aqueous 
layer was extracted with ethyl acetate (3 x 15 mL) and the combined organic extracts were 
dried with sodium sulfate, filtered and the solvent removed under reduced pressure.  The crude 
product was purified by column chromatography (petroleum ether: ethyl acetate, 2: 1, column 
diameter = 2 cm, silica = 18 cm) to give ethyl 2-benzyl-2-hydroxy-3-(2-methyl-1,3-dioxolan-2-
yl)propanoate 138 (43 mg, 0.15 mmol, 19%) as a pale yellow oil. 
Rf = 0.48 (petroleum ether: ethyl acetate 2: 1); 1H NMR (300 MHz,CDCl3) δH 7.32 – 7.01 (5H, 
m, Ar), 4.05 (2H, app td, J = 7.2, 6.1 Hz, H6), 3.87 – 3.81 (4H, m, H8/9), 2.95 (1H, d, J = 13.3 
Hz, H10), 2.84 (1H, d, J = 13.3 Hz, H10), 2.41 (1H, d, J = 14.8 Hz, H3), 2.07 (1H, d, J = 14.8 Hz, 
H3), 1.26 (3H, s, H1), 1.17 (3H, t, J = 7.2 Hz, H7); 13C NMR (101 MHz, CDCl3) δC 175.1 (C5), 
135.7 (C11), 130.6 (Ar), 128.1 (Ar), 126.9 (Ar), 109.8 (C2), 76.2 (C4), 64.3 (C8/9), 64.2 (C8/9), 
61.3 (C6), 46.6 (C10), 46.0 (C3), 25.3 (C1), 14.3 (C7); IR (neat): νmax cm-1 3533 (OH), 2982 – 
2875 (CH), 1737 (C=O); HRMS (pNSI): calcd C16H22O5Na [M+Na]+: 317.1359; observed: 
317.1359. 
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 Ethyl 2-hydroxy-4-oxopentanoate 140 
 
To a round bottomed flask was added ethyl acetopyruvate (0.27 mL, 1.90 mmol), THF (5 mL) 
and the resulting solution was cooled to 0 °C.  Sodium borohydride (27 mg, 0.71 mmol) was 
added in small portions over 5 min.  The reaction mixture stirred at 0 °C for 30 min, quenched 
with water (5 mL) and extracted with ethyl acetate (3 x 5 mL).  The combined organic extracts 
were dried with sodium sulfate, filtered and the solvent removed under reduced pressure.  The 
crude product was purified by column chromatography (petroleum ether: ethyl acetate, 2: 1, 
column diameter = 2 cm, silica = 17 cm) to give ethyl 2-hydroxy-4-oxopentanoate 140 (89 mg, 
0.56 mmol, 29%) as a colourless oil. 
Rf = 0.15 (petroleum ether: ethyl acetate, 2: 1, visualised with KMnO4 aq. solution); 1H NMR 
(300 MHz, CDCl3) δH 4.44 (1H, dd, J = 6.2, 4.1 Hz, H4), 4.20 (2H, q, J = 7.1 Hz, H6), 3.23 (1H, 
br s, OH), 2.95 (1H, dd, J = 17.4, 4.1 Hz, H3), 2.86 (1H, dd, J = 17.4, 6.2 Hz, H3), 2.16 (3H, s, 
H1), 1.25 (3H, t, J = 7.1 Hz, H7); 13C NMR (101 MHz, CDCl3) δC 206.3 (C2), 173.7 (C5), 67.0 
(C4), 62.0 (C6), 46.9 (C3), 30.6 (C1), 14.2 (C7); IR (neat): νmax cm-1 3455 (OH), 2985 – 2919 
(CH), 1713 (C=O); HRMS (pNSI): calcd C7H12O4Na [M+Na]+: 183.0625; observed: 183.0628; 
calcd (C7H12O4)2Na [2M + Na]+: 341.1205; observed: 341.1207. 
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 3-Hydroxy-5-methyldihydrofuran-2(3H)-one 143 
 
To a round bottomed flask was added ethyl acetopyruvate (0.27 mL, 1.90 mmol) and MeOH 
(5 mL).  The resultant solution was cooled to 0 °C and sodium borohydride (72 mg, 1.90 mmol) 
was added in portions over 5 min.  The reaction mixture was stirred at rt for 4 d, quenched with 
water (10 mL) and extracted with ethyl acetate (3 x 20 mL).  The combined organic extracts 
were washed with brine (50 mL), dried with sodium sulfate, filtered and the solvent removed 
under reduced pressure.  The crude product was purified by column chromatography 
(petroleum ether: ethyl acetate, 1: 2, column diameter = 2 cm, silica = 20 cm) to give 3-hydroxy-
5-methyldihydrofuran-2(3H)-one 143 (128 mg, 1.10 mmol, 58%) as a colourless oil. 
Rf = 0.34 (petroleum ether: ethyl acetate, 1: 2, visualised with KMnO4 aq. solution); 1H NMR 
(300 MHz, CDCl3) δH 4.64 – 4.45 (2H, m, H2+4), 2.73 (1H, ddd, J = 12.5, 8.3, 5.0 Hz, H3), 1.86 
(1H, ddd, J = 12.5, 11.2, 10.5 Hz, H3), 1.47 (3H, d, J = 6.2 Hz, H5); 13C NMR (75 MHz, CDCl3) 
δC 177.3 (C1), 73.6 (C2/4), 69.0 (C2/4), 38.8 (C3), 20.9 (C5); IR (neat): νmax cm-1 3408 (OH), 2984 
– 2936 (CH), 1766 (C=O); HRMS (pNSI): calcd C5H8O3Na [M+Na]+: 139.0366; observed: 
139.0362. 
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 3-(Benzyloxy)dihydrofuran-2(3H)-one 145 
 
To a Schlenk flask was added sodium iodide (150 mg, 1.00 mmol), α-hydroxy-γ-butyrolactone 
(0.39 mL, 5.00 mmol) and THF (25 mL) under a nitrogen atmosphere.  The reaction mixture 
was cooled to 0 °C, sodium bis(trimethylsilyl)amide (5.00 mL, 5.00 mmol, 1 M solution in THF) 
was added and the reaction stirred for 30 min at 0 °C.  Benzyl bromide (0.59 mL, 5.00 mmol) 
was added and the reaction mixture was stirred at rt for 18 h, quenched with water (30 mL) 
and extracted with ethyl acetate (3 x 30 mL).  The combined organic extracts were dried with 
sodium sulfate, filtered and the solvent removed under reduced pressure.  The crude product 
was purified by column chromatography (petroleum ether: ethyl acetate, 4:1, column diameter 
= 4 cm, silica = 18 cm) to give 3-(benzyloxy)dihydrofuran-2(3H)-one 145 (376 mg, 1.95 mmol, 
39%) as a pale yellow solid. 
Mp = 29.1– 30.0 °C; Rf = 0.20 (petroleum ether: ethyl acetate, 4:1, visualised with KMnO4 aq. 
solution); 1H NMR (400 MHz, CDCl3) δH 7.40 – 7.29 (5H, m, Ar), 4.91 (1H, d, J = 11.8 Hz, H5), 
4.71 (1H, d, J = 11.8 Hz, H5), 4.45 – 4.31 (1H, m, H4), 4.21 – 4.15 (2H, m, H2), 2.49 – 2.39 (1H, 
m, H1), 2.31 – 2.18 (1H, m, H1); 13C NMR (101 MHz, CDCl3) δC 175.2 (C3), 137.0 (Ar), 128.7 
(Ar), 128.3 (Ar), 128.2 (Ar), 72.5 (C2/4/5), 72.2 (C2/4/5), 65.6 (C2/4/5), 30.0 (C1); IR (neat): νmax cm-
1 3060 – 2880 (CH), 1768 (C=O); HRMS (pAPCI): calcd C11H13O3 [M+H]+: 193.0859; observed: 
193.0857; calcd C11H12O3NH4 [M+NH4]+: 210.1125; observed: 210.1123. 
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 (E)-4-(2,5-Dimethoxyphenyl)but-3-en-2-one 147 
 
To a Schlenk flask was added 2,5-dimethoxybenzaldehyde (1.66 g, 10.0 mmol), DCM (60 mL) 
and (acetylmethylene)triphenylphosphorane (3.18 g, 10.0 mmol) under a nitrogen atmosphere.  
The reaction mixture was heated at reflux for 60 h.  The solvent was removed under reduced 
pressure and the crude product was purified by column chromatography (petroleum ether: 
diethyl ether, 7:3, column diameter = 4 cm, silica = 18 cm) to give (E)-4-(2,5-
dimethoxyphenyl)but-3-en-2-one 147 (1.56 g, 7.6 mmol, 76%) as a yellow solid. 
 
Mp = 49.3 – 51.5 °C (lit. Mp = 48.0 – 50.0 °C134); Rf  = 0.44 (petroleum ether: diethyl ether 7: 
3); 1H NMR (300 MHz, CDCl3) δH 7.84 (1H, d, J = 16.5 Hz, H7), 7.05 (1H, d, J = 3.0 Hz, H1), 
6.91 (1H, dd, J = 9.0, 3.0 Hz, H3), 6.83 (1H, d, J = 9.0 Hz, H4), 6.69 (1H, d, J = 16.5 Hz, H8), 
3.83 (3H, s, H11/12), 3.77 (3H, s, H11/12), 2.37 (3H, s, H10); 13C NMR (101 MHz, CDCl3) δC 199.3 
(C9), 153.7 (C2/5), 152.9 (C2/5), 138.6 (C7), 128.0 (C8), 124.0 (C6), 117.8 (Ar), 112.6 (Ar), 112.5 
(Ar), 56.2 (C11/12), 55.9 (C11/12), 27.2 (C10); IR (neat): νmax cm-1 3002 – 2838 (CH), 1689 (C=O), 
1646 (C=C), 1616 (C=C); HRMS (ASAP): calcd C12H15O3 [M + H]+: 207.1016; observed: 
207.1016. 
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 4-(2,5-Dimethoxyphenyl)-4-(phenylthio)butan-2-one 158 and Diethyl (E)-2-(4-(2,5-
dimethoxyphenyl)-2-oxobut-3-en-1-yl)-2-hydroxymalonate 159 
 
To a Schlenk flask was added (E)-4-(2,5-dimethoxyphenyl)but-3-en-2-one 147 (101 mg, 0.49 
mmol) and DCM (5 mL) under a nitrogen atmosphere. The solution was cooled to 0 °C and 
thiophenol (50 μL, 0.49 mmol) followed by triethylamine (100 μL, 0.42 mmol) was added drop-
wise.  The reaction was stirred at room temperature for 2 hours then diethyl ketomalonate (150 
μL, 0.98 mmol) was added.  The reaction was stirred for a further 18 hours and quenched with 
5% NaOH aq. solution (10 mL).  The organic layer was separated and the aqueous layer 
extracted with DCM (3 x 15 mL).  The combined organic extracts were washed with brine (50 
mL), dried with sodium sulfate, filtered and the solvent removed under reduced pressure.  The 
products were purified through column chromatography (petroleum ether: diethyl ether 1:1, 
column diameter = 2 cm, silica = 16 cm) to give 4-(2,5-dimethoxyphenyl)-4-(phenylthio)butan-
2-one 158 (23 mg, 0.07 mmol, 15% yield) as a yellow solid and diethyl (E)-2-(4-(2,5-
dimethoxyphenyl)-2-oxobut-3-en-1-yl)-2-hydroxymalonate 159 (28 mg, 0.07 mmol, 15% yield) 
as a  yellow solid. 
4-(2,5-Dimethoxyphenyl)-4-(phenylthio)butan-2-one 158 
 
Mp = 72.2 – 72.7 °C; Rf = 0.48 (petroleum ether: diethyl ether, 1: 1); 1H NMR (400 MHz, CDCl3) 
δH 7.33 – 7.27 (2H, m, Ar), 7.24 – 7.17 (3H, m, Ar), 6.78 – 6.75 (2H, m, Ar), 6.73 – 6.68 (1H, 
m, Ar), 5.11 (1H, t, J = 7.4 Hz, H4), 3.76 (3H, s, H7/8), 3.70 (3H, s, H7/8), 3.02 (2H, d, J = 7.4 Hz, 
H3), 2.09 (3H, s, H1); 13C NMR (101 MHz, CDCl3) δC 205.9 (C2), 153.5 (C5/6), 151.0 (C5/6), 134.7 
(Ar), 132.7 (Ar), 130.4 (Ar), 128.8 (Ar), 127.4 (Ar), 114.2 (Ar), 113.0 (Ar), 112.2 (Ar), 56.3 (C7/8), 
55.8 (C7/8), 49.1 (C3), 41.7 (C4), 30.4 (C1); IR (neat): νmax cm-1 3061 – 2837 (CH), 1713 
(C=O); HRMS (pNSI): calcd for C18H21O3S [M+H]+: 317.1206; observed: 317.1209. 
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Diethyl (E)-2-(4-(2,5-dimethoxyphenyl)-2-oxobut-3-en-1-yl)-2-hydroxymalonate 159 
 
Mp = 73.9 – 74.3 °C; Rf  = 0.18 (petroleum ether: diethyl ether, 1: 1); 1H NMR (400 MHz, CDCl3) 
δH 7.90 (1H, d, J = 16.4 Hz, H8), 7.04 (1H, d, J = 3.0 Hz, H14), 6.93 (1H, dd, J = 9.0, 3.0 Hz, 
H15), 6.84 (1H, d, J = 9.0 Hz, H16), 6.73 (1H, d, J = 16.4 Hz, H7), 4.28 (4H, q, J = 7.1 Hz, H2), 
3.84 (3H, s, (H9/10), 3.77 (3H, s, H9/10), 3.55 (2H, s, H5), 1.28 (6H, t, J = 7.1 Hz, H1); 13C NMR 
(101 MHz, CDCl3) δC 197.0 (C6), 169.7 (C3), 153.6 (C11/12), 153.2 (C11/12), 139.5 (C8), 126.6 (C7), 
123.6 (C13), 118.2 (C15), 112.9 (C14), 112.5 (C16), 77.3 (C4), 62.8 (C2), 56.1 (C9/10), 55.9 (C9/10), 
44.7 (C5), 14.1 (C1); IR (neat): νmax cm-1 3475 (OH), 2982-2837 (CH), 1737 (C=O); HRMS 
(pNSI): calcd for C19H25O8 [M+H]+: 381.1544; observed: 381.1543. 
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 Ethyl 3-(2,5-dimethoxyphenyl)-3-oxopropanoate 171 and 1,5-Bis(2,5-
dimethoxyphenyl)-3-methylpentane-1,5-dione 175 
 
To a Schlenk flask was added (2,5-dimethoxy)acetophenone (0.16 mL, 1.00 mmol) and THF 
(5 mL) under a nitrogen atmosphere.  The solution was cooled to -78 °C, sodium 
bis(trimethylsilyl)amide (1.5 mL, 1.50 mmol, 1 M solution in THF) was added and the reaction 
mixture stirred for 1 h.  Diethyl carbonate (0.18 mL, 1.50 mmol) was added and the reaction 
mixture was warmed to rt and stirred for 20 h.  The reaction mixture was quenched with water 
(5 mL), acidified with HCl aq. solution (2 M) and extracted with diethyl ether (2 x 10 mL).  The 
combined organic extracts were washed with brine (30 mL), dried with sodium sulfate, filtered 
and the solvent removed under reduced pressure.  The crude product was purified by column 
chromatography  (petroleum ether: diethyl ether, 2: 1, column diameter = 2 cm, silica = 18 cm) 
to give ethyl 3-(2,5-dimethoxyphenyl)-3-oxopropanoate 171 (96 mg, 0.38 mmol, 38%) as a 
yellow oily solid and  1,5-bis(2,5-dimethoxyphenyl)-3-methylpentane-1,5-dione 175 (56 mg, 
0.14 mmol, 14%) as a light brown solid. 
Ethyl 3-(2,5-dimethoxyphenyl)-3-oxopropanoate 171  
 
Mp = 37.2 – 38.5 °C; Rf = 0.28 (petroleum ether: diethyl ether, 2: 1); 1H NMR (300 MHz, CDCl3) 
δH 7.39 (1H, d, J = 3.2 Hz, H1), 7.05 (1H, dd, J = 9.1, 3.2 Hz, H3), 6.88 (1H, d, J = 9.1 Hz, H4), 
4.16 (2H, q, J = 7.2 Hz, H10), 3.94 (2H, s, H8), 3.83 (3H, s, H12/13), 3.77 (3H, s, H12/13), 1.21 (3H, 
t, J = 7.2 Hz, H11); 13C NMR (101 MHz, CDCl3) δC 192.7 (C7), 168.2 (C9), 153.7 (C2/5), 153.4 
(C2/5), 126.1 (C6), 121.7 (C3), 113.8 (C1), 113.0 (C4), 60.9 (C10), 55.7 (C12+13), 50.5 (C8), 14.1 
(C11); IR (neat): νmax cm-1 2981 – 2842 (CH), 1727 (C=O), 1665 (C=O); HRMS (pNSI): calcd 
C13H17O5 [M + H]+: 253.1071; observed: 253.1072. 
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1,5-Bis(2,5-dimethoxyphenyl)-3-methylpentane-1,5-dione 175 
 
Mp = 60.0 - 61.7 °C; Rf = 0.13 (petroleum ether: diethyl ether, 2: 1); 1H NMR (400 MHz, CDCl3) 
δH 7.19 (2H d, J = 3.2 Hz, H1),  6.99 (2H, J = 9.0, 3.2 Hz, H3), 6.87 (2H, d, J = 9.0 Hz, H4), 3.82 
(6H, s, H11/12), 3.78 (6H, s, H11/12), 3.06 (2H, dd, J = 16.1, 6.0 Hz, H8), 2.89 (2H , dd, J = 16.1, 
7.5 Hz, H8), 2.80 – 2.65 (1H, app dt, J = 13.4, 6.6 Hz, H9) 1.00 (3H , d, J = 6.6 Hz, H10); 13C 
NMR (101 MHz, CDCl3) δC 201.9 (C7), 153.5 (C2/5), 152.9 (C2/5), 129.1 (C6), 119.6 (C3), 114.1 
(C1), 113.2 (C4), 56.1 (C11/12), 55.9 (C11/12), 50.6 (C8), 26.6 (C9), 20.6 (C10); IR (neat): νmax cm-1 
2956 – 2835 (CH), 1669 (C=O); HRMS (pNSI): calcd C23H26O6 [M + H]+: 387.1802; observed: 
387.1795. 
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 Ethyl 3-(2,5-dimethoxyphenyl)-2,3-dioxopropanoate 167 
 
To a round bottomed flask was added ethyl 3-(2,5-dimethoxyphenyl)-3-oxopropanoate 171 
(482 mg, 1.9 mmol), N-bromosuccinimide (338 mg, 1.9 mmol) and DMSO (10 mL).  The 
reaction mixture was heated at 50 °C for 72 h then poured into saturated aq. NaHCO3 solution 
(10 mL) and extracted with DCM (3 x 20 mL).  The combined organic extracts were washed 
with brine (50 mL), dried with sodium sulfate, filtered and the solvent removed under reduced 
pressure.  The crude product was purified by column chromatography (petroleum ether: ethyl 
acetate, 2: 1, column diameter = 4 cm, silica = 18 cm) to give ethyl 3-(2,5-dimethoxyphenyl)-
2,3-dioxopropanoate 167 (374 mg, 1.4 mmol, 74%) as a yellow oil. 
Rf = 0.32 (petroleum ether: ethyl acetate, 2: 1); 1H NMR (400 MHz, CDCl3) δH 7.42 (1H, d, J = 
3.2 Hz, H1), 7.19 (1H, dd, J = 9.1, 3.2 Hz, H3), 6.94 (1H, d, J = 9.1 Hz, H4), 4.36 (2H, q, J = 7.1 
Hz, H10), 3.81 (3H, s, H12/13), 3.75 (3H, s, H12/13), 1.31 (3H, t, J = 7.1 Hz, H11); 13C NMR (101 
MHz, CDCl3) δC 192.0 (C7), 183.5 (C8), 158.6 (C9), 155.4 (C2/5), 154.7 (C2/5), 125.3 (C3), 122.7 
(C6), 114.2 (C4), 111.3 (C1), 63.0 (C10), 56.7 (C12/13), 56.0 (C12/13), 14.1 (C11); IR (neat): νmax cm-
1 3061 – 2840 (CH), 1760 (C=O), 1732 (C=O), 1666 (C=O); HRMS (pNSI): calcd C13H15O6 [M 
+ H]+: 267.0863; observed: 267.0864. 
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 Ethyl 2-(2,5-dimethoxybenzoyl)-2-hydroxy-3-methylene-4-oxopentanoate 168 
 
To a Schlenk flask was added ethyl 3-(2,5-dimethoxyphenyl)-2,3-dioxopropanoate 167 (50 mg, 
0.19 mmol), 4-dimethylaminopyridine (2 mg, 0.02 mmol) and THF (3 mL) under a nitrogen 
atmosphere.  To the stirred solution was added methyl vinyl ketone (31 µL, 0.38 mmol) and 
the reaction mixture was stirred at rt for 8 d.  The solvent was removed under a stream of 
nitrogen and the crude product purified by column chromatography (petroleum ether: ethyl 
acetate, 2: 1, column diameter = 1 cm, silica = 15 cm) to give ethyl 2-(2,5-dimethoxybenzoyl)-
2-hydroxy-3-methylene-4-oxopentanoate 168 (11 mg, 0.03 mmol, 17%) as a brown oil. 
Rf = 0.13 (petroleum ether: ethyl acetate, 2: 1); 1H NMR (300 MHz, CDCl3) δH 7.16 (1H, d, J = 
3.2 Hz, H1), 7.01 (1H, dd, J = 9.0, 3.2 Hz, H3), 6.85 (1H, d, J = 9.0 Hz, H4), 6.28 (1H, d, J = 1.3 
Hz, H15), 6.02 (1H, d, J = 1.3 Hz, H15), 4.35 (2H, qd, J = 7.1, 2.4 Hz, H10), 3.81 (3H, s, H16/17), 
3.75 (3H, s, H16/17), 2.38 (3H, s, H12), 1.30 (3H, t, J = 7.1 Hz, H11); 13C NMR (101 MHz, CDCl3) 
δC 199.0 (C7/13), 198.8 (C7/13), 169.1 (C9), 154.2 (C2/5), 151.6 (C2/5), 148.4 (C14), 127.6 (C15), 
127.2 (C6), 120.1 (C3), 115.1 (C1), 112.7 (C4), 84.9 (C8), 62.8 (C10), 56.0 (C16/17), 55.8 (16/17), 
26.5 (C12), 14.2 (C11); IR (neat): νmax cm-1 3483 (OH), 2923 – 2853 (CH), 1737 (C=O), 1708 
(C=O), 1687 (C=O); HRMS (pNSI): calcd C17H22NO6 [M-H2O+NH4]+: 336.1447; observed: 
336.1439. 
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 Ethyl 3-(chloromethyl)-2-(2,5-dimethoxybenzoyl)-2-hydroxy-4-oxopentanoate 
180 
 
To a Schlenk flask was added ethyl 3-(2,5-dimethoxyphenyl)-2,3-dioxopropanoate 167 (32 mg, 
0.12 mmol), DCM (1 mL) and methyl vinyl ketone (30 µL, 0.36 mmol) under a nitrogen 
atmosphere at rt.  To this was added titanium (IV) chloride (120 µL, 0.12 mmol, 1 M solution in 
DCM) and the solution was stirred at rt for 1.5 h.  The reaction was quenched with water (2 
mL) and extracted with DCM (3 x 5 mL).  The combined organic extracts were dried with 
sodium sulfate, filtered and the solvent removed under reduced pressure.  The crude product 
was purified by column chromatography (petroleum ether: diethyl ether, 3: 2, column diameter 
= 1 cm, silica = 17cm) to give ethyl 3-(chloromethyl)-2-(2,5-dimethoxybenzoyl)-2-hydroxy-4-
oxopentanoate 180 (14 mg, 0.04 mmol, 31%) as a brown oil. 
 
Rf  = 0.18 (petroleum ether: diethyl ether, 3: 2); 1H NMR (300 MHz, CDCl3) δH 7.11 – 6.99 (2H, 
m, Ar), 6.85 (1H, d, J = 8.8 Hz, Ar), 4.71 ppm (1H, br s, OH), 4.28 (2H, q, J = 7.2 Hz, H10), 4.00 
(1H, dd, J = 9.0, 4.4 Hz, H14), 3.88 (1H, dd, J = 11.6, 4.4 Hz, H15), 3.78 (3H, s, H16/17), 3.77 (1H, 
dd, J = 11.6, 9.0 Hz, H15), 3.75 (3H, s, H16/17), 2.41 (3H, s, H12), 1.27 (3H, t, J = 7.2 Hz, H11); 
13C NMR (101 MHz, CDCl3) δC 209.7 (C13), 199.0 (C7), 168.3 (C9), 154.1 (C2/5), 151.8 (C2/5), 
126.2 (Ar), 120.8 (Ar), 115.1 (Ar), 112.7 (Ar), 85.4 (C8), 62.8 (C10), 57.9 (C14), 56.0 (C16/17), 55.6 
(C16/17), 40.9 (C15), 32.8 (C12), 14.2 (C11); IR (neat): νmax cm-1 3474 (OH), 2954 – 2838 (CH), 
1716 (C=O); HRMS (pNSI): calcd C17H22ClO7 [M+H]+: 373.1049; observed: 373.1052; calcd 
C17H23ClO6N [M-H2O+NH4]+: 373.1208; observed: 373.1213. 
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 5,8-Dimethoxy-1,4-dihydro-1,4-epoxynaphthalene 205 
 
To a Schlenk flask was added THF (6 mL) and diisopropylamine (0.57 mL, 4.08 mmol) under 
a nitrogen atmosphere.  The solution was cooled to -78 °C, n-butyllithium (1.32 mL, 3.30 mmol, 
2.5 M in hexanes) was added dropwise and the solution was stirred at -78 °C for 40 min.  Furan 
(4.40 mL, 60.00 mmol) was added to the reaction vessel followed by a solution of 1-bromo-
2,4-dimethoxybenzene (0.45 mL, 3.00 mmol) in THF  (1.5 mL) dropwise.  The reaction mixture 
was stirred at -78 °C for 1 h then quenched with water (20 mL), extracted with diethyl ether (3 
x 40 mL), dried with sodium sulfate, filtered and the solvent removed under reduced pressure.  
The crude product was purified by column chromatography (petroleum ether: diethyl ether, 3: 
1, column diameter = 2 cm, silica = 18 cm) to give 5,8-dimethoxy-1,4-dihydro-1,4-
epoxynaphthalene 205 (522 mg, 2.56 mmol, 85%) as a white solid.123 
Mp = 86.4 - 86.6 °C (lit. Mp = 86.0 – 87.0 °C123); Rf = 0.22 (petroleum ether: diethyl ether, 3: 
1); 1H NMR (300 MHz, CDCl3) δH 7.07 (2H,  app t, J = 1.0 Hz, H5), 6.54 (2H, s, H1), 5.93 (2H, 
t, J = 1.0 Hz, H4), 3.79 (6H, s, H6); 13C NMR (75 MHz, CDCl3) δC 148.1 (C2), 143.1 (C3), 137.6 
(C5), 111.8 (C1), 80.5 (C4), 56.6 (C6); IR (neat): νmax cm-1 2959 – 2832 (CH); HRMS (pAPCI): 
calcd for C12H13O3 [M+H]+: 205.0859; observed: 205.0863. 
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 5,8-Dimethoxy-3,4,4a,9,9a,10-hexahydro-9,10-epoxyanthracen-1(2H)-one 226 
 
 
To a Schlenk flask was added 3,6-di-2-pyridyl-1,2,4,5-tetrazine (24 mg, 0.10 mmol) toluene (2 
mL) and 5,8-dimethoxy-1,4-dihydro-1,4-epoxynaphthalene 205 (20 mg, 0.10 mmol) under a 
nitrogen atmosphere in the dark.  The reaction mixture was stirred at rt for 1 h then cyclohex-
2-en-1-one (10 µL, 0.10 mmol) was added and the reaction mixture was stirred at reflux for 48 
h.  The solvent was removed under reduced pressure and the crude product was purified by 
column chromatography (petroleum ether: ethyl acetate, 1: 1, column diameter = 1 cm, silica 
= 15 cm) to give to give 5,8-dimethoxy-3,4,4a,9,9a,10-hexahydro-9,10-epoxyanthracen-1(2H)-
one 226 (11 mg, 0.04 mmol, 40%) as a brown solid. 
 
Mp = 144.5 – 144.8 °C (decomposed); Rf  = 0.20 (petroleum ether: ethyl acetate, 5: 1); 1H NMR 
(300 MHz, CDCl3) δH 6.65 (1H, app s, H1/14), 6.64 (1H, app s, H1/14), 5.92 (1H, d, J = 1.0 Hz, 
H4/11), 5.26 (1H, d, J = 1.0 Hz, H4/11), 3.80 (3H, s, H15/16), 3.79 (3H, s, H15/16), 2.51 – 2.25 (4H, 
m, H5+10+7), 2.25 – 2.15 (1H, m, H8/9), 2.04 – 1.91 (1H, m, H8/9), 1.79 – 1.64 (1H, m, H8/9), 1.53 
– 1.41 (1H, m, H8/9); 13C NMR (75 MHz, CDCl3) δC 211.8 (C6), 146.8 (C2/13), 146.6 (C2/13), 134.7 
(C3/12), 133.5 (C3/12), 111.5 (C1/14), 111.4 (C1/14), 82.1 (C4/11), 79.9 (C4/11), 56.3 (C15/16), 56.2 
(C15/16), 51.6 (C5), 42.2 (C10), 39.1 (C7), 28.0 (C8/9), 20.8 (C8/9); IR (neat): νmax cm-1 2961 – 2835 
(CH), 1699 (C=O); MS (pNSI): 257.1 (71%, [M-H2O+H]+), 275.1 (49%, [M+H]+); HRMS (pNSI): 
calcd for C16H18O4H [M+H]+; 275.1278; observed: 275.1279.  
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 5,8-Dimethoxy-4a,9,9a,10-tetrahydro-9,10-epoxyanthracene-1,4-dione 227 and 
228 
 
To a Schlenk flask was added 3,6-di-2-pyridyl-1,2,4,5-tetrazine (26 mg, 0.11 mmol), toluene 
(2 mL) and 5,8-dimethoxy-1,4-dihydro-1,4-epoxynaphthalene 205 (20 mg, 0.10 mmol) under a 
nitrogen atmosphere in the dark.  The reaction mixture was stirred at rt for 1 h, p-benzoquinone 
(12 mg, 0.11 mmol) was added and the reaction mixture was stirred at 60 °C for 18 h.  The 
solvent was removed under reduced pressure and the crude product purified by column 
chromatography (petroleum ether: ethyl acetate, 5: 1, column diameter = 2 cm, silica = 20 cm) 
to give two diastereomers of 5,8-dimethoxy-4a,9,9a,10-tetrahydro-9,10-epoxyanthracene-1,4-
dione (major 227 - 22 mg, 0.08 mmol, 77%,  minor 228  - 4 mg, 0.01 mmol, 14%) as yellow-
brown solids. 
 
Endo 5,8-dimethoxy-4a,9,9a,10-tetrahydro-9,10-epoxyanthracene-1,4-dione 227 (major 
diastereomer)  
 
 
Mp = 133.2 – 134.1 °C; Rf = 0.23 (petroleum ether: ethyl acetate, 5: 1); 1H NMR (300 MHz, 
CDCl3) δH 6.64 (2H, s, H1), 5.99 (2H, s, H7), 5.93 (2H, dd, J = 3.5, 1.9 Hz, H4), 3.75 (6H, s, H8), 
3.51 (2H, dd, J = 3.5, 1.9 Hz, H5); 13C NMR (75 MHz, CDCl3) δC 195.0 (C6), 147.5 (C2), 138.7 
(C7), 131.2 (C3), 112.8 (C1), 80.7 (C4), 56.4 (C8), 49.0 (C5); IR (neat): νmax cm-1 2962 – 2850 
(CH), 1667 (C=O); MS (pNSI): 287.1 (100%, [M+H]+), 309.1 (40%, [M+Na]+), 325.0 (15%, 
[M+K]+); HRMS (pNSI): calcd for C16H14O5H [M+H]+: 287.0914; observed: 287.0916. 
Note: The relative stereochemistry was determined through analysis of the X-ray crystal 
structure of the product.   
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Exo 5,8-dimethoxy-4a,9,9a,10-tetrahydro-9,10-epoxyanthracene-1,4-dione 228 (minor 
diastereomer)  
 
Mp = 167.2 – 167.8 °C; Rf = 0.50 (petroleum ether: ethyl acetate, 5: 1); 1H NMR (300 MHz, 
CDCl3) δH 6.83 (2H, s, H7), 6.70 (2H, s, H1), 5.80 (2H, s, H4), 3.83 (6H, s, H8), 2.88 (2H, s, H5); 
13C NMR (75 MHz, CDCl3) δC 196.8 (C6), 146.8 (C2), 142.0 (C7), 133.0 (C3), 112.1 (C1), 82.8 
(C4), 56.2 (C8), 50.6 (C5); IR (neat): νmax cm-1 2953 – 2852 (CH), 1668 (C=O); HRMS (pNSI): 
calcd for C16H14O5H [M+H]+: 287.0914; observed: 287.0917. 
Note: Sample of 228 used for analysis was obtained in collaboration with L. Micheron.  
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 5,8-Dimethoxy-2,9a-dimethyl-4a,9,9a,10-tetrahydro-9,10-epoxyanthracene-1,4-
dione 233-a and 233-b 
 
To a Schlenk flask was added 3,6-di-2-pyridyl-1,2,4,5-tetrazine (814 mg, 3.5 mmol) and DCM 
(40 mL) under a nitrogen atmosphere at rt.  The solution was cooled to 0 °C and a solution of 
5,8-dimethoxy-1,4-dihydro-1,4-epoxynaphthalene 205 (640 mg, 3.1 mmol) in DCM (10 mL) 
was added dropwise.  The reaction mixture was stirred at rt for 1 h, 2,6-dimethylbenzoquinone 
(470 mg, 3.5 mmol) was added and stirring continued for 15 min.  The reaction mixture was 
diluted with DCM (30 mL) and washed sequentially with HCl aq. solution (3 x 100 mL, 0.5 M), 
saturated aq. NaHCO3 solution (100 mL) and brine (100 mL).  The organic extract was dried 
with sodium sulfate, filtered and the solvent removed under reduced pressure.  The 1H NMR 
spectrum of the crude product showed a mixture of diastereomers in a 1.0: 0.9 ratio.  The crude 
product was purified by column chromatography (petroleum ether: ethyl acetate 4: 1, column 
diameter = 4 cm, silica = 17 cm), to give two diastereomers of 5,8-dimethoxy-2,9a-dimethyl-
4a,9,9a,10-tetrahydro-9,10-epoxyanthracene-1,4-dione (major 233-a - 305 mg, 1.0 mmol, 
31%, minor 233-b - 266 mg, 0.8 mmol, 27%) as yellow solids. 
Exo 5,8-dimethoxy-2,9a-dimethyl-4a,9,9a,10-tetrahydro-9,10-epoxyanthracene-1,4-
dione 233-a (major diastereomer)  
 
Mp = 109.4 – 110.1 °C; Rf  = 0.32 (petroleum ether: ethyl acetate 3: 1); 1H NMR (300 MHz, 
CDCl3) δH 6.76 – 6.73 (1H, m, H3), 6.72 (2H, app s, H9+10), 5.68 (1H, d, J = 1.2 Hz, H6/13), 5.63 
(1H, d, J = 1.2 Hz, H6/13), 3.83 (3H, s, H15/16), 3.82 (3H, s, H15/16), 2.42 (1H, s, H5), 2.09 (3H, d, 
J = 1.4 Hz, H18), 0.94 (3H, s, H17); 13C NMR (75 MHz, CDCl3) δC 201.5 (C1/4), 196.9 (C1/4), 151.7 
(C2), 148.9 (C8/11), 146.4 (C8/11), 139.2 (C3), 133.8 (C7/12), 131.0 (C7/12), 112.4 (C9/10), 111.4 
(C9/10), 86.1 (C6/13), 83.2 (C6/13), 59.4 (C5), 56.2 (C15/16), 56.1 (C15/16), 53.8 (C14), 22.4 (C17), 17.3 
(C18); IR (neat): νmax cm-1 2962 – 2842 (CH), 1658 (C=O); HRMS (pNSI): calcd for C18H18O5H 
[M+H]+: 315.1226; observed: 315.1227. 
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Endo 5,8-dimethoxy-2,9a-dimethyl-4a,9,9a,10-tetrahydro-9,10-epoxyanthracene-1,4-
dione 233-b (minor diastereomer)  
 
Mp = 181.0 - 181.1 °C; Rf = 0.19 (petroleum ether: ethyl acetate 3: 1); 1H NMR (300 MHz, 
CDCl3) δH 6.66 (1H, d, J = 8.8 Hz, H9/10), 6.58 (1H, d, J = 8.8 Hz, H9/10), 5.95 - 5.82 (1H, m, H3), 
5.87 (1H, dd, J = 5.4, 1.0 Hz, H6), 5.35 (1H, br d, J = 1.0 Hz, H13), 3.75 (3H, s, H15/16), 3.74 (3H, 
s, H15/16), 3.13 (1H, dd, J = 5.4, 0.8 Hz, H5), 1.59 (3H, s, H17), 1.55 (3H, d, J = 1.4 Hz); 13C NMR 
(75 MHz, CDCl3) δC 198.6 (C1), 195.3 (C4), 148.4 (C2), 147.9 (C8/11), 147.1 (C8/11), 136.2 (C3), 
131.6 (C7), 130.9 (C12), 113.0 (C9/10), 112.3 (C9/10), 86.0 (C13), 81.4 (C6), 58.1 (C5), 56.4 (C15/16), 
56.1 (C15/16), 53.1 (C14), 24.2 (C17), 16.2 (C18); IR (neat): νmax cm-1 2965 – 2843 (CH), 1656 
(C=O); HRMS (pNSI): calcd for C18H18O5H [M+H]+: 315.1231; observed: 315.1227. 
Note: The relative stereochemistry of 233-b was determined through analysis of the X-ray 
crystal structure of the product.   
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 5,8-Dimethoxy-3a,4,9,9a-tetrahydro-1H-4,9-epoxybenzo[f]isoindole-1,3(2H)-
dione 235 
 
 
To a Schlenk flask was added 3,6-di-2-pyridyl-1,2,4,5-tetrazine (26 mg, 0.11 mmol), DCM (2 
mL) and 5,8-dimethoxy-1,4-dihydro-1,4-epoxynaphthalene 205 (20 mg, 0.11 mmol)  under a 
nitrogen atmosphere in the dark.  The reaction mixture was stirred at rt for 1 h, diluted with 
DCM (4 mL), cooled to 0 °C and maleimide (10 mg, 0.11 mmol) was added.  The reaction 
mixture was stirred at 0 °C for 1 h and the solvent was removed under reduced pressure.  The 
residue was dissolved in ethyl acetate (10 mL) and washed with HCl aq. solution (3 x 15 mL, 
0.5 M).  The organic layer was washed with saturated aq. NaHCO3 solution (15 mL), dried with 
sodium sulfate, filtered and the solvent removed under reduced pressure to give 5,8-
dimethoxy-3a,4,9,9a-tetrahydro-1H-4,9-epoxybenzo[f]isoindole-1,3(2H)-dione 235 (30 mg, 
0.11 mmol, 99%) as a pale brown solid, as a 1: 2 mixture of diastereomers.  
Mp = 184.1 - 186.0 °C; Rf = 0.30 (petroleum ether: ethyl acetate, 1: 1); IR (neat): νmax cm-1 
3304 (NH), 3215 (NH), 2948 – 2838 (CH), 1706 (C=O); MS (pNSI) 293.1 (100%, [M+NH4]+), 
298.1 (89%, [M+Na]+); HRMS (pNSI): calcd for C14H13NO5NH4 [M+NH4]+: 293.1132; observed: 
293.1136. 
Major diastereomer 
1H NMR (300 MHz, CDCl3) δH 8.51 (s, 1H, NH), 6.63 (2H, s, H1), 5.78 (2H, s, H4), 3.74 (6H, s, 
H7), 2.95 (2H, s, H5); 13C NMR (75 MHz, CDCl3) δC 175.9 (C6), 146.9 (C2), 132.5 (C3), 112.1 
(C1), 79.7 (C4), 56.0 (C7), 50.2 (C5). 
Minor diastereomer 
1H NMR (300 MHz, CDCl3) δH 7.37 (s, 1H, NH), 6.67 (2H, s, H1), 5.82 (2H, dd, J = 3.9, 1.9 Hz, 
H4), 3.73 (6H, s, H7), 3.70 (2H, dd, J = 3.9, 1.9 Hz, H5); 13C NMR (75 MHz, CDCl3) δC 173.5 
(C6), 147.5 (C2), 130.0 (C3), 113.1 (C1), 78.5 (C4), 56.3 (C7), 49.5 (C5). 
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 5,8-dimethoxy-3a,4,9,9a-tetrahydro-4,9-epoxynaphtho[2,3-c]furan-1,3-dione 
 
To a Schlenk flask was added 3,6-di-2-pyridyl-1,2,4,5-tetrazine (236 mg, 1.0 mmol) and DCM 
(4 mL) under a nitrogen atmosphere.  The suspension was cooled to 0 °C and a solution of 
5,8-dimethoxy-1,4-dihydro-1,4-epoxynaphthalene 205 (185 mg, 0.9 mmol) in DCM (2 mL) was 
added dropwise.  The reaction mixture was stirred at room temperature for 1 h then maleic 
anhydride (98 mg, 1.0 mmol) was added in portions over 2 min.  The reaction mixture was 
stirred at rt for 1 h, diluted with DCM (5 mL) and washed with HCl aq. solution (3 x 10 mL, 0.5 
M).  The organic layer was washed with saturated aq. NaHCO3 solution (10 mL), dried with 
sodium sulfate, filtered and the solvent removed under reduced pressure to give 5,8-
dimethoxy-3a,4,9,9a-tetrahydro-4,9-epoxynaphtho[2,3-c]furan-1,3-dione 236 (171 mg, 0.6 
mmol, 68%) as an off-white solid, as a 1.0: 1.4 mixture of diastereomers. 
Mp = 144.8 – 145.1°C; IR (neat): νmax cm-1 2963 – 2839 (CH), 1775 (C=O); HRMS (pAPCI): 
calcd for C14H13O6 [M+H]+: 277.0707; observed: 277.0709; calcd for C14H16O6N [M+NH4]+: 
294.0972; observed: 294.0975. 
Major diastereomer 
1H NMR (400 MHz, CDCl3) δH 6.72, (2H, s, H1), 5.94 (2H, s, H4), 3.80 (6H, s, H7), 3.26 (2H, s, 
H5); 13C NMR (101 MHz, CDCl3) δC 170.1 (C6), 147.0 (C2), 131.8 (C3), 112.4 (C1), 80.8 (C4), 
56.0 (C7), 50.1 (C5) 
Minor diastereomer 
1H NMR (400 MHz, CDCl3) δH 6.77 (2H, s, H1), 5.95 – 5.94 (2H, m, H4), 3.99 (2H, dd, J = 3.7, 
2.0 Hz H5), 3.79 (6H, s, H7); 13C NMR (101 MHz, CDCl3) δC 167.4 (C6), 147.4 (C2), 129.5 (C3), 
113.6 (C1), 79.1 (C4), 56.3 (C7), 49.7 (C5). 
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 4-Hydroxy-4-methylcyclohexa-2,5-dien-1-one 237 
 
To a Schlenk flask was added p-benzoquinone (540 mg, 5.00 mmol) and THF (100 mL) under 
a nitrogen atmosphere.  The solution was cooled to -78 °C and methyllithium (3.12 mL, 1.6 M 
solution in diethyl ether) was added dropwise.  The reaction mixture was stirred at -78 °C for 
30 min then quenched with saturated aq. ammonium chloride solution (150 mL) and extracted 
with DCM (3 x 200 mL).  The combined organic extracts were washed with water (3 x 200 mL), 
dried with magnesium sulfate, filtered and the solvent removed under reduced pressure.  The 
crude product was purified by column chromatography (petroleum ether: diethyl ether, 4: 1, 
0.1% diethylamine, column diameter = 3 cm, silica = 20 cm) to give 4-hydroxy-4-
methylcyclohexa-2,5-dien-1-one 237 (172 mg, 1.40 mmol, 28%) as a pale brown solid (Note: 
the isolated product contained ~ 6% hydroquinone 239 impurity as determined by analysis of 
the 1H NMR spectrum of the sample).127 
Mp = 58.6 – 59.1 °C; Rf = 0.05 (petroleum ether: diethyl ether, 2: 1, 0.1% diethylamine); 1H 
NMR (300 MHz, CDCl3) δH 6.84 (2H, d, J = 10.1 Hz, H3), 6.01 (2H, d, J = 10.1 Hz, H2), 1.39 
(3H, s, H5); 13C NMR (75 MHz, CDCl3) δC 186.2 (C1), 153.3 (C3), 126.6 (C2), 67.1 (C4), 26.7 
(C5); IR (neat): νmax cm-1 3425 (OH), 2979 - 2873 (CH), 1660 (C=O), 1616 (C=C); HRMS 
(pAPCI): calcd for C7H7O2 [M-H]+: 123.0441; observed: 123.0437; calcd for C7H8O2 [M]+: 
124.0519; observed: 124.0515; calcd for C7H8O2H [M+H]+; 125.0597; observed: 125.0593. 
NMR data of hydroquinone 239 impurity 
1H NMR (300 MHz, CDCl3) δH 6.61 (4H, s), 13C NMR (75 MHz, CDCl3) δC 149.5, 116.2.   
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 4-Hydroxy-5,8-dimethoxy-4-methyl-4a,9,9a,10-tetrahydro-9,10-epoxyanthracen-
1(4H)-one 238 
 
To a Schlenk flask was added 3,6-di-2-pyridyl-1,2,4,5-tetrazine (61 mg, 0.26 mmol) and DCM 
(1 mL) under a nitrogen atmosphere at rt.  The stirred suspension was cooled to 0 °C and a 
solution of 5,8-dimethoxy-1,4-dihydro-1,4-epoxynaphthalene 205 (53 mg, 0.26 mmol) in DCM 
(1 mL) was added dropwise.  The reaction mixture was stirred at rt for 1 h then a solution of 4-
hydroxy-4-methylcyclohexa-2,5-dien-1-one (32 mg, 0.26 mmol) in DCM (1 mL) was added.  
The reaction mixture was stirred at rt for 48 h, diluted with DCM (3 mL) and washed with HCl 
aq. solution (3 x 5 mL, 0.5 M).  The organic layer was washed with saturated aq. NaHCO3 
solution (5 mL), brine (5 mL) and dried with sodium sulfate, filtered and the solvent removed 
under reduced pressure to give 4-hydroxy-5,8-dimethoxy-4-methyl-4a,9,9a,10-tetrahydro-
9,10-epoxyanthracen-1(4H)-one 238 (72 mg, 0.24 mmol, 92%) as a brown solid. 
Mp = 171.7 – 173.0 °C; 1H NMR (300 MHz, CDCl3) δH 6.70 (1H, d, J = 8.9 Hz, H9), 6.65 (1H, 
d, J = 8.9 Hz, H10), 5.98 (1H, dd, J = 10.2, 1.7 Hz, H3), 5.80 (1H, d, J = 5.7 Hz, H13), 5.64 (1H, 
d, J = 4.7 Hz, H6), 5.00 (1H, d, J = 10.2 Hz, H2), 3.87 (3H, s, H15), 3.82 (1H, m, OH), 3.74 (3H, 
s, H16), 3.26 (1H, dd, J = 9.2, 5.7 Hz, H14), 3.11 (1H, ddd, J =  9.2, 4.7, 1.7 Hz, H5), 1.33 (3H, 
s, H17); 13C NMR (75 MHz, CDCl3) δC 195.5 (C1), 152.8 (C3), 148.2 (C8), 147.1 (C11), 132.8 
(C12), 131.4 (C7), 125.4 (C2), 112.7 (C10), 112.1 (C9), 81.3 (C13), 80.1 (C6), 69.2 (C4), 56.4 (C15), 
50.2 (C5), 48.6 (C14), 33.2 (C17); IR (neat): νmax cm-1 3461 (OH), 2925 – 2851 (CH), 1717 (C=O); 
HRMS (pNSI): calcd for C17H18O5NH4 [M+NH4]+: 320.1492; observed: 320.1493. 
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 Methyl (3R,4S,5R)-3,4,5-trihydroxycyclohex-1-ene-1-carboxylate 242 
 
To a round bottomed flask was added shikimic acid (5.00 g, 29.0 mmol), MeOH (100 mL) and 
p-toluenesulfonic acid monohydrate (0.55 g, 2.9 mmol).  The resulting solution was heated at 
reflux for 48 h.  The reaction mixture was cooled, filtered and the solvent removed under 
reduced pressure.  The crude product was purified through hot recrystallization from ethyl 
acetate to afford methyl (3R,4S,5R)-3,4,5-trihydroxycyclohex-1-ene-1-carboxylate 242 (3.93 
g, 21 mmol, 73%,) as an off-white solid. 
Mp = 114.0 – 115.1 °C (lit. Mp = 112.0 – 113.0 °C129); [α]𝐷
20 = -126.8 (c = 1, MeOH) (lit. [α]𝐷
20 =
 -125.0 (c = 1.8, EtOH)129); 1H NMR (300 MHz, MeOD-d4) δH 6.80 (1H , app dtd, J = 3.6, 1.9, 
0.6 Hz, H3), 4.46 – 4.32 (1H, m, H6), 4.01 (1H, dddd, J = 7.2, 5.5, 4.9, 0.6 Hz, H1), 3.76 (3H, s, 
H8), 3.70 (1H, dd, J = 7.2, 4.2 Hz, H2), 2.82 – 2.63 (1H, m, H5), 2.22 (1H, app ddt, J = 18.2, 
5.4, 1.7 Hz, H5); 13C NMR (75 MHz, MeOD-d4) δC 168.6 (C7), 139.0 (C3), 130.2 (C4), 72.5 (C2), 
68.3 (C1), 67.2 (C6), 52.4 (C8), 31.5 (C5); IR (neat): νmax cm-1 3308 (OH), 2956 (CH), 2901 (CH), 
1716 (C=O); HRMS (pNSI): calcd for C8H12O5Na (M+Na]+: 211.0575; observed: 211.0577.  
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 Methyl (2S,3S,4aR,8R,8aR)-8-hydroxy-2,3-dimethoxy-2,3-dimethyl-2,3,4a,5,8,8a-
hexahydrobenzo[b][1,4]dioxine-6-carboxylate 243 
 
To a round bottomed flask was added methyl (3R,4S,5R)-3,4,5-trihydroxycyclohex-1-ene-1-
carboxylate 242 (500 mg, 2.70 mmol), MeOH (10 mL), 2,3-butanedione (0.6 mL, 6.4 mmol) 
and camphorsulfonic acid (63 mg, 0.30 mmol).  To the stirred solution was added trimethyl 
orthoformate (1.8 mL, 16.0 mmol) and the reaction mixture was stirred at reflux under a 
nitrogen atmosphere for 48 h.  The reaction mixture was cooled to rt, NaHCO3 (562 mg, 6.70 
mmol) was added and the reaction mixture stirred for 10 min.  The solvent was removed under 
reduced pressure and the crude product was purified by column chromatography (petroleum 
ether: acetone, 5: 1, column diameter = 3 cm, silica = 19 cm) to give methyl 
(2S,3S,4aR,8R,8aR)-8-hydroxy-2,3-dimethoxy-2,3-dimethyl-2,3,4a,5,8,8a-
hexahydrobenzo[b][1,4]dioxine-6-carboxylate 243 (588 mg, 1.94 mmol, 73%) as an orange-
brown oil.129 
Rf = 0.20 (petroleum ether: acetone, 5: 1, visualised with KMnO4 aq. solution); [α]𝐷
20 = +43.4 
(c = 1, MeOH) (lit. [α]𝐷
20 = +23.1 (c = 0.89, DCM)129); 1H NMR (300 MHz, CDCl3) δH 6.92 – 6.85 
(1H, m, H3), 4.40 – 4.34 (1H, m, H2), 4.09 (1H, td, J = 10.7, 5.9 Hz, H6), 3.73 (3H, s, H8), 3.61 
(1H, dd, J = 10.7, 4.3 Hz, H1), 3.26 (3H, s, H12/14), 3.24 (3H, s, H12/14), 2.82 (1H, dd, J = 17.6, 
5.9 Hz, H5), 2.24 – 2.10 (1H, m, H5), 1.32 (s, 3H, H11/13), 1.29 (s, 3H, H11/13); 13C NMR (75 MHz, 
CDCl3) δC 166.4 (C7), 135.2 (C3), 131.3 (C4), 99.8 (C9/10), 99.1 (C9/10), 70.6 (C1), 64.8 (C2), 62.3 
(C6), 51.9 (C8), 47.9 (C12/14), 47.8 (C12/14), 30.0 (C5), 17.7 (C11/13), 17.5 (C11/13); IR (neat): νmax 
cm-1 3468 (OH), 2993 – 2834 (CH), 1718 (C=O); MS (pNSI): 271.1 (38%, [M-OMe]+), 320.2 
(100%, [M+NH4]+), 627.3 (51%, [2M+Na]+); HRMS (pNSI): calcd for C14H22O7NH4 [M+NH4]+: 
320.1704; observed: 320.1702. 
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 Methyl (2S,3S,4aR,8aS)-2,3-dimethoxy-2,3-dimethyl-8-oxo-2,3,4a,5,8,8a-
hexahydrobenzo[b][1,4]dioxine-6-carboxylate 247 
 
To a Schlenk flask was added methyl (2S,3S,4aR,8R,8aR)-8-hydroxy-2,3-dimethoxy-2,3-
dimethyl-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 243 (95 mg, 0.31 mmol) 
and DCM (4 mL) and meta-chloroperoxybenzoic acid (60 mg, 0.35 mmol).  The reaction 
mixture was stirred at 48 °C for 8 d, quenched with saturated aq. Na2SO3 solution (4 mL) and 
extracted with DCM (3 x 10 mL).  The combined organic extracts were dried with sodium 
sulfate, filtered and the solvent removed under reduced pressure.  The crude product was 
purified by column chromatography (petroleum ether: acetone, 4: 1, column diameter = 1 cm, 
silica = 18 cm) to give methyl (2S,3S,4aR,8aS)-2,3-dimethoxy-2,3-dimethyl-8-oxo-
2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 247 (5 mg, 0.02 mmol, 6%) as a 
white solid.   
Mp = 117.8 – 118.0 °C; Rf = 0.35 (petroleum ether: acetone, 4: 1, visualised with KMnO4 aq. 
solution); [𝛼]𝐷
20= +86 (c = 0.1, DCM); 1H NMR (300 MHz, CDCl3) δH 6.80 (1H, d, J = 3.1 Hz, 
H3), 4.31 (1H, d, J = 11.6 Hz, H1), 4.09 (1H, ddd, J = 11.6, 10.6, 5.3 Hz, H6), 3.84 (3H, s, H8), 
3.30 (3H, s, H12/14), 3.25 (3H, s, H12/14), 3.07 (1H, dd, J = 18.4, 5.3 Hz, H5), 2.64 (1H, ddd, J = 
18.4, 10.6, 3.1 Hz, H5), 1.41 (3H, s, H11/13), 1.33 (3H, s, H11/13); 13C NMR (75 MHz, CDCl3) δC 
194.5 (C2), 165.9 (C7), 144.7 (C4), 132.8 (C3), 100.4 (C9/10), 99.4 (C9/10), 75.2 (C1), 67.1 (C6), 
53.0 (C8), 48.5 (C12/14), 48.2 (C12/14), 30.6 (C5), 17.7 (C11/13), 17.6 (C11/13); IR (neat): νmax cm-1 
2957 – 2835 (CH), 1730 (C=O), 1700 (C=O); MS (pNSI): 269.1 (81%, [M-OMe]+), 318.2 (100%, 
[M+NH4]+), 618.3 (71%, [2M+NH4]+); HRMS (pNSI): calcd for C14H20O7NH4 [M+NH4]+: 
318.1547; observed: 318.1547. 
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 Methyl (2S,3S,4aR,8R,8aS)-8-((tert-butyldimethylsilyl)oxy)-2,3-dimethoxy-2,3-
dimethyl-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 250 
 
To a round bottomed flask was added methyl (2S,3S,4aR,8R,8aR)-8-hydroxy-2,3-dimethoxy-
2,3-dimethyl-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 243 (734 mg, 2.4 
mmol), DCM (10 mL), tert-butyldimethylsilyl chloride (377 mg, 2.5 mmol) and imidazole (170 
mg, 2.5 mmol) and the reaction mixture was stirred at rt for 18 h.  DCM (20 mL), tert-
butyldimethylsilyl chloride (180 mg, 1.2 mmol) and imidazole (81 mg, 1.20 mmol) were added 
to the reaction mixture and stirring was continued for 24 h.  Tert-butyldimethylsilyl chloride (180 
mg, 1.2 mmol) and imidazole (81 mg, 1.2 mmol) were added to the reaction mixture and stirring 
was continued for 54 h.  The reaction mixture was poured into water (30 mL) and extracted 
with DCM (3 x 30 mL).  The combined organic extracts were dried with sodium sulfate, filtered 
and the solvent removed under reduced pressure.  The crude product was purified by column 
chromatography (petroleum ether: acetone, 9: 1, column diameter = 4 cm, silica = 15 cm) to 
give methyl (2S,3S,4aR,8R,8aS)-8-((tert-butyldimethylsilyl)oxy)-2,3-dimethoxy-2,3-dimethyl-
2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 250 (880 mg, 2.1 mmol, 88%) as 
a white solid. 
Mp = 73.7 – 74.1 °C; Rf = 0.23 (petroleum ether: acetone, 9: 1); [𝛼]𝐷
20= -18.8 (c = 1, DCM); 1H 
NMR (300 MHz, CDCl3) δH 6.63 (1H, dd, J = 5.5, 2.5 Hz, H3), 4.19 (1H, dd, J = 5.5, 3.9 Hz, 
H2), 3.98 (1H, app td, J = 10.5, 6.0 Hz, H6), 3.6 (3H, s, H8), 3.35 (1H, dd, J = 10.8, 3.9 Hz, H1), 
3.11 (3H, s, H12/14), 3.09 (3H, s, H12/14), 2.66 (1H, dd, J = 17.6, 6.0 Hz, H5), 2.08 (1H, ddd, J = 
17.6, 10.3, 2.5 Hz, H5), 1.16 (3H, s, H11/13), 1.14 (3H, s, H11/13), 0.76 (9H, s, H17), 0.00 (3H, s, 
H15/18), -0.03 (3H, s, H15/18); 13C NMR (75 MHz, CDCl3) δC 166.7 (C7), 136.5 (C3), 129.7 (C4), 
99.4 (C9/10), 98.6 (C9/10), 70.8 (C1), 65.9 (C2), 62.3 (C6), 51.8 (C8), 47.6 (C12/14), 47.4 (C12/14), 
30.4 (C5), 25.7 (C17), 18.2 (C16), 17.7 (C11/13), 17.6 (C11/13), -4.8 (C15/18), -4.9 (C15/18); IR (neat): 
νmax cm-1 2994 – 2856 (CH), 1708 (C=O); MS (pNSI): 385.2 (82%, [M-OMe]+), 434.3 (100%, 
[M+NH4]+); HRMS (pNSI): calcd for C20H36O7SiNH4 [M+NH4]+: 434.2569; observed: 434.2561. 
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 Methyl (2S,3S,4aR,8S,8aS)-8-(benzoyloxy)-2,3-dimethoxy-2,3-dimethyl-
2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 254 
 
To a Schlenk flask was added methyl (2S,3S,4aR,8R,8aR)-8-hydroxy-2,3-dimethoxy-2,3-
dimethyl-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 243 (200 mg, 0.66 
mmol), benzoic acid (121 mg, 0.99 mmol), triphenylphosphine (260 mg, 0.99 mmol) and THF 
(10 mL) under a nitrogen atmosphere.  The solution was cooled to 0 °C and diethyl 
azodicarboxylate (155 µL, 0.99 mmol) was added dropwise.  The reaction mixture was stirred 
at room temperature for 2 h then poured into saturated aqueous NaHCO3 solution (10 mL) and 
extracted with ethyl acetate (3 x 20 mL).  The combined organic extracts were dried with 
sodium sulfate, filtered and solvent removed under reduced pressure.  The crude product was 
purified by column chromatography (petroleum ether: acetone, 9:1, column diameter = 2 cm, 
silica = 17 cm) to give methyl (2S,3S,4aR,8S,8aS)-8-(benzoyloxy)-2,3-dimethoxy-2,3-
dimethyl-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 254 (91 mg, 0.22 mmol, 
34%) as a white solid. 
Mp = 65.3 – 66.0 °C; Rf = 0.19 (petroleum ether: acetone 9: 1, visualised with KMnO4 aq. 
solution); [𝛼]𝐷
20= +203.1 (c = 1, DCM); 1H NMR (300 MHz, CDCl3) ) δH 8.10 – 7.96 (2H, m, 
H17), 7.63 – 7.49 (1H, m, H19), 7.43 (2H, app t, J = 7.6 Hz, H18), 6.74 (1H, app t, J = 2.7 Hz, 
H3), 5.85 – 5.73 (1H, m, H2), 4.07 – 3.88 (2H, m, H1+6), 3.72 (3H, s, H8), 3.28 (3H, s, H12/14), 
3.27 (3H, s, H12/14), 2.86 – 2.75 (1H, m, H5), 2.45 – 2.30 (1H, m, H5), 1.31 (3H, s, H11/13), 1.27 
(3H, s, H11/13); 13C NMR (75 MHz, CDCl3) δC 166.1 (C7/15), 165.9 (C7/15), 134.9 (C3), 133.3 (C19), 
130.4 (C4), 129.9 (C16), 129.7 (C17), 128.5 (C18), 99.4 (C9/10), 99.3 (C9/10), 72.2 (C2), 70.9 (C6), 
65.6 (C1), 52.2 (C8), 48.1 (C12/14), 47.9 (C12/14), 29.4 (C5), 17.7 (C11/13), 17.7 (C11/13); IR (neat): 
νmax cm-1 2995 – 2833 (CH), 1720 (C=O); MS (pNSI): 375.1 (100%, [M-OMe]+), 424.2 (23% 
[M+NH4]+), 830.4 (68% [2M+NH4]+); HRMS (pNSI): calcd for C21H26O8NH4 [M+NH4]+: 424.1966; 
observed: 424.1956. 
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 Methyl (2S,3S,4aR,8S,8aS)-8-((4-bromobenzoyl)oxy)-2,3-dimethoxy-2,3-
dimethyl-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 255 
 
To a Schlenk flask was added methyl (2S,3S,4aR,8R,8aR)-8-hydroxy-2,3-dimethoxy-2,3-
dimethyl-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 243 (212 mg, 0.70 
mmol), 4-bromobenzoic acid (211 mg, 1.05 mmol), triphenylphosphine (275 mg, 1.05 mmol) 
and THF (10 mL) under a nitrogen atmosphere.  The solution was cooled to 0 °C and diethyl 
azodicarboxylate (165 µL, 1.05 mmol) was added dropwise.  The reaction mixture was stirred 
at rt for 18 h then poured into saturated aq. NaHCO3 solution (10 mL) and extracted with ethyl 
acetate (3 x 20 mL).  The combined organic extracts were dried with sodium sulfate, filtered 
and the solvent removed under reduced pressure.  The crude product was purified by column 
chromatography (petroleum ether: acetone, 4: 1, column diameter = 3 cm, silica = 18 cm) to 
give methyl (methyl (2S,3S,4aR,8S,8aS)-8-((4-bromobenzoyl)oxy)-2,3-dimethoxy-2,3-
dimethyl-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 255 (257 mg, 0.53 
mmol, 76%) as a white solid. 
Mp = 145.0 – 145.7 °C; Rf = 0.4 (petroleum ether: acetone, 4:1); [𝛼]𝐷
20= +141.8 (c = 1, MeOH); 
1H NMR (300 MHz,CDCl3) δH 7.86 (2H, d, J = 8.5 Hz, H17/18), 7.55 (2H, d, J = 8.5 Hz, H17/18), 
6.71 (1H, app t, J = 2.6 Hz, H3), 5.82 – 5.71 (1H, m, H2), 4.05 – 3.86 (2H, m, H1+6), 3.71 (3H, 
s, H8), 3.25 (3H, s, H12/14), 3.24 (3H, s, H12/14), 2.80 (1H, dd, J = 17.4, 5.6 Hz, H5), 2.44 – 2.29 
(1H, m, H5), 1.29 (3H, s, H11/13), 1.25 (3H, s, H11/13); 13C NMR (75 MHz, CDCl3) δC 166.0 (C7/15), 
165.1 (C7/15), 134.5 (C3), 131.9 (C17/18), 131.2 (C17/18), 130.6 (C4), 128.8 (C16/19), 128.4 (C16/19), 
99.4 (C9/10), 99.2 (C9/10), 72.5 (C2), 70.9 (C1/6), 65.5 (C1/6), 52.2 (C8), 48.1 (C12/14), 47.8 (C12/14), 
29.4 (C5), 17.7 (C11/13), 17.7 (C11/13); IR (neat): νmax cm-1 2950 – 2832 (CH), 1717 (C=O); MS 
(pNSI): 453.1 (100%, [M-OMe]+), 507.1 (43% [M+Na]+), 988.2 (26% [2M+NH4]+); HRMS 
(pNSI): calcd for C21H25BrO8Na [M+Na]+: 507.0625, 509.0605; observed : 507.0612, 509.0591. 
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 Methyl (2S,3S,4aR,8S,8aS)-8-((2-iodobenzoyl)oxy)-2,3-dimethoxy-2,3-dimethyl-
2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 256 
 
To a Schlenk flask was added methyl (2S,3S,4aR,8R,8aR)-8-hydroxy-2,3-dimethoxy-2,3-
dimethyl-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 243 (610 mg, 2.0 mmol), 
2-iodobenzoic acid (744 mg, 3.0 mmol), triphenylphosphine (787 mg, 3.0 mmol) and THF (20 
mL) under a nitrogen atmosphere.  The solution was cooled to 0 °C and diethyl 
azodicarboxylate (472 µL, 3.0 mmol) was added dropwise.  The reaction mixture was stirred 
at rt for 18 h then poured into saturated aq. NaHCO3 solution (20 mL) and extracted with ethyl 
acetate (3 x 40 mL).  The combined organic extracts were dried with sodium sulfate, filtered 
and the solvent removed under reduced pressure.  The crude product was purified by column 
chromatography (petroleum ether: acetone, 3: 1, column diameter = 4 cm, silica = 17 cm) to 
give methyl (2S,3S,4aR,8S,8aS)-8-((2-iodobenzoyl)oxy)-2,3-dimethoxy-2,3-dimethyl-
2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 256 (622 mg, 1.2 mmol, 58%) as 
a colourless crystalline solid. 
Mp = 108.5 - 109.9 °C; Rf = 0.38 (petroleum ether: acetone, 3: 1, visualised with KMnO4 aq. 
solution); [𝛼]𝐷
20= +99 (c = 1, DCM); 1H NMR (300 MHz, CDCl3) δH 7.97 (1H, dd, J = 8.0, 1.1 
Hz, H20), 7.78 (1H, dd, J = 7.7, 1.7 Hz, H17), 7.37 (1H, td, J = 7.7, 1.2 Hz, H18), 7.13 (1H, td, J 
= 7.6, 1.7 Hz, H19), 6.78 (1H, app t, J = 2.6 Hz, H3), 5.82 - 5.72 (1H, m, H2), 4.06 – 3.83 (2H, 
m, H1+6), 3.72 (3H, s, H8), 3.26 (3H, s, H12/14), 3.25 (3H, s, H12/14), 2.80 (1H, ddd, J = 17.4, 5.3, 
1.5 Hz, H5), 2.43 - 2.29 (1H, m, H5), 1.29 (3H, s, H11/13), 1.28 (3H, s, H11/13); 13C NMR (75 MHz, 
CDCl3) δC 166.0 (C7), 165.6 (C15), 141.5 (C20), 134.5 (C2), 134.5 (C16), 132.9 (C19), 130.9 (C17), 
130.5 (C4), 128.0 (C18), 99.4 (C9/10), 99.2 (C9/10), 94.3 (C21), 72.9 (C2), 70.8 (C1/6), 65.5 (C1/6), 
52.3 (C8), 48.1 (C12/14), 48.1 (C12/14), 29.4 (C5), 17.7 (C11/13), 17.7 (C11/13); IR (neat): νmax cm-1 
2953 – 2831 (CH), 1722 (C=O); HRMS (pNSI): calcd for C21H25IO8Na [M+Na]+: 555.0486; 
observed: 507.0471. 
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 Methyl (2S,3S,4aR,8S,8aS)-8-((4-iodobenzoyl)oxy)-2,3-dimethoxy-2,3-dimethyl-
2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 257 
 
 
To a Schlenk flask was added methyl (2S,3S,4aR,8R,8aR)-8-hydroxy-2,3-dimethoxy-2,3-
dimethyl-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 243 (500 mg, 1.7 mmol), 
4-iodobenzoic acid (615 mg, 2.5 mmol), triphenylphosphine (650 mg, 2.5 mmol) and THF (15 
mL) under a nitrogen atmosphere.  The solution was cooled to 0 °C and diethyl 
azodicarboxylate (390 µL, 2.5 mmol) was added dropwise.  The reaction mixture was stirred 
at rt for 18 h then poured into saturated aq. NaHCO3 solution (20 mL) and extracted with ethyl 
acetate (3 x 40 mL).  The combined organic extracts were dried with sodium sulfate, filtered 
and the solvent removed under reduced pressure.  The crude product was purified by column 
chromatography (petroleum ether: acetone, 4: 1, column diameter = 3 cm, silica = 22 cm) to 
give methyl (2S,3S,4aR,8S,8aS)-8-((4-iodobenzoyl)oxy)-2,3-dimethoxy-2,3-dimethyl-
2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 257 (680 mg, 1.3 mmol, 77%) as 
an off-white solid (Note: the isolated sample was contaminated with ~13% 4-iodobenzoic acid 
as estimated by analysis of the 1H NMR spectrum).  
Mp = 100.1 – 100.8 °C; Rf = 0.54 (petroleum ether: acetone, 4: 1); [𝛼]𝐷
20= +137.4 (c = 1, DCM); 
1H NMR (300 MHz, CDCl3) δH 7.71 (2H, d, J = 8.3 Hz, H18), 7.65 (2H, d, J = 8.3 Hz, H17), 6.65 
(1H, app t, J = 2.6 Hz, H3), 5.74 – 5.67  (1H, m, H2), 3.98 – 3.81 (2H, m, H1+6), 3.65 (3H, s, H8), 
3.19 (3H, s, H12/14), 3.19 (3H, s, H12/14), 2.75 (1H, dd, J = 17.1, 5.3 Hz, H5), 2.30 (1H, m, H5), 
1.23 (3H, s, H11/13), 1.19 (3H, s, H11/13); 13C NMR (75 MHz, CDCl3) δC 165.9 (C7), 165.2 (C15), 
137.8 (C18), 134.5 (C3), 131.0 (C17), 130.5 (C4), 129.3 (C16), 101.1 (C19) 99.2 (C9/10), 99.2 (C9/10), 
72.4 (C2), 70.8 (C1/6), 65.4 (C1/6), 52.2 (C8), 48.0 (C12/14), 47.8 (C12/14), 29.3 (C5), 17.7 (C11/13), 
17.6 (C11/13); IR (neat): νmax cm-1 2955 – 2835 (CH), 1714 (C=O); HRMS (pNSI): calcd for 
C21H25IO8NH4 [M+NH4]+: 550.0932; observed: 550.0917. 
  
Chapter 5. Experimental 
 
191 
 
 Methyl (2S,3S,4aR,8S,8aS)-2,3-dimethoxy-2,3-dimethyl-8-((4-nitrobenzoyl)oxy)-
2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 258 
 
To a Schlenk flask was added methyl (2S,3S,4aR,8R,8aR)-8-hydroxy-2,3-dimethoxy-2,3-
dimethyl-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 243 (500 mg, 1.7 mmol), 
4-nitrobenzoic acid (414 mg, 2.5 mmol), triphenylphosphine (650 mg, 2.5 mmol) and THF (15 
mL) under a nitrogen atmosphere.  The solution was cooled to 0 °C and diethyl 
azodicarboxylate (390 µL, 2.5 mmol) was added dropwise.  The reaction mixture was stirred 
at rt for 18 h then poured into saturated aq. NaHCO3 solution (20 mL) and extracted with ethyl 
acetate (3 x 40 mL).  The combined organic extracts were dried with sodium sulfate, filtered 
and the solvent removed under reduced pressure.  The crude product was purified by column 
chromatography (petroleum ether: acetone, 6: 1, column diameter = 4 cm, silica = 22 cm) to 
give methyl (2S,3S,4aR,8S,8aS)-2,3-dimethoxy-2,3-dimethyl-8-((4-nitrobenzoyl)oxy)-
2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 258 (578 mg, 1.3 mmol, 78%) as 
a white solid. 
Mp = 190.1 – 190.4 °C; Rf = 0.33 (petroleum ether: acetone, 6: 1); [𝛼]𝐷
20= +220.4 (c = 1, DCM); 
1H NMR (300 MHz, CDCl3) δH 8.28 (2H, d, J = 8.9 Hz, H18), 8.19 (2H, d, J = 8.9 Hz, H17), 6.72 
(1H, app t, J = 2.5 Hz, H3), 5.87 - 5.76 (1H, m, H2), 4.11 - 3.87 (2H, m, H1+6), 3.73 (3H, s, H8), 
3.27 (3H, s, H12/14), 3.26 (3H, s, H12/14), 2.82 (1H, dd, J = 17.2, 5.2 Hz, H5), 2.46 - 2.30 (1H, m, 
H5), 1.31 (3H, s, H11/13), 1.26 (3H, s, H11/13); 13C NMR (75 MHz, CDCl3) δC 166.0 (C15), 164.1 
(C7), 150.8 (C19), 135.3 (C16), 134.0 (C3), 131.1 (C4), 130.9 (H17), 123.7 (C18), 99.5 (C9/10), 99.3 
(C9/10), 73.3 (C2), 70.9 (C1/6), 65.5 (C1/6), 52.3 (C8), 48.2 (C12/14), 47.9 (C12/14), 29.4 (C5), 17.8 
(C11/13), 17.7 (C11/13); IR (neat): νmax cm-1  2958 – 2838 (CH), 1720 (C=O); MS (pNSI): 474.1 
(100%, [M+Na]+), 420.1 (53%, [M-MeO]+); HRMS (pNSI): calcd for C21H25NO10Na [M+Na]+: 
474.1371; observed: 474.1363. 
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 Methyl (2S,3S,4aR,6R,7S,8S,8aS)-8-(benzoyloxy)-6,7-dihydroxy-2,3-dimethoxy-
2,3-dimethyloctahydrobenzo[b][1,4]dioxine-6-carboxylate 259 
 
To a round bottomed flask was added methyl (2S,3S,4aR,8S,8aS)-8-(benzoyloxy)-2,3-
dimethoxy-2,3-dimethyl-2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 254 (1.11 
g, 2.74 mmol) and acetone: water (8:1 v/v, 14 mL).  To the resultant stirred solution was added 
4-methylmorpholine-N-oxide (1.11 g, 8.22 mmol) followed by osmium tetroxide (0.9 mL 4% 
aqueous solution, 0.14 mmol) at rt.  The reaction mixture was stirred at rt for 6 d then quenched 
with saturated aq. Na2SO3 solution (30 mL), diluted with water (80 mL) and extracted with DCM 
(3 x 50 mL).  The combined organic extracts were washed with brine (50 mL), dried with sodium 
sulfate, filtered and the solvent removed under reduced pressure.  The crude product was 
purified by column chromatography (petroleum ether: acetone, 2: 1, column diameter = 3 cm, 
silica = 20 cm) to give methyl (2S,3S,4aR,6R,7S,8S,8aS)-8-(benzoyloxy)-6,7-dihydroxy-2,3-
dimethoxy-2,3-dimethyloctahydrobenzo[b][1,4]dioxine-6-carboxylate 259 (0.924 g, 2.08 mmol, 
76%) as a colourless crystalline solid. 
Mp = 221.2 - 222.2 °C; Rf = 0.35 (petroleum ether: acetone, 2: 1); [𝛼]𝐷
20= +52 (c = 0.1, DCM); 
1H NMR (300 MHz, CDCl3) δH 8.11 – 8.03 (2H, m, H17), 7.64 – 7.54 (1H, m, H19), 7.51 – 7.41 
(2H, m, H18), 5.43 (1H, app t, J = 9.8 Hz, H2), 4.17 (1H, dt, J = 9.6, 8.5 Hz, H6), 4.05 (1H, d, J 
= 9.5 Hz, H3), 3.95 – 3.87 (1H, m, H1), 3.85 (3H, s, H8), 3.31 (3H, s, H12/14), 3.28 (3H, s, H12/14), 
2.01 (2H, app d, J = 8.5 Hz, H5), 1.32 (3H, s, H11/13), 1.27 (3H, s, H11/13); 13C NMR (75 MHz, 
CDCl3) δC 174.0 (C7), 167.2 (C15), 133.2 (C19), 129.8 (C16), 129.8 (C17), 128.4 (C18), 99.6 (C9/10), 
99.5 (C9/10), 76.4 (C4), 75.2 (C3), 74.0 (C2), 70.9 (C1), 64.9 (C6), 53.5 (C8), 48.0 (C12/14), 47.8 
(C12/14), 35.3 (C5), 17.7 (C11/13), 17.6 (C11/13); IR (neat): νmax cm-1 3468 (OH), 3430 (OH), 2945 
– 2894 (CH), 1749 (C=O), 1724 (C=O); MS (pNSI): 409.1 (100%, [M-OMe]+), 458.2 (86%, 
[M+NH4]+); HRMS (pNSI): calcd for C21H32O10N [M+NH4]+: 458.2021; observed: 458.2014. 
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 Methyl (2S,3S,4aR,6R,8R,8aS)-8-(benzoyloxy)-2,3-dimethoxy-2,3-dimethyl-6-
((methylthio)methoxy)-7-oxooctahydrobenzo[b][1,4]dioxine-6-carboxylate 263 
 
To a Schlenk flask was added DCM (0.5 mL) and oxalyl chloride (40 µL, 0.47 mmol).  The 
resultant solution was cooled to -78 °C and DMSO (80 µL, 1.15 mmol) was added dropwise.  
The solution was stirred for 10 min and a solution of (2S,3S,4aR,6R,7S,8S,8aS)-8-
(benzoyloxy)-6,7-dihydroxy-2,3-dimethoxy-2,3-dimethyloctahydrobenzo[b][1,4]dioxine-6-
carboxylate 259 (100 mg, 0.23 mmol) in DCM (1.0 mL) was added dropwise.  The reaction 
mixture was stirred for 5 min at -78 °C then triethylamine (0.29 mL, 2.07 mmol) was added.  
The reaction mixture was stirred for 10 min at -78°C, then at rt for 35 min.  The reaction mixture 
was quenched with water (20 mL) and extracted with DCM (3 x 20 mL).  The combined organic 
extracts were washed with water (40 mL) and brine (40 mL) then dried with sodium sulfate, 
filtered and the solvent removed under reduced pressure.  The crude compound was purified 
by column chromatography (petroleum ether: diethyl ether, 1: 1, column diameter = 1.5 cm, 
silica = 20 cm) to give methyl (2S,3S,4aR,6R,8R,8aS)-8-(benzoyloxy)-2,3-dimethoxy-2,3-
dimethyl-6-((methylthio)methoxy)-7-oxooctahydrobenzo[b][1,4]dioxine-6-carboxylate 263 (14 
mg, 0.03 mmol, 12%) as a colourless solid and methyl (2S,3S,4aR,6R,8R,8aS)-8-
(benzoyloxy)-6-hydroxy-2,3-dimethoxy-2,3-dimethyl-7-oxooctahydrobenzo[b][1,4]dioxine-6-
carboxylate 262 (25 mg, 0.06 mmol, 25%) as a white crystalline solid. 
Methyl (2S,3S,4aR,6R,8R,8aS)-8-(benzoyloxy)-2,3-dimethoxy-2,3-dimethyl-6-
((methylthio)methoxy)-7-oxooctahydrobenzo[b][1,4]dioxine-6-carboxylate 263 
Mp = 143.0 – 144.3 °C (decomposed); Rf = 0.43 (petroleum ether: diethyl ether, 1: 1); [𝛼]𝐷
20= 
+48 (c = 0.1, DCM); 1H NMR (300 MHz, CDCl3) δH 8.02 – 7.94 (2H, m, H17), 7.56 – 7.47 (1H, 
m, H19), 7.39 (2H, app t, J = 7.6 Hz, H18), 5.81 (1H, d, J = 11.6 Hz, H2), 4.93 (1H, d, J = 10.6 
Hz, H20), 4.67 (1H, d, J = 10.6 Hz, H20), 4.39 (1H, ddd, J = 12.0, 9.7, 4.9 Hz, H6), 3.97 (1H, dd, 
J = 11.6, 9.7 Hz, H1), 3.71 (3H, s, H8), 3.26 (6H, app s, H12+14), 2.39 (1H, dd, J = 14.3, 4.9 Hz, 
H5), 2.29 – 2.20 (1H, m, H5), 2.27 (3H, s, H21), 1.27 (3H, s, H11/13), 1.25 (3H, s, H11/13); 13C NMR 
(75 MHz, CDCl3) δC 196.2 (C3), 168.3 (C7), 165.3 (C15), 133.4 (C19), 129.9 (C17), 129.2 (C16), 
128.5 (C18), 99.8 (C9/10), 99.6 (C9/10), 85.0 (C4), 75.8 (C2), 71.9 (C20), 71.0 (C1), 64.1 (C6), 52.7 
(C8), 48.3 (C12/14), 48.0 (C12/14), 35.0 (C5), 17.6 (C11/13), 17.5 (C11/13), 15.2 (C21); IR (neat): νmax 
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cm-1 2989 – 2831 (CH), 1759 (C=O), 1740 (C=O), 1716 (C=O); HRMS (pNSI): calcd for 
C23H30O10SNH4 [M+NH4]+: 516.1898; observed: 516.1888. 
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 Methyl (2S,3S,4aR,6R,8R,8aS)-8-(benzoyloxy)-6-hydroxy-2,3-dimethoxy-2,3-
dimethyl-7-oxooctahydrobenzo[b][1,4]dioxine-6-carboxylate 262 
 
To a Schlenk flask was added DCM (2 mL) and oxalyl chloride (0.12 mL, 1.43 mmol).  The 
resultant solution was cooled to -78 °C and DMSO (0.26 mL, 3.60 mmol) was added dropwise.  
After 10 min at -78 °C, a solution of  (2S,3S,4aR,6R,7S,8S,8aS)-8-(benzoyloxy)-6,7-dihydroxy-
2,3-dimethoxy-2,3-dimethyloctahydrobenzo[b][1,4]dioxine-6-carboxylate 259 (315 mg, 0.72 
mmol) in DCM (8 mL) was added to the reaction mixture and stirring was continued for 10 min.  
Triethylamine (0.50 mL, 3.6 mmol) was added.  The reaction mixture was stirred at -78 °C for 
2 h, quenched with water (10 mL) and extracted with DCM (3 x 15 mL).  The combined organic 
extracts were washed with water (50 mL) and brine (50 mL), then dried with sodium sulfate, 
filtered and the solvent removed under reduced pressure.  The crude product was purified by 
column chromatography (petroleum ether: acetone, 4: 1, column diameter = 2 cm, silica = 18 
cm) to give methyl (2S,3S,4aR,6R,8R,8aS)-8-(benzoyloxy)-6-hydroxy-2,3-dimethoxy-2,3-
dimethyl-7-oxooctahydrobenzo[b][1,4]dioxine-6-carboxylate 262 (269 mg, 0.61 mmol, 85%) as 
a colourless crystalline solid.  
Mp = 235.7 – 237.1 °C; Rf = 0.3 (petroleum ether: diethyl ether, 1: 1); [𝛼]𝐷
20= +133.8 (c = 1, 
DCM); 1H NMR (300 MHz, CDCl3) δH 8.02 – 7.94 (2H, m, H17), 7.55 – 7.45 (1H, m, H19), 7.40 
– 7.35 (2H, m, H18), 5.96 (1H, d, J = 11.5 Hz, H2), 4.38 (1H, ddd, J = 11.7, 9.7, 5.2 Hz, H6), 
4.11 (1H, s, OH), 3.96 (1H, dd, J = 11.5, 9.7 Hz, H1), 3.77 (3H, s, H8), 3.25 (6H, app s, H12+14), 
2.25 – 2.12 (2H, m, H5), 1.26 (3H, s, H11/13), 1.24 (3H, s, H11/13); 13C NMR (75 MHz, CDCl3) δC 
196.7 (C3), 170.7 (C7), 165.1 (C15), 133.3 (C19), 129.9 (C17), 129.3 (C16), 128.4 (C18), 99.7 
(C9/10), 99.5 (C9.10), 79.1 (C4), 74.5 (C2), 71.1 (C1), 64.3 (C6), 53.7 (C8), 48.2 (C12/14), 47.9 
(C12/14), 34.8 (C5), 17.6 (C11/13), 17.5 (C11/13); IR (neat): νmax cm-1 3412 (OH), 3003 – 2831 (CH), 
1762 (C=O), 1744 (C=O), 1725 (C=O); HRMS (pAPCI): calcd for C21H27O10 [M+H]+: 439.1599; 
observed: 439.1595; calcd for C21H26O10NH4 [M+NH4]+: 456.1864; observed: 456.1861. 
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 Methyl 3,5-dihydroxy-2-methoxy-2,3-dimethyl-2,3-dihydrobenzo[b][1,4]dioxine-
6-carboxylate 267 
 
 
To a Schlenk flask was added methyl (2S,3S,4aR,6R,8R,8aS)-8-(benzoyloxy)-6-hydroxy-2,3-
dimethoxy-2,3-dimethyl-7-oxooctahydrobenzo[b][1,4]dioxine-6-carboxylate 262 (51 mg, 0.12 
mmol) and THF (2.5 mL) and the resultant solution was cooled to -78 °C.  To this was added 
sodium bis(trimethylsilyl)amide (0.3 mL, 0.30 mmol, 1 M solution in THF) and the reaction 
mixture was stirred at -78 °C for 90 min, then at rt for 24 h.  The reaction mixture was quenched 
with saturated aq. ammonium chloride solution (10 mL), extracted with DCM (3 x 10 mL), dried 
with sodium sulfate, filtered and the solvent removed under reduced pressure.  The crude 
product was purified by column chromatography (petroleum ether: acetone, 4: 1, column 
diameter = 1 cm, silica = 15 cm) to give methyl 3,5-dihydroxy-2-methoxy-2,3-dimethyl-2,3-
dihydrobenzo[b][1,4]dioxine-6-carboxylate 267 (24 mg, 0.08 mmol, 70%) as a white solid, as 
an inseparable 1: 2 mixture of diastereomers. 
Mp = 163.8 – 165.2 °C; Rf = 0.25 (petroleum ether: acetone, 4: 1); IR (neat): νmax cm-1 3453 
(OH), 3000 – 2850 (CH), 1670 (C=O); HRMS (pNSI): calcd for C13H17O7 [M+H]+: 285.0969; 
observed: 285.0970. 
Major diastereomer 
1H NMR (500 MHz, CDCl3) δH 10.99 (1H, s, OH), 7.34 (1H, d, J = 8.9 Hz, H5), 6.42 (1H, d, J = 
8.9 Hz, H6), 3.84 (3H, s, H13), 3.22 (3H, s, H11), 1.67 (3H, s, H9/10), 1.59 (3H, s, H9/10); 13C NMR 
(126 MHz, CDCl3) δC 170.6 (C12), 152.0 (C3), 145.6 (C1), 129.8 (C2), 122.3 (C5), 108.4 (C6), 
107.0 (C4), 99.1 (C7/8), 96.0 (C7/8), 52.1 (C13), 49.5 (C11), 22.7 (C9/10), 17.3 (C9/10). 
Minor diastereomer 
1H NMR (500 MHz, CDCl3) δH 10.93 (1H, s, OH), 7.32 (1H, d, J = 8.9 Hz, H5/6), 6.39 (1H, d, J 
= 8.9 Hz, H5/6), 3.85 (3H, s, H13), 3.26 (3H, s, H11), 1.52 (3H, s, H9/10), 1.44 (3H, s, H9/10); 13C 
NMR (126 MHz, CDCl3) δC 170.5 (C12), 151.8 (C3), 144.4 (C1), 131.0 (C2), 122.0 (C5), 108.0 
(C6), 107.1 (C4), 98.7 (C7/8), 97.2 (C7/8), 52.2 (C13), 49.5 (C11), 20.3 (C9/10), 16.7 (C9/10). 
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4-(2,5-Dimethoxyphenyl)-4-(phenylthio)butan-2-one 158 
 
 
 
Table 1 Crystal data and structure refinement for mjh150005_fa. 
Identification code  mjh150005_fa  
Empirical formula  C18H20O3S  
Formula weight  316.40  
Temperature/K  150.0(2)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  16.69736(17)  
b/Å  5.57877(4)  
c/Å  18.13732(17)  
α/°  90  
β/°  110.3522(11)  
γ/°  90  
Volume/Å3  1584.03(3)  
Z  4  
Appendix 
204 
 
ρcalcg/cm3  1.327  
μ/mm-1  1.897  
F(000)  672.0  
Crystal size/mm3  0.26 × 0.16 × 0.1  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  5.646 to 133.86  
Index ranges  -19 ≤ h ≤ 19, -6 ≤ k ≤ 6, -21 ≤ l ≤ 21  
Reflections collected  40835  
Independent reflections  2820 [Rint = 0.0304, Rsigma = 0.0101]  
Data/restraints/parameters  2820/0/202  
Goodness-of-fit on F2  1.033  
Final R indexes [I>=2σ (I)]  R1 = 0.0275, wR2 = 0.0683  
Final R indexes [all data]  R1 = 0.0303, wR2 = 0.0701  
Largest diff. peak/hole / e Å-3  0.23/-0.20  
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Diethyl (E)-2-(4-(2,5-dimethoxyphenyl)-2-oxobut-3-en-1-yl)-2-hydroxymalonate 159 
 
 
Table 1 Crystal data and structure refinement for mjh150020.  
Identification code  mjh150020  
Empirical formula  C19H24O8  
Formula weight  380.38  
Temperature/K  150.0(2)  
Crystal system  monoclinic  
Space group  C2/c  
a/Å  29.9185(15)  
b/Å  9.2785(4)  
c/Å  13.9811(8)  
α/°  90  
β/°  103.344(6)  
γ/°  90  
Volume/Å3  3776.3(3)  
Z  8  
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ρcalcg/cm3  1.338  
μ/mm-1  0.880  
F(000)  1616.0  
Crystal size/mm3  0.44 × 0.23 × 0.2  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  6.072 to 133.658  
Index ranges  -34 ≤ h ≤ 35, -11 ≤ k ≤ 8, -16 ≤ l ≤ 15  
Reflections collected  13592  
Independent reflections  3332 [Rint = 0.0302, Rsigma = 0.0230]  
Data/restraints/parameters  3332/5/264  
Goodness-of-fit on F2  1.048  
Final R indexes [I>=2σ (I)]  R1 = 0.0404, wR2 = 0.0975  
Final R indexes [all data]  R1 = 0.0526, wR2 = 0.1074  
Largest diff. peak/hole / e Å-3  0.20/-0.34  
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5,8-Dimethoxy-4a,9,9a,10-tetrahydro-9,10-epoxyanthracene-1,4-dione 227 
 
Table 1 Crystal data and structure refinement for mjh150019.  
Identification code  mjh150019  
Empirical formula  C16H14O5  
Formula weight  286.27  
Temperature/K  150.0(2)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  7.27400(10)  
b/Å  25.1661(3)  
c/Å  7.79454(11)  
α/°  90  
β/°  110.0773(16)  
γ/°  90  
Volume/Å3  1340.14(3)  
Z  4  
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ρcalcg/cm3  1.419  
μ/mm-1  0.886  
F(000)  600.0  
Crystal size/mm3  0.47 × 0.3 × 0.23  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  7.026 to 134.012  
Index ranges  -8 ≤ h ≤ 8, -29 ≤ k ≤ 29, -9 ≤ l ≤ 7  
Reflections collected  9593  
Independent reflections  2383 [Rint = 0.0203, Rsigma = 0.0143]  
Data/restraints/parameters  2383/0/192  
Goodness-of-fit on F2  1.080  
Final R indexes [I>=2σ (I)]  R1 = 0.0372, wR2 = 0.0981  
Final R indexes [all data]  R1 = 0.0401, wR2 = 0.1008  
Largest diff. peak/hole / e Å-3  0.42/-0.25  
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5,8-Dimethoxy-2,9a-dimethyl-4a,9,9a,10-tetrahydro-9,10-epoxyanthracene-1,4-dione 
233-b 
 
Table 1 Crystal data and structure refinement for mjh150017_off_2.  
Identification code  mjh150017_off_2  
Empirical formula  C18H18O5  
Formula weight  314.32  
Temperature/K  150.0(2)  
Crystal system  orthorhombic  
Space group  Fdd2  
a/Å  52.964(16)  
b/Å  14.9766(17)  
c/Å  7.5116(7)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  5958(2)  
Z  16  
ρcalcg/cm3  1.402  
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μ/mm-1  0.846  
F(000)  2656.0  
Crystal size/mm3  0.24 × 0.16 × 0.15  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  6.676 to 134.356  
Index ranges  -62 ≤ h ≤ 61, -15 ≤ k ≤ 17, -8 ≤ l ≤ 8  
Reflections collected  20456  
Independent reflections  2624 [Rint = 0.0322, Rsigma = 0.0141]  
Data/restraints/parameters  2624/1/212  
Goodness-of-fit on F2  1.048  
Final R indexes [I>=2σ (I)]  R1 = 0.0274, wR2 = 0.0673  
Final R indexes [all data]  R1 = 0.0282, wR2 = 0.0680  
Largest diff. peak/hole / e Å-3  0.10/-0.16  
Flack parameter -0.05(7) 
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Methyl (2S,3S,4aR,8S,8aS)-2,3-dimethoxy-2,3-dimethyl-8-((4-nitrobenzoyl)oxy)-
2,3,4a,5,8,8a-hexahydrobenzo[b][1,4]dioxine-6-carboxylate 258 
 
MJH150021           355 
 
Data collected at Diamond Light Source, July 2015 
Bill Clegg, Mike Probert and Paul Waddell 
 
There are two molecules in the asymmetric unit, with the same relative and absolute 
configuration; the absolute configuration cannot be reliably established from the diffraction 
experiment and has been assumed from the synthesis information provided. 
 
The crystal was found to be a non-merohedral twin with approximately equal components. 
 
 
 
The two molecules in the asymmetric unit 
 
Table 1.  Crystal data and structure refinement for mjh150021. 
Identification code    mjh150021 
Chemical formula (moiety)  C21H25NO10 
Chemical formula (total)  C21H25NO10 
Formula weight    451.42 
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Temperature     100(2) K 
Radiation, wavelength   synchrotron, 0.6889 Å 
Crystal system, space group   monoclinic, P21 
Unit cell parameters   a = 14.912(4) Å  = 90° 
     b = 7.466(2) Å  = 104.150(3)° 
     c = 21.319(6) Å  = 90° 
Cell volume    2301.5(11) Å3 
Z     4 
Calculated density    1.303 g/cm3 
Absorption coefficient   0.098 mm1 
F(000)     952 
Crystal colour and size  colourless, 0.100  0.040  0.010 mm3 
Reflections for cell refinement 4185 ( range 2.6 to 20.2°) 
Data collection method  Rigaku Saturn 724+ on kappa diffractometer 
     wide-frame  scans 
 range for data collection  1.4 to 24.2° 
Index ranges    h 17 to 17, k 8 to 8, l 25 to 25 
Completeness to  = 24.2°  99.9 %  
Reflections collected   25692 
Independent reflections  7519 (Rint = 0.0921) 
Reflections with F2>2  4672 
Absorption correction   none 
Structure solution   direct methods 
Refinement method   Full-matrix least-squares on F2 
Weighting parameters a, b  0.0591,  
Data / restraints / parameters  25692 / 1 / 589 
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Final R indices [F2>2]  R1 = 0.0572, wR2 = 0.1152 
R indices (all data)   R1 = 0.1151, wR2 = 0.1365 
Goodness-of-fit on F2   0.938 
Absolute structure parameter   0.7(6) 
Extinction coefficient   0.013(2) 
Largest and mean shift/su  0.000 and 0.000 
Largest diff. peak and hole  0.24 and 0.25 e Å3 
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Methyl (2S,3S,4aR,6R,7S,8S,8aS)-8-(benzoyloxy)-6,7-dihydroxy-2,3-dimethoxy-2,3-
dimethyloctahydrobenzo[b][1,4]dioxine-6-carboxylate 259 
 
Table 1 : Crystal data and structure refinement for mjh150029_fa.  
Identification code  mjh150029_fa  
Empirical formula  C21H28.4O10.2  
Formula weight  444.04  
Temperature/K  150.0(2)  
Crystal system  orthorhombic  
Space group  P212121  
a/Å  10.98455(7)  
b/Å  12.06305(9)  
c/Å  16.99567(11)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  2252.05(3)  
Z  4  
Appendix 
215 
 
ρcalcg/cm3  1.310  
μ/mm-1  0.889  
F(000)  944.0  
Crystal size/mm3  0.23 × 0.21 × 0.11  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  8.99 to 134.022  
Index ranges  -13 ≤ h ≤ 13, -14 ≤ k ≤ 14, -20 ≤ l ≤ 20  
Reflections collected  62461  
Independent reflections  4009 [Rint = 0.0471, Rsigma = 0.0147]  
Data/restraints/parameters  4009/0/297  
Goodness-of-fit on F2  1.061  
Final R indexes [I>=2σ (I)]  R1 = 0.0292, wR2 = 0.0707  
Final R indexes [all data]  R1 = 0.0314, wR2 = 0.0722  
Largest diff. peak/hole / e Å-3  0.16/-0.20  
Flack parameter 0.01(4) 
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Methyl (2S,3S,4aR,6R,8R,8aS)-8-(benzoyloxy)-6-hydroxy-2,3-dimethoxy-2,3-dimethyl-7-
oxooctahydrobenzo[b][1,4]dioxine-6-carboxylate 262 
 
Table 1 : Crystal data and structure refinement for mjh150032.  
Identification code  mjh150032  
Empirical formula  C21H26O10  
Formula weight  438.42  
Temperature/K  150.0(2)  
Crystal system  monoclinic  
Space group  P21  
a/Å  9.83490(11)  
b/Å  10.70993(10)  
c/Å  10.79595(14)  
α/°  90  
β/°  111.7181(14)  
γ/°  90  
Volume/Å3  1056.43(2)  
Z  2  
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ρcalcg/cm3  1.378  
μ/mm-1  0.936  
F(000)  464.0  
Crystal size/mm3  0.52 × 0.12 × 0.08  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  8.816 to 133.936  
Index ranges  -11 ≤ h ≤ 11, -12 ≤ k ≤ 12, -12 ≤ l ≤ 12  
Reflections collected  36511  
Independent reflections  3744 [Rint = 0.0461, Rsigma = 0.0183]  
Data/restraints/parameters  3744/1/288  
Goodness-of-fit on F2  1.080  
Final R indexes [I>=2σ (I)]  R1 = 0.0283, wR2 = 0.0716  
Final R indexes [all data]  R1 = 0.0301, wR2 = 0.0730  
Largest diff. peak/hole / e Å-3  0.22/-0.19  
Flack parameter -0.04(5) 
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